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Tumour-associated macrophages (TAMs) have been shown to play an important role 
in tumour survival and progression. Thus, high numbers of macrophages in the 
tumour tissue are often associated with a poor prognosis. Identification of factors 
responsible for recruiting macrophages to the sites of different types of tumours 
might help to develop more effective cancer treatment.      
Burkitt's lymphoma (BL) is characterised by uncontrolled cell proliferation, high rate 
of spontaneous apoptosis and significant macrophage infiltration. Although BL cells 
undergo extensive apoptosis, in situ their corpses are cleared very effectively by 
macrophages infiltrating the tumour. It is now widely believed that dying cells are 
themselves able to release chemotactic molecules to ensure macrophage chemotaxis 
and subsequent clearance of their site of death. Previous work carried out in this 
laboratory identified fractalkine/CX3CL1 (FKN) released from dying BL cells to be 
an important player in macrophage chemotaxis to BL. Yet, these results have also 
indicated that FKN may not be the only chemokine involved in this process. 
Following from those observations, the first part of this work focused on examination 
of the potential role of monocyte chemoattractant protein-1 (MCP-1) in macrophage 
recruitment to BL. Despite the initial promising results, careful analysis of the data 
obtained by various techniques led to the conclusion that MCP-1 is, probably, not 
expressed by BL cells.  
Subsequently, effort was concentrated on understanding mechanisms regulating FKN 
processing during cell death. The studies performed before in this laboratory 
identified a new form of FKN to be present in apoptotic BL cells and showed that 
this is the form that is, most likely, responsible for mediating macrophage migration. 
Here, this apoptosis-related 60 kDa FKN was found to be a likely caspase-3 cleavage 
product. Moreover, it was demonstrated that FKN and active caspase-3 are released 
together in apoptotic BL cell-derived microparticles, suggesting that the proteolytic 
events could take place also extracellularly. 
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In the final results chapter the differences between BL cell lines in the way they 
process FKN during cell death were revealed and a new cell death-associated 55 kDa 
FKN was observed. Through several lines of evidence, this new form was identified 
to be a possible product of calpain-mediated proteolysis.  
To conclude, this work provides the first evidence for a possible direct participation 
of the two major cell death executioner proteases – caspases and calpains, in 
production of ‘find me’ signals for macrophages and thus, ensuring effective 
clearance of dying cells. These results indicate that FKN cleavage and release might 
be of key importance during cell death. Moreover, the studies presented here 
contribute to better understanding of the process of FKN secretion. 
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Chapter 1  
Introduction 
1.1 Burkitt’s lymphoma 
1.1.1 General characteristics 
Burkitt’s lymphoma (BL) is an aggressive, B-cell, non-Hodgkin’s neoplasm. 
Originally characterised by Burkitt in children in equatorial Africa (Burkitt 1972), 
this malignancy occurs also in immunodeficient (e.g. HIV-carrying) individuals 
(Carbone & Gloghini 2005; Grogg et al. 2007). Although much less common, it is 
reported as well in immunocompentent individuals in other parts of the world 
(Banthia 2003). In its “endemic” African form, the malignancy is highly associated 
with Epstein-Barr virus (EBV) infection, with over 95 per cent of cases being EBV-
positive (Bornkamm 2009a). Additionally, infection with malaria-causing 
Plasmodium falciparum has been shown to be an important co-factor in the endemic 
form pathogenesis (Rochford et al. 2005; Chene et al. 2009). Unlike endemic form, 
only 10 – 20 per cent of “sporadic” and 30 – 50 per cent of HIV-associated BL cases 
are EBV-positive (Brady et al. 2007; Allday 2009; Bornkamm 2009).  
All BL types share the same morphological and phenotypical characteristics. It is a 
monoclonal neoplasm, consisting of monomorphic medium-sized B cells with a 
diffuse pattern of growth (Swerdlow 2008). The rate of BL cell division is among the 
highest observed in tumours, with over 95% of cells being positive for Ki-67 
(Cooper et al. 1966; Hecht & Aster 2000). BL cells are also characterised by their 
increased susceptibility to apoptotic cell death (Gregory et al. 1991). The rate of cell 
death is reflected by substantial level of macrophage infiltration observed in situ. The 
infiltrating macrophages, often containing apoptotic cell debris, produce the 
characteristic “starry sky” appearance (Berard et al. 1969). 
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Phenotypically, BL cells are typified by expression of B cell markers (CD19+, 
CD20+, IgM+) and markers characteristic of germinal centre (GC) B cells: CD10+, 
CD23-, CD39-, CD77+ as well as Bcl-6+ and Bcl-2- (Gregory et al. 1987; Gregory et 
al. 1991; Henderson et al. 1991). BL-derived cell lines with such a surface phenotype 
(biopsy-like) were classified as group I BL lines (Rowe et al. 1987). 
Recent studies carried out in this laboratory have revealed that BL cells can actively 
regulate immune cell infiltration of the tumour and therefore, the immunological 
response directed towards the tumour.  Apoptotic lymphoma cells have been shown 
to prevent tumour infiltration of potentially harmful neutrophils by releasing 
lactoferrin, an agent with neutrophil-repulsion properties (Bournazou et al. 2009). At 
the same time, fractalkine – a chemokine with the property of attracting mononuclear 
phagocytes has been found to be released from dying BL cells and to be involved in 
mediating macrophage infiltration of the tumour (Truman et al. 2008).   
1.1.2 Cellular origin 
Although the pattern of surface markers expressed by BL cells suggests they 
originate from germinal centre B cells (Gregory et al. 1987), controversy still exists 
over the B cell developmental stage from which BL cells derive. Close analysis of 
immunoglobulin gene rearrangements revealed the existence of differences between 
EBV-positive and EBV-negative BL cases as to the range of mutations. The higher 
percentage of hypermutation found in EBV-positive cases (when compared with 
EBV-negative ones) indicating a later differentiation stage and thus, probably late 
germinal centre origin of these cells (as opposed to early GC origin of EBV-positive 
BL cases) (Chapman et al. 1995; Bellan et al. 2005). Other observations made by 
Bellan et al. (on ongoing mutation and signs of antigen selection) suggested further 
differences between EBV-positive and –negative cases and would indicate that while 
the virus-negative tumours may derive from early centroblasts, virus-associated cases 
would origin from either late germinal centre cells (with completed mutation 
process) or from memory B cells (Bellan et al. 2005; Thorley-Lawson & Allday 
2008). It has to be noted however, that these observations were not in a full 
agreement with results previously presented by others suggesting that both types of 
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BL may derive from germinal centre cells (Chapman et al. 1995; Chapman et al. 
1996). 
1.1.3 Role of c-Myc in BL  
Irrespective of the associated factors and origin of the B-cell population, the three 
forms of BL (endemic, sporadic and HIV-associated) are characterised by 
chromosomal translocation of Myc proto-oncogene into one of immunoglobulin (Ig) 
loci. In 80 per cent of cases, Myc (from chromosome 8) is juxtaposed to the enhancer 
region of Ig heavy chain on chromosome 14. The majority of the remaining cases 
contain translocation to one of Ig light chain regions (chromosome 2 or 22). In 
mature B cells, Ig enhancers are active and thus, the juxtaposition leads to gross 
overexpression of c-Myc in mutated cells (Klein 1983; Allday 2009). This has a 
profound effect on the cell fate, as a transcription factor c-Myc is known to be 
(directly or indirectly) involved in regulation of around 15 per cent of all human 
genes and can affect various cellular functions, including growth, division, 
metabolism, motility and death (Dang et al. 2006; Schlee et al. 2007). As the 
constitutive activation of c-Myc results in increased rate of cell growth and division, 
it can eventually lead to development of cancer (Coller et al. 2000; Hecht & Aster 
2000; Allday 2009). On the other hand, c-Myc upregulation is known to enhance cell 
susceptibility to apoptotic cell death (Evan et al. 1992; Harrington et al. 1994; Juin et 
al. 2002; Hoffman & Liebermann 2008). The increased rate of proliferation and 
apoptosis observed in BL has also been shown to be driven by excessive expression 
of c-Myc (Milner et al. 1993).  
Studies aiming at developing murine models of BL provided further evidence of the 
oncogenic role of c-Myc. Kovalchuk and colleagues managed to generate transgenic 
mice spontaneously developing BL-like tumours by fusing the Myc gene with 
control regions of Ig λ chain (Kovalchuk et al. 2000). Zhu et al. achieved similar 
effects by mimicking the translocation most commonly found in human BL (t(8:14)) 
by placing Myc under control of Ig heavy chain enhancer (Zhu et al. 2005). Although 
the histological appearance of these murine tumours resembled that of human BL, 
unlike in human, the malignant cells have been shown to originate from naïve BL 
cells. Additionally, in the more recently established model, containing cells with an 
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immunophenotype reminiscent of that of human BL cells, a role for antigen 
stimulation in development of BL-like tumours from c-Myc overexpressing cells has 
been demonstrated (Refaeli et al. 2008).  
While c-Myc translocation and subsequent protein overexpression are seen as the key 
events in tumourigenic transformation of B cells, it is assumed that they have to be 
accompanied by other types of dysregulation for BL to develop. Alteration of 
expression of many apoptosis-regulating proteins (e.g. p53, Bim, MDM2 or 
p14ARF) has been demonstrated, and it is believed these allow the c-Myc-directed 
apoptosis induction to be overcome (Gaidano et al. 1991; Thorley-Lawson & Allday 
2008; Allday 2009). On the other hand, upregulation of the E2F1 transcription factor 
has recently been identified in BL tumour cells (Molina-Privado et al. 2009). It has 
been suggested that E2F1 can contribute to BL development by supporting cell cycle 
progression of, potentially arrested in G2 phase of the cycle, c-Myc overexpressing 
cells.          
1.1.4 Role of Epstein-Barr virus in BL  
EB virus, a member of the γ-herpesvirus group, was discovered during analysis of a 
cell line derived from endemic BL tumour (Epstein et al. 1964). It was initially 
thought to be the main factor involved in BL pathogenesis. Although this view has 
been modified by the subsequent discovery of EBV-negative BL tumours as well as 
identification of c-Myc deregulation as the main feature of all BL tumours, the fact 
that EBV-positive endemic BL tumours have a much higher prevalence than the 
sporadic form, suggested that EBV infection gives some advantage to the potential 
tumour cells. On the other hand, as EBV infection is extremely common (affecting 
over 95 % of human population worldwide), it appeared that additional factors are 
required for EBV to exert its tumourigenic function. Malaria (in the endemic form of 
BL) and HIV (in the immunodeficiency-associated) have been identified as the co-
factors. Both malaria and HIV infection lead to massive B cell activation (Brady et 
al. 2007; Bornkamm 2009; Rowe et al. 2009). P. falciparum infection can constrain 
host immunological response by inhibiting cytotoxic T cells activation, thus, 
indirectly enabling EBV expansion (Rochford et al. 2005). Moreover, P. falciparum 
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erythrocyte membrane protein 1 (PfEMP1) has been shown to induce EBV lytic 
cycle (Chene et al. 2009).  
It is now believed that EBV, which has a capacity for inhibiting death of infected 
cells and inducing cell immortality, is mainly responsible in BL for providing anti-
apoptotic signals to B cells that have acquired a c-Myc mutation during the activation 
process driven by malaria or HIV infection (Bornkamm 2009; Rowe et al. 2009). The 
important role of EBV infection on BL cell survival rate has been clearly 
demonstrated in the studies performed by Kelly and colleagues, who observed that 
EBV latent gene expression effectively, suppressed c-Myc-mediated death of BL 
cells (Kelly et al. 2006).  
In various EBV-associated pathologies, different sets of the EBV latent genes are 
known to be expressed. In the majority of cases of BL, the expression is limited to 
only one viral protein – EBNA-1 (Epstein-Barr virus nuclear antigen-1). 
Additionally, viral non-coding RNA fragments: EBERs (EBV-encoded RNAs) and 
BARTs (BamHI A rightward transcripts) are detected. This restricted mode of EBV 
expression has been classified as a type I latency programme (Rowe et al. 2009).  
In accordance with the hypothesised anti-apoptotic role of EBV during BL 
development, both EBNA-1 and EBERs have been shown to have potency to 
suppress B cell death triggered by various stimuli. Kennedy and colleagues have 
demonstrated that the inhibition of EBNA-1 results in death of EBV-positive BL 
cells and that introduction of EBNA-1 into EBV-negative cells improves their 
survival (Kennedy et al. 2003). EBERs have been found responsible for protecting 
BL cells from death mediated by IFN-α (Nanbo et al. 2002). Also, EBV-expressed 
microRNA BART5 has been implied to suppress the expression of pro-apoptotic 
protein PUMA (Choy et al. 2008).       
All the BL cell lines used during the studies presented in this thesis belong to group I 
BL lines in respect to their surface marker expression. As for viral gene expression, 
Mutu I and SAV BL cells are characterised by type I latency, while BL2 and L3055 
cells are EBV-negative.  
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1.2 Cell death 
Two major types of cell death are generally discriminated, apoptosis and necrosis. 
While these two types death are characterised by sets of fairly distinct features, it 
should be noted that in very many experimental systems, cell death possessing 
attributes of both apoptosis and necrosis have been observed (Blomgren et al. 2007; 
Kroemer et al. 2009). Apart from these two major types of cell death, several less 
well understood mechanisms of cell demise have been described, e.g. autophagy, 
mitotic catastrophe, anoikis, paraptosis, pyroptosis, pyronecrosis or entosis (Kroemer 
et al. 2009). However, many of these forms of death seem to be characteristic only 
for some very specific physiological processes and often the features by which they 
were typified overlap with each other and with those of apoptotic or necrotic death. 
The current state of knowledge of these processes is such that it is unclear whether 
any of them truly is a distinct type of cell death.  
1.2.1 Apoptosis 
Apoptosis is regarded as a genetically regulated, quiet suicidal form of death, serving 
to remove unwanted and damaged cells. The term apoptosis was first proposed by 
Kerr and colleagues in 1972. Cells undergoing apoptosis were defined by shrinkage 
of organelles and cytoplasm, fragmentation of the nucleus and release of their 
contents in the form of variously sized vesicles called apoptotic bodies (Kerr et al. 
1972). Later, this list has been expanded to include DNA fragmentation or exposure 
of the membrane lipid phosphatidylcholine (PS) to the outer leaflet of the plasma 
membrane (Kroemer et al. 2009).  
Insight into the molecular mechanism of apoptosis was made by studies on genetic 
regulation of programmed cell death in Ceanorhabditis elegans. Three main genes – 
ced-3, ced-4 and ced-9 have been shown to regulate this process in nematodes (Yuan 
& Horvitz 2004). Identification of human homologues of these genes has allowed for 
identification of the key mediators of mammalian apoptosis. The caspase family of 
proteases has been shown to be homologous to ced-3, apoptosome-forming protein 
Apaf-1 to ced-4 and anti-apoptotic members of the Bcl-2 family to ced-9 (Degterev 
et al. 2003; Yuan & Horvitz 2004). Subsequent studies have revealed the enormous 
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complexity of the various interplaying mechanisms that drive the process of death by 
apoptosis. The key mechanisms will be introduced below. It should be mentioned 
however, that in the numerous studies on the molecular mechanisms of apoptotic 
death, several additional players have been described and huge variation observed as 
to which proteins and mechanisms operate in different cell types and under various 
death-inducing stimuli.  
 At the very centre of all apoptotic mechanisms lies the activity of caspases. 
Normally present in cells as inactive pro-enzymes, they become activated under 
death stimuli and regulate and execute the demise process (Taylor et al. 2008). Two 
major canonical apoptosis-inducing pathways that lead to caspase activation have 
been characterised. The extrinsic, “death receptor pathway” is responsible for 
transmitting death signals (for example, TNFα, FasL or TRAIL) from the cell 
environment. The signalling is mediated through the death receptors (e.g. TNFR1 
and 2, Fas, TRAIL-R). Upon binding with their substrates, these death domain-
containing receptors multimerise and, together with many adaptor proteins (FADD, 
TRADD, DAXX, RIP, RAIDD and FLIP) and multiple molecules of caspase-8 
(and/or caspase-10), form death inducing signalling complex (DISC). DISC-
formation results in caspase-8 (10) molecule interactions and their autoproteolytic 
activation, which in turn can activate executioner caspases -3, -6 and -7 (Kischkel et 
al. 2001; Sprick et al. 2002; Degterev et al. 2003). 
Another apoptosis-inducing pathway, “the mitochondrial pathway” is the cell 
response to intracellular signals like DNA damage, reactive oxygen species or 
cytotoxic drugs. These signals are transduced by various pro-apoptotic BH3-only 
proteins (Bad, Bid, Bik, Bim, HRK, NOXA or PUMA) which promote the release of 
cytochrome c from the mitochondrial intermembrane space. BH3-only proteins 
enable oligomerisation of Bcl-2 family members Bak and Bax and thus, formation of 
pores in the outer mitochondrial membrane through which cytochrome c can be 
released to the cytosol (Taylor et al. 2008). The process of Bak and Bax 
oligomerisation has been found to be an important regulatory point. The interaction 
of anti-apoptotic members of Bcl-2 family (Bcl-2 itself as well as Bcl-XL, Bcl2A1, 
Bcl-B, Bcl-W or Mcl-1) with BH3-only proteins may result in the blockade of 
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Bak/Bax oligomerisation and so, cytochrome c release form mitochondria (Danial & 
Korsmeyer 2004; Lomonosova & Chinnadurai 2008).  
The release of cytochrome c drives the formation of the apoptosome – complex 
formed by oligomerised Apaf-1 (apoptotic protease activating factor-1) and  
caspase-9. Caspase-9 interactions with Apaf-1 result in its activation. Like active 
caspase-8, activated caspase-9 mediates cleavage of effector caspases -3, -6 and -7 
(Bao & Shi 2007).  
It is noteworthy that, under certain circumstances, during activity of the extrinsic 
pathway of apoptosis, active caspase-8 may amplify apoptotic signals by cleaving 
BH3-only protein Bid and consequently, activating the mitochondrial pathway 
(Degterev et al. 2003; Taylor et al. 2008). In addition, Bid has been identified as a 
substrate of other caspases as well as of calpains or cathepsins and so, shown to be an 
important mediator coupling mitochondrial death signalling with various death 
stimuli (Billen et al. 2008).    
One of less common apoptotic pathways is dependent on granzyme B. This serine 
protease can be released from NK cells or cytotoxic T cells and directly activate 
apoptosis in target cells by cleaving effector caspases or Bid (Sutton et al. 2000). 
Activated executioner caspases mediate cellular breakdown selectively cleaving a 
vast number of their specific substrates. These processes eventually lead to the 
development of the morphology that was described by Kerr et al. (Kerr et al. 1972; 
Taylor et al. 2008).    
1.2.2 Necrosis  
From the morphological perspective, necrotic death is discriminated by the swelling 
of cytoplasm and organelles as well as by the rupture of lysosomes, early disruption 
of plasma membrane integrity and leakage of the cell content, which can potentially 
induce inflammatory reactions and damage of the surrounding cells (Kroemer et al. 
2009). While necrosis progression is independent of caspase activation, in many 
instances calpains and cathepsins, which become activated as a consequence of 
increase of intracellular Ca2+ concentration, may be required for mediating necrosis 
progression (Golstein & Kroemer 2007). A decrease in the level of cellular ATP and 
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overproduction of reactive oxygen species (ROS) are also observed in cells dying by 
necrosis (Festjens et al. 2006; Kroemer et al. 2009).  
Necrosis was originally proposed to be a cellular reaction to irreversible injuries of 
various origins and was seen as an uncontrolled process. However, substantial 
evidence has emerged demonstrating that at least part of cell death with 
morphological features of necrosis is in fact governed by tightly regulated 
mechanisms.  
This programmed necrosis (sometimes also called necroptosis) may, like apoptosis, 
be induced via death domain receptors (Fas, TNFR1, TRAIL-R). This mechanism 
has been shown to be in operation particularly in the apoptosis-incompetent cells i.e. 
having defects in apoptosis activation pathways or under treatment with Z-VAD-
FMK (e.g. Vercammen et al. 1998; Holler et al. 2000; Denecker et al. 2001). 
Although both necrosis and apoptosis can be induced by signalling through the death 
domain receptors, unlike in apoptosis, in necrosis this does not result in the 
involvement of Bcl-2 family members or in cytochrome c release from mitochondria 
(Degterev et al. 2005). Death domain receptor-interacting kinase RIP1 has been 
found to play a central role in directing cells to the necrosis pathway after signalling 
through the death domain receptors (Holler et al. 2000; Kalai et al. 2002; Degterev et 
al. 2008). Specific RIP1 inhibitors – necrostatins, have been shown to inhibit the 
progression of necrotic death, or even redirect cells to the apoptotic death pathway 
(Degterev et al. 2005; Degterev et al. 2008; Han et al. 2009). Also RIP1-regulating 
kinase RIP3 is believed to play a central role in regulating cell reaction to TNF death 
stimulus and promoting necrosis (Cho et al. 2009; Declercq et al. 2009; Zhang et al. 
2009; Christofferson & Yuan 2010). 
Interestingly, induction of necrosis has also been observed after stimulation of Toll-
like receptors 3 and 4, treatment with Clostridium α-toxin or as a consequence of 
viral infection (Festjens et al. 2006; Cho et al. 2009; Kennedy et al. 2009).        
Programmed necrosis is recently gaining recognition for its role in various clinical 
conditions. It has been reported to contribute to ischemia reperfusion injury or 
progression of various neurodegenerative disorders (Degterev et al. 2005; Festjens et 
al. 2006; Rosenbaum et al. 2010).  
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1.2.3 Proteases in cell death  
Proteases are the major players in the induction phase of cell death, in the regulation 
of the process and in the effector phase, when the cell content is being broken down 
and life processes stopped. Although caspases are postulated to be in the centre of 
these events, other families of proteases, particularly calpains and cathepsins, appear 
to also be involved and in some systems can in fact drive apoptosis in the absence of 
caspases (e.g. Fettucciari et al. 2006). The latter two families, unlike caspases, seem 
to be particularly prominent during necrotic death (Golstein & Kroemer 2007). 
Additionally, other, less characterised serine proteases, like Omi (HtrA2), AP24 or 
granzymes A and B have been found to contribute to cell death progression (Garrido 
& Kroemer 2004; Vandenabeele et al. 2005; O'Connell & Stenson-Cox 2007).      
1.2.3.1 Caspases 
Caspases are a family of evolutionary highly conserved cysteine-dependent 
aspartate-directed proteases. They are known to specifically cleave their substrates 
after an aspartic acid (Asp; D) residue. The specificity for an Asp residue appears to 
be up to four orders of magnitude higher than for a glutamic acid (Glu; E) residue 
(Timmer & Salvesen 2007). The initial studies on caspase specificity resulted in 
identification of the canonical caspase-3 cleavage motif: P4 –DXXD-P1, with X being 
any amino acid (Talanian et al. 1997). However, more recently it has been 
appreciated that other surrounding amino acids, like one in the position P1’ are as 
important in the recognition of the target protein (Timmer & Salvesen 2007). The 
importance of distant recognition sites – exosites, is now hypothesised (Timmer & 
Salvesen 2007). In fact, a growing number of caspase-3 substrates have been 
reported to be cleaved in the non-canonical sites (Nicholson 1999; Fischer et al. 
2003). This might support the possibility that the exosites play an important role in 
the recognition process. Equally, the position of, perhaps less specific, cleavage 
motifs on the solvent-exposed parts of protein, where they can be more easily 
accessed by the proteases might be responsible for the observed discrepancy 
(Timmer & Salvesen 2007; Pop & Salvesen 2009).  
The differences in the substrate specificity between different members of the caspase 
family have been shown to depend, at least partly, on the composition of amino acids 
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adjacent to the scissile bond (Thornberry et al. 1997). However, the degree of 
overlap in specificity, especially in the in vitro studies, seems to be high. Caspase-3 
is generally considered to be the most potent of all the caspases, being likely to win 
the competition with other family members over the shared substrates (McStay et al. 
2007; Walsh et al. 2008).    
The human family consists of twelve members, which can be divided into groups 
based on their chemical structure. Caspases -2, 8, 9, 10 have long N-terminal 
prodomains. In case of caspase -8 and -10 these are two death effector domains 
(DED). Caspases -2 and -9 contain caspase recruitment domains (CARDs). The 
prodomains are indispensable for the recruitment of these proteins to apoptosis 
activation complexes (apoptosome, DISC) and their subsequent activation. 
Conversely, caspases -3, 6, 7 and -14 do not contain prodomains and require 
proteolytic cleavage for their activation (Kumar 2007; Taylor et al. 2008).   
Caspases -8, 9, 10 (and to a lesser extent -2) are involved in the initiation phase of 
apoptosis. Once proteolytically active, they amplify apoptotic signal by directing the 
proteolysis of effector caspase (-3, 6, 7) zymogens (Kumar 2007).  
Cleavage of the specific substrates by executioner caspases may have a dual effect; 
the target protein may become either inactivated or deactivated (Timmer & Salvesen 
2007). The list of substrates that were identified as being processed during the 
effector phase of apoptosis contains several hundreds of proteins and is growing 
rapidly thanks to the application of high-throughput analysis methods (Luthi & 
Martin 2007; Dix et al. 2008; Mahrus et al. 2008). Most apoptotic caspase substrates 
have been shown to belong to a few main pathways or functional groups, for 
example regulating transcription, cell adhesion, those responsible for DNA repair or 
anti-apoptotic or cytoskeletal proteins (Fischer et al. 2003; Mahrus et al. 2008).   
Although mediation of apoptosis is the best-recognised function of caspases, they are 
also known to serve other functions. Caspases -1, 4, 5, 11, 12 and -14 are associated 
mainly with non-apoptotic functions. However, caspase -3, 8, 9 and 10 have also 
been reported to operate in non-apoptotic conditions (Lamkanfi et al. 2007; 
Chowdhury et al. 2008). The best recognised out of these non-apoptotic caspase roles 
are the maturation of pro-inflammatory cytokines, activation of NF-κB and the 
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regulation of cell cycle and differentiation (Lamkanfi et al. 2007; Chowdhury et al. 
2008). 
  As caspases have a critical role in deciding on cell fate, their activity has to be 
closely regulated. Unsurprisingly, several cellular caspase inhibitors have been 
identified. CrmA (cytokine response modifier A), one of the best characterised 
inhibitors, has been found to inhibit caspases -8 and -10 as well as caspase-1. It has 
been reported to successfully block the induction of apoptosis via death receptors. 
Additionally, it is capable of inhibiting apoptosis resulting from forced 
overexpression of caspase-1 in vitro. Furthermore, XIAP, a member of the IAP 
(inhibitors of apoptosis) family, using its different domains, can block the activity of 
both caspases -3, 7 and caspase-9. Another well-characterised cellular inhibitor of 
caspases, FLIP, contains death effector domains (DEDs) and can competitively bind 
to FEDD, therefore, inhibiting caspase-8 association with DISC and activation.  It is 
noteworthy that, most of the described inhibitors were first identified when viral 
mechanisms of inhibiting host cell apoptosis were studied (Callus & Vaux 2007; 
Kumar 2007; Pop & Salvesen 2009).  
1.2.3.2 Calpains  
A family of calcium-dependent cysteine proteases – the calpains consists of two 
ubiquitous and fairly well characterised major isozymes (calpain I and II or µ and m, 
respectively) and several less-described tissue-specific forms (n-caspases). The 
ubiquitous forms of calpain are heterodimers consisting of a common small (28 kDa) 
subunit and different large (80 kDa) subunits. They differ as to the Ca2+ 
concentrations required for their activity. Whilst for calpain I low-millimolar 
concentrations were sufficient, calpain 2 needed almost micromolar Ca2+ 
concentrations in vitro. In the event of Ca2+ influx, calpains undergo autoproteolytic 
cleavage. This is known to be a two-step process, in the case of calpain I initially 
leading to generation of a 78 kDa (79 kDa for calpain II) fragment of the large 
subunit and in the next stage, the 78 kDa-sized subunit is turned into a 76 kDa one 
(78 kDa for calpain II) (Zimmerman & Schlaepfer 1991; Brown & Crawford 1993). 
The small subunit is processed in three steps from 28 kDa to 18 kDa (McClelland 
1989). Autoproteolysis has initially been shown to reduce the Ca2+ concentration 
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required for calpain activity (Zimmerman & Schlaepfer 1991; Brown & Crawford 
1993; Li et al. 2004) . However, the true role of these autolytic steps remain a source 
of the controversy, as several studies have shown that even the 80 kDa unprocessed 
large subunit may be proteolytically active (Johnson & Guttmann 1997; Li et al. 
2004).     
In addition to Ca2+ concentration, calpain activity can be regulated by a ubiquitous, 
specific, cellular inhibitor of calpains – calpastatin (Wendt et al. 2004; Melloni et al. 
2006). The initial studies on the two proteins interactions indicated that calpastatin 
can bind calpain (and so, inhibit its action) when Ca2+ levels are elevated (Barnoy et 
al. 1999). The results presented more recently by Melloni et al. have indicated that 
this interaction can take place also at physiological Ca2+ levels (Melloni et al. 2006). 
Additionally, calpain activity has been found to be modulated by local redox 
conditions (Guttmann & Johnson 1998) or by specific phosphorylation (either of 
calpain itself or of the substrate) (Shiraha et al. 2002; Smith et al. 2003; Chen et al. 
2010).  
Calpains hydrolyse their substrates at a limited number of sites and it is believed that 
the cleavage serves to modify the substrate function rather than to cause its 
degradation (Chan & Mattson 1999; Goll et al. 2003). Given that calpain selectivity 
seems to be so tightly regulated, it would be expected that these proteases have a 
high requirement for a specific cleavage motif. Perhaps surprisingly, no consensus 
cleavage sequence has been found (Tompa et al. 2004; Cuerrier et al. 2005). Amino 
acid preferences seemed to be only partly responsible for substrate recognition and it 
has therefore been suggested that the primary structural characteristic of the scissile 
bond-adjacent area might be involved in the recognition (Tompa et al. 2004; Cuerrier 
et al. 2005). Calpain cleavage sites have been found to be more likely situated in the 
unstructured regions of their target proteins (Tompa et al. 2004).  
Calpains have a well-recognised role in necrosis. Under some types of death 
stimulus, they appeared to be essential for the death process to take place (Golstein & 
Kroemer 2007). It is the Ca2+ overload, often observed in cells that have suffered an 
insult, that is believed to drive calpain overactivation and consequently, cellular 
demolition (Goll et al. 2003). During this process cytoskeletal (e.g. actin-binding 
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proteins), membrane (ion transporters, growth factor receptors, adhesion molecules) 
or signalling (various kinases, phosphatases, and transcription factors) proteins are 
targeted by calpains (Rami 2003). Furthermore, after the calpain-mediated 
permeabilisation of the lysosomal membrane, the cathepsins are released into the 
cytosol and contribute to cell breakdown (Yamashima 2000). Although the 
mechanism has not yet been clarified, calpains are also considered responsible for the 
early plasma membrane rupture observed in necrotic cells (Liu et al. 2004). This type 
of calpain activity is implicated in various pathologies, including acute processes like 
ischemic injury or chronic disorders, like Alzheimer’s, Huntington’s and Parkinson’s 
diseases (Rami 2003).  
Although calpain activity has mainly been associated with necrotic death, it plays an 
important role in various mechanisms involved in apoptosis. Amongst many others, 
calpain inhibitors have been found to block T cell apoptosis triggered by anti-CD3 
antibodies (Rami 2003). Calpain involvement in apoptotic processes seems to be 
finely regulated. It has been demonstrated that caspases can have a role in activating 
calpains e.g. calpastatin is known to be hydrolysed not only by calpains but also by 
caspases during apoptosis (Wang et al. 1998; De Tullio et al. 2000; Shi et al. 2000). 
In fact, calpain-caspase crosstalk is even more complex, as, under some death 
conditions, calpain has been reported to activate caspases (Ruiz-Vela et al. 1999; 
Blomgren et al. 2001; Altznauer et al. 2004). On the other hand, it can cause caspase 
degradation and inactivation (Chua et al. 2000). Like caspases, calpains can regulate 
the process of apoptosis by directly modulating both pro-apoptotic: Bid, Bax (Chen 
et al. 2001; Cao et al. 2003) and anti-apoptotic: Bcl-2, Bcl-XL (Nakagawa & Yuan 
2000; Gil-Parrado et al. 2002) members of Bcl-2 family.  
Remarkably, a considerable number of proteins that can be cleaved by both caspases 
and calpains have been identified (Chan & Mattson 1999; Wang 2000; Liu et al. 
2006), suggesting that these enzymes can have complementary functions. Among 
these substrates, many cytoskeletal, plasma membrane and signal-transducing 
proteins have been found. Even more interestingly, during experimental transient 
brain injury, where both the proteases are activated, they have been shown to cleave 
their substrates simultaneously (Liu et al. 2006). In many of the dually cleaved 
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proteins, caspases- and calpain-driven cleavage leads to the production of similarly 
sized products (Wang 2000).  
1.2.3.3 Cathepsins  
Cathepsins are a heterogeneous group of lysosomal proteases, consisting of aspartic 
– cathepsins D, E; serine – A, G; and several cysteine proteases – cathepsins B, L, H, 
plus others (Conus & Simon 2008). Recent years have brought ample evidence for 
their role in various death-mediating mechanisms. The involvement of cathepsins in 
death progression starts when they become released from lysosomes into the cytosol 
as a result of lysosomal destabilisation or lysosomal membrane permeabilisation 
(LMP) (Stoka et al. 2007). This has been found to be caused by Fas, TNFα or TRAIL 
signalling (Deiss et al. 1996; Nagaraj et al. 2006; Nagaraj et al. 2007), oxidative 
stress (Roberg & Ollinger 1998), the direct action of Bax (through its insertion into 
lysosomal membrane) (Kågedal et al. 2005) as well as by several chemical 
lysosomotropic agents (Stoka et al. 2007; Conus & Simon 2008). The diversity of the 
factors and mechanisms inducing cathepsin release from lysosomes shows that they 
can be primary players in apoptosis induction (death signals – Fas, TNFα, TRAIL or 
oxidative stress) or may have a secondary role in cell death, perhaps being part of a 
death signal enhancing loop, when apoptosis was induced by other stimuli (Bax-
driven LMP). 
Once in the cytosol, cathepsins are believed to act mainly by mediating Bid cleavage 
and activating mitochondrial pathway of apoptosis (Stoka et al. 2001; Cirman et al. 
2004; Blomgran et al. 2007). More recent advances have revealed, however, that the 
role of cathepsins might be more complex than this, as most cysteine cathepsins have 
been found to be able to cleave anti-apoptotic members of Bcl-2 family – Bcl-2,  
Mcl-1, Bcl-XL and even more interestingly, cellular caspase inhibitor – XIAP 
(Droga-Mazovec et al. 2008).  
In addition to being active in apoptosis, cathepsins have an important function during 
necrotic cell death. In fact, they seem to be indispensable for some forms of necrosis 
to take place (Golstein & Kroemer 2007). The extent of the lysosomal damage 
induced by a death trigger seems to regulate whether apoptotic (after moderate 
damage) or necrotic (after serious damage) death mechanisms will be switched on 
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(Li et al. 2000). For example, in the necrotic insults where intracellular Ca2+ levels 
are significantly increased, activated caspases can mediate lysosomal disruption and 
subsequent cathepsin release (Yamashima 2000). In addition, recent evidence 
suggests that cathepsin Q is a direct product of p53 and that DNA damage triggers 
p53-dependent activation of this cathepsin, which in turn (together with ROS) is 
responsible for mediating necrosis (Tu et al. 2009). 
1.2.4 Clearance of dying and dead cells  
Dying cells are known to produce signals that allow for their recognition and 
removal. Moreover, the way in which a dying cell interacts with the cell that engulfs 
it is thought to modulate the immune response (Savill & Fadok 2000).  
1.2.4.1 Clearance of apoptotic cells 
Signals mediating apoptotic cell recognition and engulfment 
The mechanisms involved in the clearance of cells dying by apoptosis have been 
studied extensively and numerous molecules, which take part in the process of 
recognition and engulfment of these cells, have been identified.  
Thus far, the rearrangement of the plasma membrane phospholipids and translocation 
of phosphatidylcholine (PS) to the outer leaflet of the membrane appears to be the 
best characterised event that is responsible for labelling of apoptotic cells for 
phagocytic uptake (“eat me” signal) (Fadok et al. 1992; Ravichandran & Lorenz 
2007). PS translocation takes place in the early stage of the apoptotic process and it 
has been thought to be a caspase-dependent phenomenon (Martin et al. 1996; Fadok 
et al. 2001), however, some later studies have demonstrated that in cells deficient in 
caspase-3, PS has also been externalised during apoptosis and cell clearance seemed 
unimpaired (Fadok et al. 1998; Zheng et al. 1998; Turner et al. 2003).  
Various molecules have been shown to participate in phagocyte detection of PS on 
the surface of apoptotic cells. Among them, several soluble “bridging” molecules 
have been found to be involved in PS binding. PS-associated milk fat globule protein 
MFG-E8 mediates apoptotic cell recognition through binding to αvβ3(5) integrins 
(Hanayama et al. 2002). In a similar manner, Gas6 (growth arrest-specific 6) 
molecule can indirectly contribute to PS detection by binding to receptor tyrosine 
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kinase MER on the phagocytic cell (Nagata et al. 1996; Nakano et al. 1997) and 
complement component C1q can act through binding to CD91/calreticulin or, 
possibly, CD93 on the phagocyte membrane (Ogden et al. 2001; Vandivier et al. 
2002; Norsworthy et al. 2004; Gardai et al. 2005; Païdassi et al. 2008). Protein S has 
also been found to be bound to PS on apoptotic cells and to have a role in ingestion 
of these cells (Anderson et al. 2003). Furthermore, macrophage scavenger receptor 
CD36 mediates phagocyte recognition of PS on the apoptotic cells. This may require 
the formation of a complex with thrombospondin/ αvβ3 integrin (Savill et al. 1992) or 
might take place directly (Tait & Smith 1999; Greenberg et al. 2006). Huge progress 
has been made in recent years in identifying direct receptors for PS. Tim4, BAI1 and 
stabilin-2 were found to be capable of directly binding PS (Miyanishi et al. 2007; 
Park et al. 2007; Park et al. 2008). While downstream signalling leading to 
phagocytosis has been well characterised for BAIl and stabilin-2, the capability of 
Tim4 to signal directly has recently been questioned (Park et al. 2009).   
Although PS appears to be in the centre of all signalling events leading to the 
apoptotic cell clearance, it has been demonstrated that PS exposure alone is not 
sufficient for apoptotic cell uptake to take place (Devitt et al. 2003). In addition to 
PS, other molecular interactions are implicated. Phagocyte scavenger receptors SR-
A, LOX-1 and CD36 interaction with their common ligand - oxidised low-density 
lipoprotein (OX-LDL) on the surface of apoptotic cells is known to play a role in the  
phagocytosis of the apoptotic cells (Endemann et al. 1993; Platt et al. 1996; Oka et 
al. 1998; Chang et al. 1999). An important role in apoptotic corpse disposal has also 
been described for the pattern recognition receptor CD14 (Devitt et al. 1998).  
ICAM-3, which expression on the plasma membrane has been found to be altered in 
apoptotic cells, might serve as the CD14 substrate (Moffatt et al. 1999). Moreover, 
exposure of calreticulin on the surface of the dying cell and its subsequent binding to 
the scavenger receptor CD91 on the phagocyte, participate in dead cell uptake 
(Ogden et al. 2001; Gardai et al. 2005). Two members of the collectin family, C1q 
and mannose-binging lectin (MBL), which bind to the surface of dying cells and can 
mediate signalling via calreticulin/CD91, have also been shown to have an important 
role in the process of dead cell ingestion (Ogden et al. 2001; Stuart et al. 2005; 
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Païdassi et al. 2008) . Finally, annexin 1, like PS, has been found to translocate to the 
surface of apoptotic cells and to mediate their ingestion (Arur et al. 2003).                                        
In addition to the positive “eat me” signals described above, the negative regulation 
of some signals (“don’t eat me”) displayed by target cells are as important for 
binding and phagocytosis of apoptotic cell corpses. Surface molecule CD31, which 
has a role in leukocyte detachment from phagocytes, has also been shown to become 
disabled in apoptotic cells, therefore allowing for apoptotic cell binding and 
subsequent engulfment by a phagocyte (Brown et al. 2002). In a similar manner, 
CD47 (on target cells) interaction with SIRPα (on phagocytes) is disrupted as a 
consequence of apoptosis due to the altered CD47 expression on the dying cells. 
Under normal circumstances CD47-SIRPα cooperation is known to prevent cell 
uptake by phagocytes (Oldenborg 2000; Oldenborg et al. 2001; Gardai et al. 2005) 
and the interruption to this signalling has been demonstrated to enable calreticulin-
CD91-mediated phagocytosis (Gardai et al. 2005).       
“Find me” signals 
Although in the majority of cases apoptotic cells are engulfed by their neighbours, 
when death occurs in high numbers, help from specialised phagocytic cells might be 
required (Kerr et al. 1972; Gregory & Devitt 2004). Molecules having chemotactic 
properties for phagocytes, so called “find me” signals, are therefore released from 
dying cells. Thus far, only a few chemoattractants that are released from apoptotic 
cells have been identified.  
Studies performed by Knies and colleagues have revealed that in murine embryos, 
elevated expression of the  inflammatory cytokine and chemoattractant for 
mononuclear phagocytes - EMAP II, was associated with  areas of intense apoptosis 
and substantial macrophage infiltration (Knies et al. 1998). The processing and 
release of mature EMAP II was initially demonstrated to be caspase-dependent and 
consecutive studies have implicated caspase-7 in this process (Knies et al. 1998; 
Behrensdorf et al. 2000). Interestingly, it has also been shown that EMAP II 
processing under hypoxic conditions was mediated by proteases other than caspase 
(Matschurat et al. 2003). Some studies, however, have questioned the capability of 
caspases to cleave pro-EMAP II (Zhang & Schwarz 2002; Liu & Schwarz 2006).  
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A role in attracting phagocytes to sites of apoptosis has also been attributed to the 
ribosomal protein S19 dimer (Horino et al. 1998). Horino et al. observed its release 
from heat-treated HL-60 cells and found it was responsible for macrophage 
migration to the site of injection of these cells in vivo. G protein-coupled receptor for 
C5a (CD88) is responsible for mediating S19-dependent migration of macrophages 
(Nishiura et al. 1998).  
In the course of further investigations, phospholipid lysophosphatidylcholine (LPC) 
has been shown to mediate the migration of THP-1 monocytic cells to UV-irradiated 
MCF-7 cells (Lauber et al. 2003). The release of this phospholipid is dependent on 
caspase-3-driven activation of phospholipase A2β (iPLA2β). LPC is known to 
mediate chemoattraction of mononuclear phagocytes also via G-protein coupled 
receptor, G2A (Yang et al. 2005; Peter et al. 2008).   
Later, another lipid factor, sphingosine-1-phosphate (S1P), was also shown to be 
released from Jurkat and U937 cells in an apoptosis-dependent manner to induce 
migration of mononuclear phagocytes (Gude et al. 2008).  
Finally, Elliott et al. reported that nucleotides ATP and UTP are released from 
apoptotic T cells to mediate chemotaxis of phagocytes. Here again, the liberation of 
chemotactic factor has been shown to be caspase inhibitor-sensitive (Elliott et al. 
2009).   
1.2.4.2 Clearance of necrotic cells 
The mechanisms of phagocyte recognition and uptake of cells undergoing necrosis 
remain far less characterised. Interestingly, necrotic cells have been shown, just like 
apoptotic cells, to externalise PS in response to death stimuli (Cocco & Ucker 2001; 
Krysko et al. 2004) and the exposed PS has been reported to contribute to the 
engulfment of necrotic cells (Cocco & Ucker 2001; Hirt & Leist 2003; Brouckaert et 
al. 2004; Böttcher et al. 2006) . However, while in the report from Hirt and Leist, PS 
appeared to be the main component responsible for necrotic cell phagocytosis, the 
studies by Cocco et al. and Bottcher et al. rather suggested that PS is only partly 
responsible for necrotic cell recognition and uptake (Cocco & Ucker 2001; Hirt & 
Leist 2003; Böttcher et al. 2006)  .  
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Some other molecules that have previously been implicated in apoptotic cell 
clearance are often found to be involved in recognition and phagocytosis of primary 
or secondary necrotic cells in addition to, or instead of their role in clearance of 
apoptotic cells. For instance, studies of Nauta and colleagues on mannose-binding 
lectin ability to bind to dying cells revealed that it had a preference for (secondarily) 
necrotic cells (Nauta et al. 2003). Similarly, components of the classical complement 
pathway, which were associated mainly with the engulfment of apoptotic cells 
(Ogden et al. 2001; Païdassi et al. 2008), have been shown in other studies to assist in 
the clearance of both primary and secondary necrotic cells (Gaipl et al. 2001); 
Gullstrand et al. 2009). Blume et al. have reported that annexin 1, previously found 
to be externalised on apoptotic cells (Arur et al. 2003), is associated mainly with 
secondary necrotic cells and is responsible for inhibition of the phagocyte pro-
inflammatory response (Blume et al. 2009). Likewise, C-reactive protein, apart from 
binding apoptotic cells (Gershov et al. 2000) can opsonise secondary necrotic cells 
(Hart et al. 2005). An effect of the latter protein binding on the rate of dying cell 
uptake by macrophages, however, has not been observed (Hart et al. 2005). Further, 
Rovere et al. have demonstrated that in addition to C-reactive protein, another 
pentraxtin - PTX3, could bind to both apoptotic and necrotic cells and that its binding 
could affect dying cell phagocytosis by dendritic cells (Rovere et al. 2000).    
Despite involvement in the clearance of apoptotic and necrotic cells of several 
common molecules, the two types of death have been shown to elicit different modes 
of uptake by macrophages. While during the internalisation process of cells dying by 
apoptosis formation of classical phagosome can be observed and cells are engulfed in 
a “zipper-like” mechanism (Krysko et al. 2006), necrotic cells have been shown to be 
uptaken using less efficient micropinocytic mechanism (Krysko et al. 2006). 
1.2.4.3 Immunological consequences of cell death  
Perhaps the most essential difference between the cells dying by apoptosis and 
necrosis occurs in the immunological consequences of their clearance. In most 
situations, cells dying by apoptosis are able to drive an anti-inflammatory response of 
phagocytes (Fadok et al. 1998) whereas necrotic cells in the majority of cases are 
known to elicit a release of pro-inflammatory factors from the phagocytic cells 
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(Festjens et al. 2006). However, under some conditions both apoptotic-mediated 
inflammatory reactions and a “quiet” death by necrosis have been observed (Gregory 
& Devitt 2004; Green et al. 2009).   
Evidence accumulated that apoptotic cell interactions with phagocytes can elicit an 
anti-inflammatory response. It was demonstrated that the presence of apoptotic cells 
led to the secretion of IL-10, TGFβ, PAF or PGE2 from mononuclear phagocytes 
(Voll et al. 1997; Fadok et al. 1998; Freire-de-Lima et al. 2000). Moreover, the anti-
inflammatory effects of apoptotic cells are strong enough to inhibit inflammatory 
cytokine release from LPS-treated phagocytes (Voll et al. 1997; Fadok et al. 1998). 
Further analysis has implicated PS and signalling through CD36 in this process (Voll 
et al. 1997; Huynh et al. 2002). In addition to these mechanisms, the secretion of 
anti-inflammatory agents has been shown to be a part of the process of apoptosis - 
IL-10, TGFβ and HO-1 release from the apoptising cells have been detected (Gao et 
al. 1998; Chen et al. 2001; Weis et al. 2009). 
Strikingly, despite the fact that antigens from these cells are presented in the context 
of MHC class I by immature dendritic cells (Albert et al. 1998), the immunological 
response is not triggered. The observation that following apoptotic cell ingestion 
immature dendritic cells could only present antigens to CD8+ T cells but not to CD4+ 
T cells (Griffith et al. 2007) helped to propose another mechanism partly responsible 
for apoptotic cell-mediated immunosuppression. It has been assumed that CD8+ T 
cells, which become activated in the absence of active CD4+ T cells and thus, lack of 
priming from CD4+ T cell-activated DCs, differentiate into “helpless” cytotoxic T 
lymphocytes (Green et al. 2009). These otherwise functional cells, upon re-encounter 
of the apoptotic cell-derived antigen could release the death molecule, TRAIL, 
causing death of other helpless CTLs and possibly active CD4+ T cells and therefore, 
induce tolerance (Griffith et al. 2007; Green et al. 2009).  
In case of necrotic cells, it is believed that the main process responsible for their 
immunogenicity is the rapid leakage of their contents, including molecules described 
as “danger signals” or DAMPs (danger-associated molecular patterns) (Festjens et al. 
2006; Kono & Rock 2008; Green et al. 2009). Several molecules have been 
implicated, among them high-mobility group box 1 protein (HMGB1), various heat 
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shock proteins, uric acid, S100 proteins, nucleosomes or ATP (Kono & Rock 2008). 
Being mostly ligands for various TLRs and scavenger receptors, these factors can 
very effectively induce inflammation and adaptive immune responses (Kono & Rock 
2008; Mosser & Edwards 2008). Most of these damage signals are not released form 
apoptotic cells until they lose plasma membrane integrity. Nevertheless, the 
existence of a protective mechanism, which neutralises the damage signals has been 
observed. Inhibition of HMGB1 activity is achieved by its oxidation. This caspase- 
and ROS-dependent process has been found indispensable for apoptotic cells 
induction of immunological tolerance (Kazama et al. 2008).          
1.2.5 Tumour-associated macrophages (TAMs) 
Macrophages are among the immune cells most commonly found in the tumour 
tissues (Solinas et al. 2009). Although under various danger stimuli they are known 
to produce pro-inflammatory factors and induce adaptive immunological responses, 
as resident cells tumour associated macrophages are mainly linked with the 
phenotype described as “M2-like”, “alternatively activated” or “regulatory” and anti-
inflammatory and pro-tumour actions (Mantovani et al. 2002). As a consequence, a 
high number of tumour infiltrating macrophages is often considered to be a poor 
prognostic sign (Qian & Pollard 2010).  
TAMs are postulated to derive predominantly from peripheral blood monocytes that 
were attracted to the tumour tissue (Mantovani et al. 2002). Several chemokines that 
are produced by cells from various tumours have been found to take part in this 
process; MCP-1 (CCL2) and CCL5 have been implicated in several types of 
neoplasms but CCL3, CCL4, CCL8, CXC18, CCL22 or CXCL8 are among others 
involved (Lamagna et al. 2006; Solinas et al. 2009; Mantovani & Sica 2010). Aside 
from chemokines, vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF) and colony stimulating factor-1 (CSF-1) were also found to be 
important (Mantovani et al. 2002; Solinas et al. 2009). Furthermore, various cleaved 
extracellular matrix components e.g. fibronectin or fibrinogen might serve as 
additional chemotactic stimuli (Solinas et al. 2009). A contribution from the factors 
secreted by dying or damaged tumour cells, for example EMAP II, has also been 
implied (Murdoch et al. 2004).      
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It is the cooperation of various tumour environment components that is believed to 
lead to macrophage acquisition of the “regulatory” and pro-tumour phenotype. Some 
tumour-secreted cytokines have been directly implicated. For instance, MCP-1, in 
addition to its role in macrophage attraction to the tumour site, has also been reported 
to mediate TAM survival and their shift towards “regulatory” phenotype (Roca et al. 
2009). Similarly, Burkitt’s lymphoma cells are known to release IL-10, which can 
directly mediate macrophage drift towards a “regulatory” phenotype (Stewart et al. 
1994; Ogden et al. 2005).    
Additionally, hypoxic conditions, which are common in many tumours, can 
markedly influence the pattern of genes expressed by TAMs. Increased production of 
IL-10 and PGE2 by macrophages in hypoxic areas has been detected (Biswas et al. 
2008). Moreover, induction of hypoxia-induced factor-1α (HIF-1α) and 
consequently, an increased expression of pro-angiogenic factors like VEGF, have 
also been observed (Murdoch et al. 2004; Biswas et al. 2008). HIF-1α upregulation 
in the tumour is commonly seen as a poor prognostic indicator for the anti-tumour 
treatment outcome (e.g. Theodoropoulos et al. 2004; Chai et al. 2008;).     
As it is a case with other macrophages, encounter of apoptotic cells by tumour 
macrophages should result in the induction of anti-inflammatory response. It has 
been demonstrated that apoptotic tumour cells were able to suppress a macrophage-
mediated anti-tumour response (Reiter et al. 1999). Subsequent studies by Weigert et 
al. have revealed that apoptotic tumour cell-derived sphingosine-1-phosphate 
mediates downregulation of macrophage production of TNFα and IL-12 as well as 
increasing production of IL-10 and IL-8 (Weigert et al. 2007).  
In an attempt to identify other tumour-derived factors that help to induce TAMs pro-
tumour properties, Kuang and colleagues have shown that hyaluronan produced by 
tumour cells can also be involved (Kuang et al. 2007). Their studies demonstrated 
that intermediate-sized fragments of hyaluronan can alter macrophage expression 
profiles, reduce the production of typical “classical activation”-associated molecules 
such as CD64, CD86, HLA-DR or TNFα and instead, stimulate the production of  
IL-10. In other models, similar effects on macrophage phenotype shift have been 
reported for IgG or released nucleotides (Mosser & Edwards 2008).        
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Altogether, the release of anti-inflammatory cytokines (IL-10, PGE2) and pro-
angiogenic factors has a profound impact on the tumour environment, suppressing 
anti-tumour immune responses as well as supporting development of the vasculature 
and consequently, improving nutrient supply to the tumour cells. However, TAMs’ 
effects on the tumour reach even further as they have been shown to secrete survival 
and proliferative agents too. Importantly in the context of this work, in BL, TAMs 
have been shown to release BAFF (B cell-activating factor of the TNF family), a 
survival factor for B lymphoma cells (Levens et al. 2000; Ogden et al. 2005). 
Moreover, in various tumours milieu TAMs have been shown to release proteolytic 
enzymes, particularly of the MMP family, which engage in extracellular matrix 
degradation and can contribute to basement membrane destruction, facilitating 
metastasis. MMPs, particularly MMP-9, activity have an equally important role in 
the process of neo-vascularisation (Mantovani et al. 2009; Qian & Pollard 2010).        
Finally, the environment-driven induction of macrophage chemoattractants (e.g. 
MCP-1, CCL5 or CXCL12) secretion by TAMs themselves can result in further 
magnification of the effect of TAMs on the tumour progression process (Solinas et 
al. 2009).    
1.3 Chemokines 
Chemokines are a group of small-molecular weight, chemoattractant cytokines. As of 
today, the human family consists of 46 chemokine members for which there are 19 
identified functional receptors (Zlotnik et al. 2006). Based on the position of the 
conserved cysteines in their amino acid sequence, chemokines are subdivided into 4 
groups: XC, CC, CXC, and CX3C. The largest subfamily, the CC group (CCL1 - 
CCL28), consists of proteins in which the first two of four cysteines are located next 
to each other. In the second biggest group, CXC (CXC1-CXC17), the first two 
cysteines are separated by one amino acid. Fractalkine (CX3CL1), the only protein 
of the CX3C group contains three amino acids between its cysteines whereas the 
only two members of XC subfamily have only two of the four cysteines (Zlotnik et 
al. 2006).  
 40 
Despite the sequence differences, most chemokines are similarly sized secreted 
proteins (60-125 amino acids; 8-15 kDa) with similar three-dimensional structure 
(Olson & Ley 2002; Onuffer & Horuk 2002). The exceptions are fractalkine 
(CX3CL1) and CXCL16, much bigger transmembrane proteins, in which the 
classically built chemokine fragment is located atop a long, mucin-like stalk (Ludwig 
& Weber 2007). 
Chemokine signalling is mediated via a seven-transmembrane subfamily of G-
protein coupled receptors (CCR1 - CCR10, CXCR1 - CXCR7, XCR1, and CX3CR1) 
(Zlotnik et al. 2006). In addition to the functional receptors involved in signal 
transduction, regulatory, non-signalling chemokine “interceptors” have been 
identified (D6, Duffy antigen, and possibly also CXCR7) (Graham 2009). Unusually, 
the network of chemokine ligand - receptor interactions is highly complex, with 
some ligands binding to more than one receptor and some of the receptors having 
several ligands (Gerard & Rollins 2001; Zlotnik et al. 2006).  
This elaborate system allows chemokines to tune a great number of physiological 
processes. Chemokine signalling has mainly been associated with regulating diverse 
aspects of leukocyte trafficking, including directing the migration of various subsets 
of cells at different stages of immunological responses as well as their development 
and maturation processes (Moser & Willimann 2004). However, chemokines also 
exert their effects on other types of cells and their function in angiogenesis (mainly 
CXC chemokines) or neuron-microglial interactions has been recognised (Harrison et 
al. 1998; Belperio et al. 2000). Not surprisingly therefore, dysregulated chemokine 
expression is a common feature of multiple pathologies, often significantly 
contributing to their development and progression (Gerard & Rollins 2001; Jin et al. 
2008).              
1.3.1 MCP-1   
MCP-1 (Monocyte chemoattractant protein-1; CCL2), a member of a CC chemokine 
subfamily, is one of the most abundantly expressed and so, studied, chemokines (Van 
Coillie et al. 1999). This 76 amino acid-long protein exists in several 8 – 15 kDa 
forms depending on the state of its glycosylation and the presence of the signalling 
sequence (Ishii et al. 1995; Proost et al. 1998).  
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Secretion of MCP-1, either constitutive or upon certain stimulation, is a common 
feature of numerous types of cells. It was reported for instance by mononuclear, 
epithelial and endothelial cells, fibroblasts, smooth muscle cells, chondrocytes, 
microglia or eosinophils (Van Coillie et al. 1999). In addition, various neoplastic 
cells have been found to release this chemokine (Mantovani et al. 2002). 
To exert its function MCP-1 binds to the CCR2 receptor. The best-characterised role 
of MCP-1 is to induce chemotaxis of cells carrying CCR2 in the direction of higher 
concentrations of MCP-1, allowing them to transmigrate from the blood stream to the 
tissues. This chemokine is mainly seen as a strong chemoattractant for mononuclear 
phagocytes but it can also act on T cells, B cells and natural killer cells (Allavena et 
al. 1994; Qin et al. 1996; Corcione et al. 2002). The effect of MCP-1 on the 
migratory properties of neutrophils is, however, very weak (Rollins et al. 1991). On 
top of its ability to regulate trafficking of leukocytes, MCP-1 has also been found to 
induce chemotaxis of endothelial cells, vascular smooth muscle cells, neuronal 
progenitors and hepatic stellate cells (Marra et al. 1999; Widera et al. 2004; Arefieva 
et al. 2005; Ma et al. 2007). 
Although the mediation of chemotaxis is perhaps the most important function of 
MCP-1, other direct effects on its target cells have been described. In monocytes, 
upon MCP-1 binding an increase in the intracellular Ca2+ level and respiratory burst 
have been observed (Rollins et al. 1991). In addition, Jiang and colleagues have 
demonstrated that MCP-1 binding affects cytokine and adhesion molecule expression 
pattern in monocytes (Jiang et al. 1992). Moreover, an increase in NK and T cell 
cytotoxicity might be a result of MCP-1 signalling (Taub et al. 1996). MCP-1-driven 
proliferation of vascular smooth muscle cells has been reported by Seltzman et al. 
whereas Roca with co-workers have provided evidence for its role in promoting 
monocyte survival and mediating their differentiation towards M2-like phenotype 
(Selzman et al. 2002; Roca et al. 2009).   
An increased MCP-1 expression is characteristic for many disorders, in particular 
inflammatory conditions like atherosclerosis, rheumatoid arthritis or Crohn’s disease 
(Van Coillie et al. 1999; Deshmane et al. 2009). Moreover, MCP-1 is believed to be 
an important player in the process of tumourigenesis. It is one of the most abundantly 
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expressed chemokines in tumours (Mantovani et al. 2002). Tumour cell-derived 
MCP-1 is believed to substantially contribute to macrophage infiltration. In fact, a 
correlation has been observed between the amount of MCP-1 produced by the 
tumour and the number of TAMs (Zhang et al. 1997; Nesbit et al. 2001; Murdoch et 
al. 2004). As was discussed above, MCP-1 can support the malignant progression by 
stimulating angiogenesis, for example by driving the chemoattraction and 
proliferation of vascular smooth muscle cells (Salcedo et al. 2000; Selzman et al. 
2002; Ma et al. 2007). Pro-tumour effects of MCP-1 can also be achieved through its 
contribution to survival and M2-like-polarisation of tumour macrophages (Roca et al. 
2009).     
1.3.2 Fractalkine (CX3CL1) 
1.3.2.1 Structure and functions of fractalkine 
Fractalkine (FKN) the only chemokine in the CX3C group, is distinct from most 
other chemokines by its complex structure and plasma membrane exposure. The 
conserved chemokine fragment (76 amino acid-long) is placed at the NH2-terminal 
end of the protein and makes up less than one third of its size (Bazan et al. 1997). A 
highly glycosylated mucin-like stalk constitutes the biggest central part of the 
chemokine while a transmembrane domain and intracellular tail are located at the 
COOH-end of the protein (Bazan et al. 1997) (Figure 1.1).  
Fractalkine is expressed by many cell types, including neurons, epithelial and 
endothelial cells, mature dendritic cells, smooth muscle and vascular smooth muscle 
cells as well as B and non-B lymphocytes (Harrison et al. 1998; Harrison et al. 1999; 
Papadopoulos et al. 1999; Lucas et al. 2001;Ludwig et al. 2002; Truman et al. 2008). 
CX3CR1, the only identified receptor for FKN, has been detected on microglia, other 
mononuclear phagocytes, neuronal cells, dendritic cells, NK cells, subsets of T cells, 
platelets and smooth muscle cells (Imai et al. 1997; Combadiere et al. 1998; 














Figure 1.1 Schematic picture of fractalkine 
Mechanism of fractalkine-mediated cell adhesion 
The structural complexity of FKN is reflected in the complexity of its functions and 
their regulation. Surface exposed FKN’s interaction with CX3CR1 may result in a 
firm adhesion of receptor-carrying cells (Imai et al. 1997). In order to perform a 
classical chemokine role in directing chemotaxis FKN needs to be liberated from the 
surface by proteolytic cleavage (Imai et al. 1997). Interestingly, FKN/CX3CR1-
mediated adhesion, unlike FKN/CX3CR1-driven chemotaxis, seems to be 
independent of further receptor signalling that involves G-protein activation (Imai et 
al. 1997). This has been observed both in studies where pertussis toxin was used to 
uncouple the receptor from G proteins and in experiments involving mutated non-
signalling forms of CX3CR1 (Fong et al. 1998; Haskell et al. 1999). In some studies, 
however, FKN/CX3CR1 binding was able to induce Ca2+ flux in the adherent cells 
but the response was weaker than that stimulated by the soluble form of FKN 
(Harrison et al. 1998). An interaction between NK cells and the membrane-anchored 
FKN seems to be an exception for this rule as it is known to mediate NK cell 
activation (Robinson et al. 2003; Yoneda et al. 2003).  
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It has been demonstrated that it is the FKN chemokine domain that is responsible for 
adhesion. No difference in the binding efficacy has been observed in studies with 
proteins in which the FKN chemokine domain was placed on top of other protein 
stalks (Fong et al. 2000). Nevertheless, exposure of the chemokine domain on the 
long projection has been found to be indispensable, as the immobilised chemokine 
domain by itself was much less efficient than full length FKN in mediating capture 
and adhesion of cells under flow (Fong et al. 2000). More recent analysis revealed 
that for effective adhesion surface-exposed FKN has to form aggregates (Hermand et 
al. 2008). However, Haskell and colleagues who analysed the affinity with which 
chimeric proteins compromised of various chemokines fused to the FKN mucin-like 
stalk, mediated adhesion have observed that FKN chemokine domain was the most 
efficient (Haskell et al. 2000). This led to the conclusion that this is not only the 
exposure on the mucin stalk but also the special type of FKN chemokine 
domain/CX3CR1 interaction that is important for the strength of FKN-dependent 
adhesion (Haskell et al. 2000).    
The 95-100 kDa-sized (Bazan et al. 1997; Garton et al. 2001) membrane-anchored 
FKN is known be cleaved and shed. This process, mediated by two proteases from 
the ADAM family – ADAM-10 and ADAM-17, is believed to regulate  
FKN-dependent adhesiveness (Garton et al. 2001; Tsou et al. 2001; Hundhausen et 
al. 2003; Hundhausen et al. 2007). ADAM-10 has been found responsible for the 
constitutive shedding of FKN, while ADAM-17 activity, is observed after cell 
stimulation, for example with PMA (Garton et al. 2001; Tsou et al. 2001; 
Hundhausen et al. 2003) . Proteolysis, which generates a 90-95 kDa fragment of 
FKN, is known to take place in a membrane-proximal area of the chemokine within 
the last 45 amino acids of the mucin stalk (Garton et al. 2001; Hundhausen et al. 
2007).  
Evidence has accumulated that regulation of FKN-driven cell-cell adhesion can also 
be mediated through its internalisation. Liu et al. found that FKN is in constant 
movement between the plasma membrane and a poorly characterised endocytic 
compartment (Liu et al. 2005). A recent report from the same group has shown that 
the process of internalisation is clathrin/dynamin-dependent (Huang et al. 2009). 
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Furthermore, the critical role of the FKN C-terminus in this process has been 
demonstrated (Andrzejewski et al. 2010).    
Generation and functions of soluble fractalkine 
FKN proteolysis can also be mediated by proteases other than ADAM-10 and 
ADAM-17. Cathepsin S has been found to be involved in the process of release of an  
as yet unidentified fragment of FKN from the neuronal cells under neuropathic 
conditions (Clark et al. 2009). Additionally, MMP-2 has also been implicated (Dean 
& Overall 2007; Bourd-Boittin et al. 2009). Dean and Overall identified FKN as a 
potential MMP-2 substrate using a degradomic approach and have provided 
confirmation that MMP-2 is capable of cleaving FKN. The potential cleavage site for 
MMP-2 is situated at the boundary between the FKN chemokine domain and its 
mucin stalk (Dean & Overall 2007). This would be expected to give rise to a FKN 
fragment within the size-range of other small secreted chemokines (i.e. 8-15 kDa). 
However, the existence of such a small N-terminal fragment of FKN has never been 
confirmed in either in vivo or ex vivo studies. 
Various scientific publications have reported on the chemoattractant properties of 
soluble FKN for mononuclear phagocytes, NK cells, T cells, microglia and smooth 
muscle cells (e.g. Bazan et al. 1997; Imai et al. 1997; Lucas et al. 2003). However, 
substantial discrepancies exist between different studies on the ability of soluble 
FKN to attract mononuclear phagocytes. While in some of these studies FKN was 
found to attract these cells very effectively (e.g. Bazan et al. 1997; Harrison et al. 
1998; Chapman et al. 2000; Lucas et al. 2003), in others the FKN effect appeared to 
be rather poor: ( Imai et al. 1997; Pan et al. 1997; Umehara et al. 2001; Ludwig et al. 
2002; Vitale et al. 2004). Unfortunately, in most of these reports limited information 
is available on the source or length of the tested FKN fragment and therefore, 
explanations for the observed differences cannot be easily identified. 
In a manner similar to that previously described here for MCP-1, soluble FKN has 
also been shown to play roles other than mediation of chemotaxis. For instance, there 
is a growing evidence for FKN acting as a survival signal for monocytic phagocytes. 
Boehme et al. have observed that the presence of FKN strongly supports cultured 
microglia survival, even when they are induced to undergo death by Fas ligand 
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binding (Boehme et al. 2000). FKN has also been shown to support the survival of 
cultured monocytes (Landsman et al. 2009).  
Moreover, Landsman and colleagues observed that in vivo, FKN or CX3CR1 knock 
out resulted in apoptosis and depletion of a Gr1low CX3CR1high subset of monocytes 
(Landsman et al. 2009). FKN has also been found to serve as a cell survival factor 
for intestinal epithelial cells (Brand et al. 2002).  
It has also been demonstrated that soluble FKN may provide support for the process 
of neovascularisation. This can be exerted by mediation of endothelial cell 
proliferation and new vessel formation (Lee et al. 2006). FKN is believed to act as an 
anti-apoptotic and mitogenic signal for vascular smooth muscle cells as well (White 
et al. 2010). 
In addition, FKN seems capable of modulating gene expression and so, type of 
immunological response of microglial cells. Studies on LPS or IFN-γ-treated 
microglia have revealed that addition of FKN results in the inhibition of the release 
of TNFα, IL-6 and NO (Zujovic et al. 2000; Mizuno et al. 2003). These observations 
have been further confirmed by Cardona et al. who showed that CX3CR1-deficient 
mice suffered from excessive neurotoxicity after LPS injection (Cardona et al. 2006). 
Furthermore, FKN can promote apoptotic cell clearance by macrophages by inducing 
the production of MFG-E8. This process can further contribute to macrophage shift 
towards M2-like phenotype (Miksa et al. 2007). 
Interestingly, the outcome of FKN signalling seems to be dependent on the 
concentration of FKN present in the target cell environment. Mizutani and colleagues 
tested the effect of different concentrations of soluble FKN on the amount of 
TNFα released from LPS-treated macrophages and found that only low 
concentration of FKN resulted in reduction of secretion of the inflammatory agent.  
Conversely, high concentrations of FKN caused additional release of TNFα and  
IL-23 (Mizutani et al. 2007).    
1.3.2.2 The role of fractalkine in the central nervous system 
In the central nervous system, FKN is abundantly and constitutively expressed by 
neurons whereas its receptor, CX3CR1 is found on microglial cells (Harrison et al. 
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1998). FKN/CX3CR1 interactions have been found to be an important, although very 
complex, method of neuron-microglia communication.   
Initial studies demonstrated that FKN would function in the brain during acute 
events, as a chemoattractant and activator for microglia (Pan et al. 1997; 
Maciejewski-Lenoir et al. 1999; Chapman et al. 2000). The fact that FKN-deficient 
mice have been shown to be partly protected from ischemia-reperfusion-driven 
injury strongly supports this notion (Soriano et al. 2002). 
At the same time, FKN has been found to play an important role in inhibiting 
microglial-mediated neurotoxicity. Such an effect of FKN has been observed both in 
the previously described, in vitro experiments on LPS and IFN-γ-treated microglia 
(Zujovic et al. 2000; Mizuno et al. 2003) and in a convincing in vivo study on 
CX3CR1-deficient mice (Cardona et al. 2006). The effect’s dependence on the 
chemokine concentration may again be an explanation for the observed dual role of 
FKN (Maciejewski-Lenoir et al. 1999). 
On top of that, FKN release from neurons (perhaps cathepsin S-dependent) has been 
implicated in mediation of pathological pain (Milligan et al. 2004; Clark et al. 2007).    
1.3.2.3 The role of fractalkine in disease  
In most normal cells, FKN expression is induced by inflammatory agents. IL-1,  
IFN-γ, TNFα and LPS have been implicated ( Harrison et al. 1999; Fujimoto et al. 
2001; Ludwig et al. 2002). Not surprisingly therefore, its elevated expression has 
been found in most inflammatory diseases (e.g. atherosclerosis, rheumatoid arthritis, 
inflammatory bowel disease and glomerulonephritis), where it is believed to 
considerably contribute to the disease progression (Muehlhoefer et al. 2000; Furuichi 
et al. 2000; Volin et al. 2001; Combadiere et al. 2003). 
FKN’s role in tumourigenesis has also been investigated. In most tumours in which 
FKN expression was detected, it appeared to correlate with better prognosis (Ohta et 
al. 2005; Matsubara et al. 2007; Yu et al. 2007; Blum et al. 2008; Hyakudomi et al. 
2008). Interestingly, it has been observed that high but not low FKN concentrations 
had an anti-tumour effect (Matsubara et al. 2007). This seemed to be in agreement 
with the findings of Mizutani et al. (discussed above) on the high concentration-
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dependence induction of inflammation and immune tolerance depending on low 
concentrations of FKN (Mizutani et al. 2007). Consequently, the anti-tumour action 
of FKN has been demonstrated to rely on the activation of NK cells, cytotoxic T cells 
and DCs (Guo, Chen, et al. 2003; Guo, Zhang, et al. 2003).    
These propensities of FKN have been found useful when tested as a potential anti-
cancer therapy. When colon carcinoma, melanoma or lymphoma cell lines were 
modified to express FKN, they were shown to have a reduced capability for forming 
tumours in vivo (Lavergne et al. 2003; Xin et al. 2005; Vitale et al. 2007).    
In addition, CX3CR1 expressed by tumour cells has been found to home to sites of 
FKN expression during the process of metastasis (Shulby et al. 2004; Marchesi et al. 
2008).        
1.4 Aims of the project 
Given the potential that tumour-associated macrophages may have in mediating 
tumour progression (Mantovani et al. 1992), the broad aim of this project was to 
increase our understanding of mechanisms that lead to macrophage infiltration of 
Burkitt’s lymphoma. As BL cells in the tumour are known to undergo spontaneous 
apoptosis at a high rate (Gregory et al. 1991) and apoptotic cells have previously 
been shown to be a source of chemoattractant agents for macrophages (e.g. Horino et 
al. 1998; Knies et al. 1998; Lauber et al. 2003; Gude et al. 2008), the focus was on 
chemotactic factors released from dying BL cells.  
Following on from work carried out in the past in this laboratory by Truman, who 
identified fractalkine as a factor released from apoptotic BL cells  responsible for 
macrophage chemotaxis, and also showed that another classical chemokine might be 
involved in this process (Truman 2005), initial studies were carried out to identify 
that chemokine. Later, the attention was transferred to fractalkine. The process of cell 
death-specific modulation of FKN and mechanisms of its release after death-stimuli 
were investigated in detail. 
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Chapter 2  
Materials and Methods  
2.1 Cells 
2.1.1 Primary cells isolation and culture 
2.1.1.1 Monocytes and HMDMs 
Primary cells were obtained from peripheral blood of healthy volunteer donors. 
Mononuclear cells were isolated from the peripheral blood by Ficoll gradient (Ficoll-
Paque Plus; GE Healthcare). In a 50 ml Falcon tube (BD Biosciences), 35 ml of 
blood diluted with sterile PBS was layered on 15 ml of room temperature Ficoll. 
Cells were centrifugated at 900 x g, at room temperature for 20 min, with the break 
off. The cell pellet was collected from Ficoll/serum interface, transferred to a fresh 
tube and washed in PBS (900 x g, room temperature, 10 min, break on). The washing 
procedure was repeated three times. Monocytes were sorted by positive selection 
from isolated cells incubated with anti-CD14 magnetic micro beads (Miltenyi 
Biotec). 20 µl of beads was added to each 80 µl of MACS buffer (PBS, 
2 mM EDTA, 0.5% BSA) containing 1 x 107 cells. Reaction tubes were incubated on 
ice for 15 min. Cells were washed and re-suspended in 500 µl of MACS buffer, then 
passed through a MACS MS column (Miltenyi Biotec) placed in a magnetic field. 
CD14+ cells were eluted in MACS buffer after the column was removed from the 
magnetic field. Monocyte purity was monitored by CD14 labelling. Over 90% of 
separated cells were CD14-positive. 
To obtain human monocyte-derived macrophages (HMDMs), cells pelleted in the 
last PBS-wash step were re-suspended in IMDM (PAA) (containing L-glutamine 
(2mM) (PAA), 25mM HEPES, 100 IU/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen)) at 4 x 106/ml concentration. 3 ml of cells were seeded per well of  
6-well plates. After 1 hr incubation (37°C, 5% CO2) medium and non-adherent cells 
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were removed and IMDM containing L-glutamine, HEPES, penicillin/streptomycin 
and supplemented with 10% autologous serum was instead added to the wells. Cells 
were fed at day 3. HMDMs were collected at day 6 by washing with cold PBS and 
incubating for 5 min with detachment buffer (HBSS (without Ca and Mg), 
5 mM EDTA, 0.2% BSA). Subsequently, a cell lifter was used to detach the cells. 
Cells were washed twice to remove excess of EDTA.     
2.1.1.2 Mouse germinal centre cells 
Germinal centre and resting, follicular B cells were separated from spleens of wild-
type mice immunised with sheep red blood cells (SRBCs). The reaction was boosted 
after 14 days and the spleens were harvested after a further 12 days. In order to 
obtain germinal centre B cells, splenocyte suspensions were incubated with rat anti-
IgD antibodies (BD Biosciences). Subsequently, IgD-expressing cells were depleted 
using magnetic separation with goat anti-rat IgG microbeads (Miltenyi Biotec). 
Then, anti-mouse B220 antibodies (eBioscience) were used to select IgD-negative  
B cells (Truman et al. 2008). Further control analysis using GL7 antibodies 
(eBioscience) demonstrated that more than 65% of the obtained IgD-negative B cells 
expressed high levels of Ly-77 and less than 10% of the IgD-positive follicular B cell 
fraction expressed high levels of Ly-77.  
2.1.1.3 Human germinal centre cells 
Human germinal centre B cells were isolated form tonsils within approximately  
15 hrs after tonsillectomy. Tonsils were transferred to a Petri dish containing RPMI 
with antibiotics and cut into pieces to release cells. Cells were recovered from the 
supernatant after sedimentation at 1 x g then washed in fresh RPMI.  Mononuclear 
cells (MNC) were isolated by density gradient centrifugation on Ficoll-Paque Plus at 
800 x g for 20 min. MNCs harvested from the media interface were then washed 
twice in RPMI. T cells were depleted by rosette formation with AET-treated SRBCs.  
T cell rosettes were then removed by sedimentation on Ficoll-Paque Plus as above. 
Resting B cells were obtained from T cell-depleted MNCs by depletion of residual  
T cells and activated B cells including germinal centre B cells by magnetic cell 
separation using mouse anti-human CD14, 61D3, mouse anti-human CD38, OKT10 
(Birmingham University), mouse anti-human CD3, OKT3 (Birmingham University) 
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antibodies and goat anti-mouse IgG-coated MACS microbeads (Miltenyi Ltd). For 
isolation of germinal centre B cells, residual T cells and resting B cells were depleted 
by magnetic cell separation using Dynabeads (Dynal Ltd). T cell-depleted MNCs 
were incubated with mouse anti-human CD14, mouse anti-human CD39, AC2 
(Birmingham University), mouse anti-human CD3, OKT3 (Birmingham University) 
and mouse anti-human IgD, HJ9 (Becton Dickinson) antibodies and with Dynabeads 
coupled with sheep anti-mouse IgG and subsequently separated on a magnet. 
Recovered cells were subjected to a second round of magnetic depletion as above. 
Remaining germinal centre B cells were then washed twice in RPMI.    
 
2.1.2 Cell lines maintenance  
Group I (biopsy-like) EBV-negative (BL2, BL2/Bcl-2, L3055) and EBV-positive 
(Mutu I, SAV) Burkitt's lymphoma cell lines were used in the studies. Apoptosis 
resistant BL2/Bcl-2 cells were previously generated in this group from BL2 cells by 
stable transfection with bcl-2 (using pEFbcl2-MC1neopA vector, following formerly 
established protocol (Wang et al. 1996)). All BL cell lines as well as HL-60 cells 
(human promyelocytic leukaemia cells) were cultured in suspension in RPMI 1640 
(Invitrogen) supplemented with 10% foetal calf serum (PAA), 2mM L-glutamine, 
100 IU/ml penicillin and 100 µg/ml streptomycin.   
2.2 Induction and evaluation of 
apoptosis 
BL cells from confluent cultures were washed 3 x 5 min (220 x g) in serum-free 
RPMI 1640 (with L-glutamine and penicillin/streptomycin), counted and re-
suspended in the same medium at 10 x 106/ml. Apoptosis was induced in BL cells by 
treatment with 1µM staurosporine (Calbiochem), 2 µM ionomycin (Calbiochem) or 
by UVB irradiation (100mJ/cm2). Cells were kept in cell culture incubators (37°C, 
5%CO2) for indicated period of time (1-24 hrs). The level of apoptosis was evaluated 
by staining with Annexin V (AxV)-FITC and propidium iodide (PI) (Bender 
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Medsystems), using Beckton XL flow cytometre. In short, 1 x 106 cells were placed 
in a FACS tube, spun down and re-suspended in 100 µl of Annexin V binding buffer 
(10 mM HEPES/NaOH (pH 7.4); 140 mM NaCl; 2.5 mM CaCl2). 1 µl of Annexin 
V-FITC was added per tube and incubated for 10 min on ice. Cells were next washed 
and re-suspended in 500 µl of binding buffer. 10 µl of propidium iodide was added 
to each tube prior to FACS measurement.  
2.2.1 Inhibitor studies 
BL cells were prepared as described above. Protease inhibitors (at the concentrations 
indicated in Table 2-1) were added to cell culture 30 min prior to induction of cell 
death.  
Table 2-1. List of inhibitors and used concentrations 
inhibitor Specificity working 
concentration 
reference 




10-50 µM Garton et al. 2001; 
Litterst et al. 2007 
TIMP-1 metalloproteinases:
MMPs, ADAM-10 




5-20 µM Tsou et al. 2001; 
Ito et al. 2004 
chymostatin cysteine and serine 
proteases 
(cathepsin A, B, D, 
chymotrypsin) 
100 µM Marchetti et al. 2003 




100 µM Marchetti et al. 2003 
E-64-d cysteine proteases 
(cathepsin B,H,L) 
10 µM Rofstad et al. 2006 




0.5 µM Goselink et al. 2006 
Z-Leu-Leu-
CHO 
Calpains 25 µM Tsubuki et al. 1996 





caspase-1 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-VDVAD-
FMK 
caspase-2 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-DEVD-
FMK 
caspase-3 (-6,-7,-8) 25-100 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-LEVD-
FMK 
caspase-4 (-5) 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-WEHD-
FMK 
caspase-5 (-1,-4,-8) 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-VEID-FMK caspase-6 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-IETD-FMK caspase-8 
(granzyme B) 
25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-LEHD-
FMK 
caspase-9 (-8) 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-AEVD-
FMK 
caspase-10 (-6,-8) 25-100 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
Z-LEED-
FMK 
caspase-13 25 µM Garcia-Calvo et al. 1998; 
Pereira and Song 2008 
 
2.3 Microparticles isolation and analysis 
For isolation of MPs, BL cells from confluent cultures were washed 3 x 5 min 
(220 x g) in serum-free RPMI 1640 (supplemented with L-glutamine and 
penicillin/streptomycin). Cells were resuspended at 1 x 107/ml and induced into 
apoptosis using 1 µM staurosporine. After two hrs, cells were pelleted by 
centrifugation (5 min, 300 x g). Supernatants were transferred to fresh tubes and 
centrifuged again at (1400 x g) for 10 min to remove bigger cellular debris. MPs 
were isolated by ultracentrifugation of the obtained supernatants (placed in 
polyallomer tubes (Beckman Coulter)) using an Optima TLX ultracentrifuge 
(Beckman Coulter) (100 000 x g, 4oC, 30 min). Supernatants were discarded and 
particle pellets were re-suspended and analysed further. For FACS analysis, MPs 
were re-suspended in PBS. MP size was assessed by flow cytometry by comparison 
with 50 nm (Miltenyi Biotec) and 1 µm (Invitrogen) diameter beads. For Western 
blot analysis MPs were re-suspended in lysis buffer (1 mM EDTA, 10 mM HEPES, 
1% Triton-X-100) and incubated for 30 min on ice prior to addition to LDS sample 
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buffer (NuPAGE, Invitrogen). For confocal microscopy studies, MPs were re-
suspended in fixation medium from Fix&Perm cell permeabilisation kit (Invitrogen).     
All reagents used for MP isolation and studies were passed through 0.22 µm filters. 
2.4 Immunostaining 
1 x 106 of BL cells were placed in each FACS tube. For surface staining, cells were 
incubated for 30 min with 5% normal goat serum in PBS. After washing in 
1% BSA/PBS, cells were re-suspended in 100 µl of 1% BSA/PBS containing 
antibodies of choice (or corresponding isotype control antibodies) and incubated for 
30 min at 4°C. Next, cells were washed in 1% BSA/PBS and then incubated in 
100 µl of 1% BSA/PBS containing matching secondary FITC- or PE-conjugated 
antibodies (30 min, 4°C). For intracellular staining, before incubation with 
antibodies, cells were fixed and permeabilised according to the manufacturer’s 
protocol using Cytofix/Cytoperm kit (BD Pharmingen) or Fix&Perm cell 
permeabilisation reagents (Invitrogen). Cells were analysed immediately or were 
kept in 1% formaldehyde/1% BSA/PBS at 4°C prior to analysis. Antigen expression 
was assessed using Beckton XL flow cytometre. Concentrations of antibodies are 
shown in Table 2-2. Post-measurement analyses were performed in FlowJo (Tree 
Star). Histograms of unfixed (surface-stained) cells were drawn only from cells that 
fell into a “viable” gate based on their forward versus side scatter.  
2.5 Immunohistochemistry 
Slides containing 5 µm formalin-fixed, paraffin-embedded tumour sections obtained 
from xenograft tumours, generated by subcutaneous injection of 10 x 106 BL2 cells 
into SCID mice, were stained with mouse monoclonal antibodies anti-human MCP-1 
(R&D Systems, MAB2791). Slides were first dewaxed in histoclear (2 x 5 min), 
dehydrated in dilutions of ethanol (100% - 90% - 70%) (5 min in each) and next 
heated in Antigen Retrieval Solution (Vector Laboratories) in a microwave oven 
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(3 x 5 min). After cooling in tap water (~20 min), slides were incubated with 
2% hydrogen peroxide in order to block endogenous peroxidase activity (15 min). 
After washing in PBS (2 x 3 min) and transferring to Sequenza chambers (Thermo 
Scientific) slides were blocked with serum-free Protein Block (Dako Cytomation) 
(10 min). MAB2791 antibodies diluted in ChemMate Antibody Diluent (Dako 
Cytomation) were then added to the chambers and incubated overnight at 4°C. Next, 
anti-mouse-biotin-conjugated antibodies diluted in ChemMate Diluent were added to 
chambers for 30 min (room temperature). Vectastain Elite ABC reagent (Vector 
Laboratories) was then added to amplify signal (30 min) and next the enzyme 
substrate 3,3'-diaminobenzidine (DAB) (Vector Laboratories) was used (5 min). 
Chambers were washed in PBS between the staining steps. Slides were 






Table 2-2 List of antibodies and used concentrations 
antibodies catalogue no Producer* used concentration** 
   WB IF IHC ELISA N 
mouse monoclonal anti-human MCP-1 
(clone 23002) 
MAB2791 RDS 4 µg/ml 15 µg/ml 25 µg/ml   
mouse monoclonal anti-human MCP-1 
(clone 23007) 
MAB679  RDS 2 µg/ml   1 µg/ml  
goat polyclonal anti-human MCP-1 AF279-NA  RDS 1 µg/ml    2µg/ml 
mouse monoclonal anti-human FKN 
(clone 81513) 
MAB3651  RDS  2 µg/ml 15 µg/ml    
goat polyclonal anti-human FKN C-
terminus 
sc-7225 SCB 0.5 µg/ml     
rabbit polyclonal anti-mouse FKN TP-233 TPB 1 µg/ml     
rabbit polyclonal anti-caspase-3 antibodies 9662 CST 1:500     
rabbit polyclonal anti-active caspase-3 
antibodies 
9661 CST  1:50    
rabbit polyclonal anti-active caspase-3 
antibodies 
PC679 C 0.5 µg/ml     
rabbit polyclonal anti-human calpain I 
large subunit 
2556 CST 1:500 1:25    
rabbit polyclonal anti-human calpain II 
large subunit 
2539 CST  1:25    
mouse monoclonal anti-β-actin (clone AC-
15) 





Table 2-2 continued 
antibodies catalogue no Producer used concentration 
mouse IgG1 M9269 SA  20 µg/ml    
mouse IgG2 M9144 SA  20 µg/ml    
sheep anti-mouse IgG-HRP NXA931 GEH 1:2000   1:1000  
goat anti-mouse IgG-biotin BA-9200 VL   1:250   
goat anti-mouse IgG-FITC F0257 SA  1:100    
goat anti-mouse IgG-PE P9287 SA   1:100    
goat anti-mouse IgG-AF488 A11001 I  1:50    
goat anti-rabbit IgG-HRP PO448 DC 1:2000     
goat anti-rabbit IgG-FITC F0382 SA  1:100    
goat anti-rabbit IgG-PE P9795 SA  1:100    
goat anti-rabbit IgG-AF594 A11012 I  1:50    
rabbit anti-goat IgG-HRP PO449 DC 1:2000     
* RDS=R&D Systems; SCB= Santa Cruz Biotechnology; TPB= Torrey Pines Biolabs; CST= Cell Signaling Technology; C= 
Calbiochem; SA= Sigma Aldrich; GEH= GE Healthcare; VL= Vector Laboratories; I= Invitrogen; DC= DakoCytomation; 




2.6.1 Sandwich ELISA 
MCP-1 release was assessed by sandwich ELISA of supernatants collected from 
overnight cultures of HL-60 cells (5 x 106/ml in culture medium, alone or stimulated 
with LPS (1 ng/ml)) as well as supernatants collected from BL2, BL2/Bcl-2 and 
Mutu I cells treated with 1 µM staurosporine for 3 hrs to induce apoptosis 
(1 x 107/ml in serum-free RPMI). ELISA DuoSet (R&D Systems) for human MCP-1 
was used according to the manufacturer’s protocol. In short, ELISA plates (Nunc) 
were coated with goat anti-MCP-1 antibodies (1 µg/ml in PBS; 50 µl/well) and 
incubated overnight at 4°C. Plates were washed 3 times with 0.05% Tween-20/PBS 
and blocked using 2% FCS/PBS (1 hr/room temperature). Plates were washed and 
cell supernatants were added to the wells (100 µl/well) and incubated for two hrs at 
room temperature. Next, supernatants were removed, plates were washed thoroughly 
and detection mouse anti-MCP-1 antibodies were added (0.5 µg/ml; 100 µl/well). 
Plates were incubated for two hrs at room temperature and washed again before 
adding biotinylated anti-mouse antibodies (0.5 µg/ml; 100 µl/well) for 1 hr at room 
temperature. Following washing, plates were incubated with streptavidin-HRP 
(diluted 1:200, 100 µl/well) for 20 min at room temperature. After the final washing 
step Tetramethylbenzidine/H2O2 (Sigma-Aldrich) substrate was added to the wells 
(100 µl/well) and incubated for ~20 min. Reaction was stopped with 2N H2SO4 
(50 µl/well). Plate was measured on plate reader at 450 nm. All conditions were set 
up in triplicate. Negative control wells were coated with assay buffer (serum-free 
RPMI 1640 with 2mM L-glutamine and 100 IU/ml penicillin and 100 µg/ml 
streptomycin) or blocking solution (4% BSA/PBS).  
2.6.2 Direct ELISA 
96-well ELISA plates were coated directly with cell-free supernatants from 
staurosporine-treated BL cells (cultured at 1 x 107/ml for 1 – 3 hrs) (100 µl/well). 
Plates were incubated for 4 hrs at 37°C, and subsequently blocked with 4% BSA in 
PBS at 37°C for 30 min. MCP-1 was detected using mouse monoclonal  
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anti-human MCP-1 antibodies (R&D Systems, MAB679) (1 hr incubation at room 
temperature) and visualised by incubation with goat anti-mouse IgG-HRP-
conjugated antibodies (1 hr at room temperature) (see Table 2-2 for antibody 
concentrations). Plates were washed 3 times with 0.05% Tween-20/PBS between the 
incubation steps. Tetramethylbenzidine mix with H2O2 was used to develop the 
plates. Reactions were stopped with 2N H2SO4. Results were measured on a plate 
reader at 450 nm. All conditions were set up in duplicate. Negative control wells 
were coated with assay buffer (serum-free RPMI 1640 with 2mM L-glutamine and 
100 IU/ml penicillin and 100 µg/ml streptomycin) or blocking solution 
(4% BSA/PBS).  
2.7 Transmigration assay 
Transmigration assays were performed by using modified Boyden chambers 
(Figure 2.1). Polycarbonate membrane transwells with 5 µm pore size (Costar 
Corning) were used in the assays. RPMI containing 0.1% low-endotoxin BSA 
(Sigma-Aldrich) was used as the assay medium. Monocytes (2 x 106/ml) and 6-day-
old HMDMs (1 x 106/ml) were placed in the upper chamber. Recombinant human 
MCP-1 (1 - 100 ng/ml; R&D Systems); cell-free supernatants from UV-treated BL2 
cells, collected 3 hrs post UV-exposure; C5a - positive control (6.25 ng/ml; R&D 
Systems) or assay medium - negative control, were placed in the lower chamber. 
When indicated, mouse polyclonal neutralising antibodies anti-human MCP-1 
(R&D Systems, AF-479-NA) were also added in the lower chamber to counteract the 
effect of MCP-1. Monocyte migration assays were carried out for 90 min and 
HMDM for 240 minutes. Subsequently, cells were removed from the inside of 
transwells with a cotton bud and transwells were fixed in 100% methanol for 10 min, 
followed by staining with Diff-Quik (Reagena) (20 min). Number of migrating cells 
was calculated by counting cells on the underside of the transwell membrane using 
an inverted microscope. Ten high power fields (x 400) were counted per transwell. 












Figure 2.1 Schematic diagram of transmigration assay 
2.8 Immunoblotting 
2.8.1 Whole cell lysate preparation 
For preparation of whole cell lysate samples, cells were collected from the 
experimental cultures, spun down to remove the supernatants and subsequently re-
suspended in lysis buffer (1 mM EDTA, 10 mM HEPES, 1% Triton-X-100) (12.5 µl 
of the buffer per 1 x 106 cells of initial culture). Samples were vortexed intensively 
and incubated on ice for 30 min. Next, samples were spun at 18 000 x g, 4°C for 
10 min. Supernatants, free of cellular debris, were transferred to fresh tubes and kept 
at -20°C for further analysis. Protein concentration in whole cell lysate samples was 
assessed using Bradford dye reagent (Bio-Rad). Dilutions of lysate samples were 
mixed with the dye and colour concentration was measured on plate-reader at 
595 nm wavelength. Protein concentration was calculated based on the readings from 
serial dilution of human IgG samples of known concentration, which were analysed 
in parallel with whole cell lysate samples. For each sample 30 µg of proteins was 
mixed with NuPAGE LDS sample buffer (Invitrogen) containing NuPAGE reducing 




2.8.2 Supernatants preparation 
In order to analyse proteins released from cells (1 x 107 cells/ml) during experiments, 
proteins were first precipitated from supernatants using trichloroacetic acid (TCA). 
For each sample analysed on the gel, 1 ml of supernatant was mixed with 100 µl of 
100% TCA and incubated on ice for 30 min. Samples were then spun down at 
18 000 x g, 4°C for 10 min. Supernatants were discarded and protein precipitates 
were washed with 1 ml of ice-cold acetone and spun down as before. Acetone was 
discarded and precipitates were let to dry and subsequently, were re-suspended in 
NuPAGE LDS sample buffer with NuPAGE reducing agent. Samples were 
denatured for 10 min at 70°C prior to loading into the gel. 
2.8.3 Electrophoresis and Western blotting             
Electrophoretic sample separation and their transfer to nitrocellulose membranes 
were performed using the Invitrogen NuPAGE system and reagents, according to the 
manufacturer’s protocol. Samples, prepared as described above, were loaded into 
NuPAGE pre-cast 4-12% Bis-Tris gels. SeeBlue Plus2 pre-stained standard 
(Invitrogen) was used as molecular weight indicator. Protein separation was 
performed in NuPAGE MES SDS running buffer at 200 V for approximately 35 min. 
Subsequently, proteins were transferred on to PVDF membranes in NuPAGE transfer 
buffer, at 30 V for 1 hr. The membranes were blocked at 4°C overnight in 
0.1% Tween-20/PBS containing 5% milk. Next, the membranes were incubated with 
antibodies of choice diluted in 0.1% Tween-20/PBS containing 1% milk (see Table 
2-2 for antibody concentrations) for 1 hr at room temperature, washed thoroughly in 
0.1% Tween-20/PBS for 1 hr and then incubated with matching HRP-conjugated 
secondary antibodies (diluted in 0.1% Tween-20/PBS/1% milk ). After final washing 
in 0.1% Tween-20/PBS, bands were developed using ECL reagents (GE Healthcare). 
Chemiluminescence was detected on photographic film (GE Healthcare). 
For the purpose of multiple staining with different antibodies membranes were 
washed in stripping buffer (100 mM Glycine, 150 mM NaCl, pH 2.6 ) for 2 hrs and 
washed in 0.1% Tween-20/PBS prior to re-labelling.  
 
 62 
2.9 In vitro cleavage assays  
Protease capability of cleaving FKN was studied in vitro as follows: 
2.9.1 Caspase cleavage 
75 ng of recombinant human FKN (rh FKN) (R&D Systems) and 300 – 500 ng of 
recombinant human caspases (-3, -7, -10) (R&D Systems) were diluted in caspase 
reaction buffer (25 mM HEPES pH 7.5, 10 mM DTT, 0.1% CHAPS) (final volume: 
100 µl) and were incubated for 2 hrs at 37°C. When indicated, 2 – 3 µg of caspase 
inhibitor (Z-VAD-FMK or Z-DEVD-FMK) (R&D Systems) were also added to the 
samples. Rh FKN incubated in caspase reaction buffer alone served as a control. 
100 µg of total protein from untreated BL2 whole cell lysates and 300 – 500 ng of 
recombinant human caspases (-3, -7, -10) were diluted in caspase or ADAM 
(25 mM Tris pH 9.0, 2.5 µM ZnCl2, 0.005% Brij 35) reaction buffers (final volume: 
100 µl) and were incubated for 2 hrs at 37°C. When indicated, 2 – 3 µg of caspase 
inhibitor (Z-VAD-FMK or Z-DEVD-FMK) was also added to the samples. 100 µg of 
total protein from BL2 cell lysates incubated in caspase or ADAM reaction buffer 
alone served as a control. 
2.9.2 Calpain cleavage 
75 ng of recombinant human FKN and 240 ng of active human calpain 1 (BioVision) 
were diluted in calpain reaction buffer (30 mM Tris-HCl pH 7.5, 1.5 mM DTT, 
750 µM CaCl2) (final volume: 100 µl) and were incubated for 30 min at 37°C. When 
indicated, 40 ng of calpeptin (Alexis Biochemicals) was also added to the samples. 
Rh FKN incubated in calpain reaction buffer alone served as a control. 
100 µg of total protein from untreated BL2 cell whole lysates and 240 ng of active 
human calpain 1 were diluted in ADAM reaction buffer (25 mM Tris pH 9.0, 
2.5 µM ZnCl2, 0.005% Brij 35) (final volume: 100 µl) and were incubated for 30 min 
at 37oC. When indicated, 40 ng of calpeptin was also added to the samples. 100 µg of 
total protein from BL2 cell lysates incubated in ADAM reaction buffer alone served 
as a control. 
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2.10 Caspase-3 activity fluorogenic assay 
100 µg of total protein from whole cell lysates of untreated or apoptotic (2 hrs post-
staurosporine) or 50 µl of MP lysate (prepared from MPs released from 5 x 107 BL2 
cells during 2 hr-incubation with staurosporine; ~90 µg total protein) was diluted in 
ADAM reaction buffer containing 1.5 µg of caspase-3 fluorogenic substrate 
(Z-DEVD)2-Rh110-bisamide (Calbiochem) (total volume: 100 µl). Samples 
containing only ADAM reaction buffer or lysis buffer combined with 1.5 µg of 
substrate served as controls. All conditions were set up in duplicate. Reactions were 
carried out for 2 hrs at room temperature. A fluorescent plate reader was used to 
measure the outcome (excitation ~485 nm; emission ~535 nm).  
2.11 Confocal microscopy 
For analysis of intracellular localisation of FKN and active caspase-3 1 x 106 of 
untreated or staurosporine-treated BL2 cells (2 hrs post-treatment) were fixed and 
permeabilised using Fix&Perm cell permeabilisation reagents (Invitrogen) according 
to the manufacturer’s protocol. Surface FKN expression was analysed by firstly 
fixing untreated BL cells or MPs isolated by centrifugation from supernatants of 
6 x 107 apoptotic BL cells (2 hrs post-staurosporine) using fixation medium from the 
Fix&Perm kit. Next, cell and MP samples were blocked in 5% normal goat 
serum/PBS for 30 min on ice. After washing in 1% BSA/PBS, cells or MPs were re-
suspended in 1% BSA/PBS containing mouse monoclonal anti-human FKN 
antibodies (R&D Systems; MAB3651) and rabbit anti-human active caspase-3 
antibodies (Cell Signaling Technology; 9661) (or the corresponding isotype control 
antibodies) and incubated for 30 min at 4°C. Subsequently, samples were washed in 
1% BSA/PBS and then incubated in 1% BSA/PBS containing secondary anti-mouse 
IgG AF488-conjugated or anti-rabbit IgG AF594-conjugated antibodies (30 min, 
4°C, in the dark). After the final wash, samples were re-suspended in 2 drops of 
ProLong Gold antifade reagent (containing DAPI) (Invitrogen). 15 µl of sample was 
spread on a microscope slide and covered with a cover slip (thickness 1). Slides were 
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left overnight (in the dark) for mountant to solidify. Samples were analysed on a 
Leica SP5C confocal laser scanning microscope. Blue diode (405 nm excitation line), 
argon (488 nm) and HeNe 2 (594 nm) lasers and 63 x oil objective were used for 
image acquisition. Huygens Professional software (SVI) was used for spectral 
deconvolution. Merged images were created in ImageJ software.    
Antibody concentration details are collected in Table 2-2. 
2.12 Time lapse video microscopy 
1 ml of 1 x 106/ml BL2 cells in 25 mM HEPES-buffered RPMI 1640 + 10% foetal 
calf serum medium (which was saturated with 5 % CO2 prior to starting the 
experiment) were induced into death with 1 µM staurosporine and placed in a POC 
mini chamber (PeCon) on a heated microscope stage (37°C) of an Olympus 
widefield inverted microscope equipped with an Olympus F-View camera. A low-
magnification image (10 x objective) of the cells was collected every 15 sec, for 
150 min, starting 30 min after the cells were exposed to staurosporine. Cell-P 
software (Olympus) was used to operate the system.  
2.13 Molecular biology techniques 
2.13.1 Reverse transcription PCR  
RNA was isolated from cells using RNeasy Mini kit (Qiagen), according to the 
manufacturer’s protocol. The concentration of eluted RNA was measured using a 
NanoDrop (Thermo Scientific).  
cDNA was synthesised using reverse transcriptase by mixing 2 µg RNA, 1 µl oligo 
dT (Promega), 1 µl dNTP mix (Promega) and DEPC-treated H2O up to 13 µl and 
incubating at 65°C for 5 min before placing on ice  to cool down. The following 
reagents were then added to each sample: 4 µl of 5 x First strand buffer (Invitrogen), 
1 µl 0.1M DTT (Invitrogen), 1 µl RNase inhibitor (Invitrogen) and 1 µl reverse 
transcriptase (SuperScript) (Invitrogen). The reagents were mixed and incubated at 
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50°C for 75 min, followed by 10 min incubation at 90°C. Samples were cooled down 
on ice, centrifuged briefly and used immediately for the PCR reactions or stored at 
-20°C. 
Primers used in the reactions:  
MCP-1 (from Ohta et al. 2003):  
forward 5’-CTGTGCCTGCTGCTCATA-3’ 
reverse 5’-ATTTCCCCAAGTCTCTGT-3’ 
Caspase-3 (from Winter et al. 2001): 
forward 5’-TTCAGAGGGGATCGTTGTAGAAGTC-3’ 




All primers were sequenced by Eurofins MWG Operon. 
Each reaction mixture contained: 2 µl of cDNA, 5 µl 10 x reaction buffer (Promega), 
3 µl of MgCl2 (Promega), 1 µl of dNTPs (Promega), 1 µl of forward primer (10 
pmol/µl), 1 µl of reverse primer (10 pmol/µl), 0.5 µl of Taq polymerase (Promega) 
and 36.5 µl of DEPC-treated H2O. 
PCR reactions were carried out in thermocycler as follows:  
for MCP-1:  step 1 - 94°C for 7 min, step 2 - 94°C for 1 min, step 3 - 56°C for 
1 min, step 4 - 72°C for 1 min, repeat steps 2 - 4  for 40 cycles, step 5 - 72°C for 
5 min. 
for caspase-3: step 1 - 94°C for 5 min, step 2 - 94°C for 1 min, step 3 - 52°C for 
1 min, step 4 - 72°C for 45 sec, repeat steps 2 - 4 for 28 cycles, step 5 - 72°C for 
5 min. 
for GAPDH: step 1 - 94°C for 7 min, step 2 - 94°C for 1 min, step 3 - 50°C for 




Reaction products were analysed on 1% agarose gels containing ethidium bromide.  
2.13.2 Caspase-3 knock-down  
Small interfering RNA (MISSION shRNA; Sigma-Aldrich) was used to silence 
caspase-3 in BL2 cells. Five bacterial clones carrying lentiviral plasmids 
(pLKO.1-Puro) with different anti-caspase-3 constructs from supplied stocks were 
plated out onto LB (Lysogeny broth) agarose plates containing 100 µg/ml of 
ampicillin (Sigma-Aldrich). Plates were incubated overnight at 37°C. Colonies 
picked from each plate were amplified in 3 ml of LB broth (with 100 µg/ml 
ampicillin) for 8 hrs (on shaker). 0.5 ml of each culture was than used to inoculate 
500 ml LB broth for overnight culture (37°C, shaking). 
Plasmids were purified form 300 ml of cultures using Plasmid Maxi kit (Qiagen), 
following the manufacturer’s instructions precisely.   
Purified plasmids and ViraPower lentiviral packaging mix (pLP1, pLP2, 
pLP-VSV-G; Invitrogen) were later used for co-transfection of 293FT cells. For each 
lentiviral plasmid a mix was prepared containing 3 µg of plasmid, 9 µl of the 
lentiviral packaging mix in 1.5 ml Opti-MEM (Invitrogen). Each of these mixtures 
was combined with a mix of 36 µl of lipofectamine 2000 (Invitrogen) in 1.5 ml Opti-
MEM and incubated for 20 min at room temperature. Each combined 
plasmid/lipofectamine mix was then added to a well of a 6-well plate containing 
6 x 106 of 293FT cells in 10 ml of DMEM supplemented with 5% FCS. After 24 hrs 
cell medium was replaced with DMEM supplemented with 10% FCS, 100 IU/ml 
penicillin and 100 µg/ml streptomycin (10 ml/well). Supernatants containing virus 
particles were collected after 48 hrs, passed through 0.45 µm filters and stored at 
-80°C.   
For transduction of BL2 cells, 5-fold serial dilutions of the supernatants in BL cell 
culture medium were prepared. 1 ml of undiluted supernatant and 1 ml of 7 
successive dilutions were placed in wells of a 48-well plate. 0.6 x 106 of BL2 cells in 
300 µl culture medium were added per well. Puromycin at a final concentration of 2 
µg/ml was added after 48 hrs to select transduced cells. MISSION non-target shRNA 
control vector (Sigma-Aldrich) was used as a negative control. 
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2.13.3 Site-directed mutagenesis (SDM) 
TrueORF pCMV6-Entry vector containing C-terminal Myc- and DDK-tagged human 
fkn (Figure A.4) was purchased from Origene. Point mutations in Asp (D) residues in 
fkn gene were introduced using the following mutagenic primers: 
D122    forward 5’- CCGGGGGAATGGAGGAGTCTGTGGTCC - 3’ 
             reverse 5’- GGACCACAGACTCCTCCATTCCCCCGG -3’ 
D177    forward 5’- GCCAAAGGCTCAGGAAGGAGGGCCTGTGGG -3’ 
             reverse 5’- CCCACAGGCCCTCCTTCCTGAGCCTTTGGC -3’ 
D223    forward 5’- CGTCCACCCAGGAGCCCTCCACCCAGG -3’ 
             reverse 5’- CCTGGGTGGAGGGCTCCTGGGTGGACG – 3’ 
D273    forward 5’- CCAGCGCACACGGAAGCCTTCCAGGACTGG -3’ 
             reverse 5’- CCAGTCCTGGAAGGCTTCCGTGTGCGCTGG -3’ 
D277    forward 5’- GCCTTCCAGGAGTGGGGGCCTGGC -3’ 
             reverse 5’- GCCAGGCCCCCACTCCTGGAAGGC -3’ 
D320    forward 5’- CCATGCCACCATGGAGCCCCAGAGGCTGG -3’ 
             reverse 5’- CCAGCCTCTGGGGCTCCATGGTGGCATGG -3’ 
D333    forward 5’- CACTCCTGTCCCTGAGGCCCAGGCTGCC -3’ 
             reverse 5’- GGCAGCCTGGGCCTCAGGGACAGGAGTG -5’ 
Primers were synthesised by Eurofins MWG Operon.  
Each SDM reaction mixture contained: 1 µl of TruORF plasmid (200 ng), 1 µl of 
primer forward (125 ng), 1 µl of primer reverse (125 ng), 5 µl of 10 x reaction buffer 
(Stratagene), 1 µl 10 mM dNTPs (Promega), 40 µl DEPC H2O and 1 µl PfuUltra 
high-fidelity polymerase (Stratagene). Control reactions without primers and without 
template were also prepared. 
Reactions were carried out in thermocycler as follows: step 1 - 94°C for 2 min, step 2 
- 94°C for 1 min, step 3 - 55°C for 1 min, step 4 - 68°C for 9 min, repeat steps 2 - 4 
for 18 cycles, step 5 - 68°C for 30 min. 
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Parental copies of the plasmid were then removed from the digestion reaction using 
Dpn I restriction enzyme (Promega). 1 µl of Dpn I was added to each 50 µl SDM 
reaction and samples were incubated at 37°C for 3 hrs.  
Consequently, the reactions were used for bacterial transformation. 250 µl of DH5α 
competent cells (Invitrogen) were incubated for 30 min on ice with 10 µl of Dpn I 
digest. Next, cells were heat-shocked for 2 min at 42°C. After 2 min incubation on 
ice, 500 µl of SOC medium (Super optimal broth with catabolite repression 
(supplemented with glucose)) was added. Cells were then shaken for 1 hr at 32°C 
and subsequently, plated out onto LB agar plates containing 25 µg/ml of kanamycin 
(Sigma Aldrich). Plates were incubated overnight at 37°C. 2 colonies were picked 
from each plate. Each colony was amplified in 3 ml of LB broth containing 25 µg/ml 
of kanamycin for 8 hrs, at 37°C, with intense shaking. 0.5 ml of culture was next 
transferred to 500 ml of LB broth (with kanamycin). Culture bottles were incubated 
overnight at 37°C with shaking.  
Plasmids were purified form 300 ml of cultures using Plasmid Maxi kit (Qiagen), 
following the manufacturer’s instructions precisely.   
Introduction of point mutations was confirmed by plasmid sequencing (DNA 
Sequencing & Services, University of Dundee). TrueORF pCMV6-Entry vector 
sequencing primers (Origene) were used:  
• VP1.5 (forward) - 5’-GGACTTTCCAAAATGTCG-3’  
• XL39 (reverse) - 5’-ATTAGGACAAGGCTGGTGGG-3’  
2.14 List of chemicals, reagents and 
equipment 
Antibodies – see Table 2-2 
Cell culture reagents 
DMEM - PAA 
FCS -PAA 
IMDM - PAA 
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L-glutamine - PAA 
Penicillin/streptomycin - Invitrogen 
RPMI-1640 - Invitrogen 
X-Vivo - Lonza 
Immunohistochemistry 
DAB - Vector Laboratories 
ChemMate antibody diluent - Dako Cytomation 
Histo-Clear II – National Diagnostics, USA 
Serum-free protein block - Dako Cytomation 
Vectastain Elite ABC reagent - Vector Laboratories 
Inhibitors  
Aprotinin – Sigma-Aldrich 
Calpeptin – Alexis Biochemicals 
Chymostatin – Sigma-Aldrich 
E64 – Sigma-Aldrich 
GM6001 – Calbiochem 
Leupeptin – Sigma-Aldrich 
TAPI-2 – Calbiochem 
TIMP-1 - Calbiochem 
Z-AEVD-FMK - BioVision, R&D Systems 
Z-DEVD-FMK - BioVision, R&D Systems 
Z-IETD-FMK – BioVision 
Z-LEED-FMK - BioVision 
Z-LEHD-FMK - BioVision 
Z-Leu-Leu-CHO - BioVision 
Z-LEVD-FMK - BioVision 
Z-VAD-FMK – BioVision, R&D Systems 
Z-VDVAD-FMK – BioVision 
Z-VEID-FMK - BioVision 
Z-WEHD-FMK - BioVision 
Z-YVAD-FMK - BioVision 
Molecular biology reagents 
100bp DNA Ladder - Promega 
Agarose – Invitrogen 
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Ampicillin – Sigma-Aldrich 
dNTP mix - Promega 
Ethidium bromide – Sigma-Aldrich 
GoTaq Flexi DNA Polymerase - Promega 
GoTaq Flexi PCR buffer (5x) - Promega 
Library Efficiency DH5α Competent Cells – Invitrogen 
Lipofectamine 2000 – Invitrogen 
Magnesium chloride (25 mM) - Promega 
Mission shRNA glycerol stock (against human caspase-3) – Sigma-Aldrich 
Oligo(dT)15 Primer – Promega 
Opti-MEM - Invitrogen 
PfuUltra High-Fidelity DNA Polymerase - Stratagene 
Plasmid Maxi kit - Qiagen 
Puromycin - Invitrogen 
RNaseOUT - Invitrogen 
RNeasy Mini kit - Qiagen 
SuperScript III Reverse Transcriptase – Invitrogen 
TrueORF pCMV6-Entry Vector (containing human fkn) - Origene 
ViraPower lentiviral packaging mix - Invitrogen 
Proteins 
Active human calpain I - BioVision 
Recombinant human C5a - R&D Systems 
Recombinant human Caspase-3 – R&D Systems 
Recombinant human Caspase-7 – R&D Systems 
Recombinant human Caspase-10 – R&D Systems 
Recombinant human Fractalkine (full-length) – R&D Systems 
Recombinant human MCP-1 – R&D Systems 
Western blotting reagents 
Bradford’s assay solution - Bio-Rad 
Hyperfilm ECL (18x24cm) – GE Healthcare 
Hybond-P membrane – GE Healthcare 
NuPAGE pre-cast 4-12% Bis-Tris gels - Invitrogen 
NuPAGE LDS sample buffer - Invitrogen 
NuPAGE MES SDS running buffer - Invitrogen 
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NuPAGE reducing agent - Invitrogen 
NuPAGE transfer buffer - Invitrogen 
PVDF membrane - GE Healthcare 
SeeBlue Plus2 pre-stained standard - Invitrogen 
Others 
Acetone - Fisher Scientific 
Annexin-V-FITC – Bender Medsystems 
Bradford dye reagent – Bio-Rad 
Brij 35 solution - Sigma-Aldrich 
BSA - PAA 
Calcium chloride – Sigma-Aldrich 
CHAPS – Sigma-Aldrich 
Cytofix/Cytoperm Kit - BD Pharmingen 
Diff-Qwik - Reagena 
DTT - Invitrogen 
Dulbecco’s PBS - PAA 
Dynabeads coupled with sheep anti-mouse IgG – Dynal 
EDTA - Sigma-Aldrich 
ELISA DuoSet – R&D Systems 
Ethanol – Fisher Scientific 
Ficoll-Paque Plus - GE Healthcare 
Fix&Perm Cell Permeabilisation Reagents - Invitrogen 
Formaldehyde - Sigma-Aldrich 
Glycine - Fisher Scientific 
Hank’s BSS (without Ca and Mg) - PAA 
HEPES - Sigma-Aldrich 
Human IgG - Sigma-Aldrich 
Hydrogen peroxide - Sigma-Aldrich 
Ionomycin - Calbiochem 
Low-endotoxin BSA – Sigma-Aldrich 
LPS – Sigma-Aldrich 
Methanol - Fisher Scientific 
Microbeads anti-human CD14 – Miltenyi Biotec 
Microbeads goat anti-mouse IgG - Miltenyi Biotec 
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Microbeads goat anti-rat IgG - Miltenyi Biotec 
Microspheres 1 µm - Invitrogen 
Mouse anti-human CD14 antibodies, 61D3 - Birmingham University 
Mouse anti-human CD3 antibodies, OKT3 - Birmingham University 
Mouse anti-human CD38 antibodies, OKT10 - Birmingham University 
Mouse anti-human CD39 antibodies, AC2 - Birmingham University 
Mouse anti-human IgD antibodies, HJ9 - Becton Dickinson 
Normal goat serum - Biosera 
ProLong Gold Antifade Reagent (with DAPI) - Invitrogen 
Propidium iodide – Bender Medsystems 
Rat anti-IgD antibodies (clone 11-26c.2a) – BD Biosciences 
Rat anti-B220 antibodies - eBioscience 
Rat anti-Ly-77 (GL7) antibodies - eBioscience 
Sheep red blood cells - TCS Biosciences Ltd 
Sodium chloride - Fisher Scientific 
Sodium hydrogen - Fisher Scientific 
Staurosporine - Calbiochem 
Sulphuric acid – Fisher Scientific 
Trichloroacetic acid - Sigma-Aldrich 
Tethramethylbenzidine – Sigma-Aldrich 
Tris - Sigma-Aldrich 
Tris-HCL - Sigma-Aldrich 
Triton-X-100 - Sigma-Aldrich 
Tween-20 - Sigma-Aldrich 
 (Z-DEVD)2-Rh110-bisamide - Calbiochem 




BS748 improved neubauer haemocytometer - Weber 
Class II microbiological safety cabinets - BIOMAT 
Incubators - LEEC 
Polypropylene tubes (15, 50 ml) – BD Biosciences, Greiner bio-one 
Polyvinyl uncoated transwells - Costar 
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Tissue culture flasks - Iwaki 
Tissue culture plates – Nunc 
Centrifuges  
Beckman GS-6R – Beckman Coulter 
Optima TLX – Beckman Coulter 
Rotina 46R - Hettich 
Sigma 1-15K – Sigma 
Microscopes 
Fluorescence microscope, Axioskop 2 - Zeiss 
Leica SP5C confocal laser scanning microscope – Leica Microsystems 
Olympus CK2 light microscope - Olympus 
Olympus widefield inverted microscope – Olympus 
Zeiss Axiovert 25 - Zeiss 
Others 
Anthos It-2 plate reader – Anthos Labtec Instruments 
Coulter EPICS XL-MCL flow cytometre – Beckman Coulter 
Horizon gel tanks – Life technologies 
NanoDrop - Thermo Scientific  
Polyallomer tubes - Beckman Coulter 
Transilluminator Uvidoc - Uvitec 
XCell SureLock Mini-Cell with XCell II Blot Module – Invitrogen 
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Chapter 3  
Role of MCP-1 in 
attracting mononuclear 
phagocytes to Burkitt’s 
lymphoma 
3.1 Introduction 
Macrophages are found in almost all types of tumours and are commonly referred to 
as tumour-associated macrophages (TAMs). TAMs have been shown to play an 
important role in tumour survival and progression. Thus, high numbers of 
macrophages in the tumour tissue are often associated with a poor prognosis 
(Mantovani et al. 1992; Lewis & Pollard 2006). Characterisation of factors 
responsible for recruiting macrophages to the sites of different types of tumours 
might help to develop more effective cancer treatment.      
Burkitt's lymphoma (BL) is an aggressive type of lymphoproliferative disorder 
characterised by uncontrolled cell proliferation, high rate of spontaneous apoptosis 
and significant macrophage infiltration. Although BL cells undergo extensive 
apoptosis, in situ their corpses are cleared very effectively by macrophages 
infiltrating the tumour tissue (Cooper et al. 1966; Berard et al. 1969; Levens et al. 
2000). It is now widely believed that dying cells are themselves able to release 
chemotactic molecules to ensure macrophage chemotaxis and subsequent clearance 
of their site of death (Horino et al. 1998; Knies et al. 1998; Lauber et al. 2003; Gude 
et al. 2008; Truman et al. 2008; Elliott et al. 2009). So far however, mechanisms 
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responsible for macrophage recruitment to the BL tumour site are not fully 
understood.  
Previous work carried out in this laboratory identified fractalkine/CX3CL1 (FKN) to 
be an important player in macrophage chemotaxis to BL (Truman et al. 2008). Yet, 
from the results presented by Truman and colleagues it can also be concluded that 
FKN may not be the only chemokine involved in this process. The authors have 
demonstrated that macrophages migrate to the supernatants collected from apoptotic 
BL cells. To understand the nature of this migration viral macrophage inflammatory 
protein II (vMIP-II) and pertussis toxin (PTX) were included in the assay. vMIP-II is 
a broad-range chemokine antagonist of the viral origin. It is known to efficiently 
block CC and CXC receptors as well as CX3CR1 - the only known FKN receptor 
(Chen et al. 1998; DeBruyne et al. 2000). PTX has the ability to block signal 
transduction through chemokine receptors by blocking G proteins to which 
chemokine receptors are coupled.  Both vMIP-II and PTX caused considerable 
abrogation of macrophage chemotaxis, suggesting that it was a chemokine-driven 
phenomenon. However, the usage of CX3CR1-deficient macrophages in a similar 
type of experiment caused the drop in the chemotaxis rate by only around fifty per 
cent when compared with the wild type macrophages. Based on these observations a 
hypothesis was formulated that apart from FKN another member(s) of chemokine 
family might have a role in the process of macrophage recruitment to Burkitt’s 
tumours (Truman et al. 2008). Lysophosphatidylcholine (LPC), which has been 
shown to be released from apoptotic MCF-7 cells and to have an ability to attract 
macrophages (Lauber et al. 2003), is also known to act through G protein-coupled 
receptor (Lin & Ye 2003; Radu et al. 2004; Yang et al. 2005; Peter et al. 2008). The 
experiments previously performed in this laboratory indicated, however, that LPC is 
not involved in macrophage chemotaxis to apoptotic BL cells (Truman, 
unpublished).  
Monocyte chemoattractant protein-1 (MCP-1, CCL2) has been selected as a 
candidate factor. MCP-1 is a very potent chemotactic molecule for monocytes. It 
regulates the migration of monocytes from the blood into tissue where they become 
tissue macrophages and, very importantly, is one of the chemokines most frequently 
found in tumours (Graves et al. 1989; Zhang et al. 1997; Nesbit et al. 2001; 
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Mantovani et al. 2002). A positive correlation between the level of MCP-1 
expression and the number of infiltrating macrophages has also been reported 
(Murdoch et al. 2004).     
The studies presented in this chapter were undertaken to determine the potential role 
of MCP-1 in macrophage recruitment to BL. 
3.2 MCP-1 expression in BL 
The starting point for this study was to examine MCP-1 expression in BL cells. Two 
human BL cell lines were used for this purpose – BL2 and BL2/Bcl-2 (BL2 that was 
previously transfected with the anti-apoptotic gene bcl-2). The cells were 
immunofluorescently labelled with anti-MCP-1 mononuclear antibodies (MAB2791) 
and subsequently analysed on the flow cytometer.  The level of total MCP-1 was 
assessed in permeabilised cells, whereas the intact cells were used for the surface 
expression measurements. Figure 3.1 shows a high level of MCP-1 expression in 
both BL2 and BL2/Bcl-2 cells (upper panel). On the lower panel it can be seen that 
there was no MCP-1 detected on the surface of these cells. The latter result is 
consistent with what was expected, knowing that MCP-1 is a classical small secreted 
chemokine, normally not present on cell surface. 
Having demonstrated that MCP-1 is present in BL cell lines, we next wanted to 
confirm this result using a mouse model of BL in which SCID mice were 
xenografted with BL2 cells. Monoclonal anti-MCP-1 antibodies (MAB2791) were 
used for immunohistochemistry staining of the tumour sections. As shown in  
Figure 3.2 the brown staining that represents MCP-1, was abundant in these sections. 
Significantly, the staining seemed to be associated mainly with B cells. The 
macrophages scattered throughout the tissue generally remained unstained, with the 
exception of the apoptotic cell debris that was visible inside the vacuoles. These 
observations led to the conclusion that the B cells, but not the macrophages are 





















































Figure 3.1 Expression of MCP-1 in BL cells. 
Permeabilised (upper panels) or intact (lower panels) BL2 and BL2/Bcl-2 cells 
were stained for MCP-1 using a mouse monoclonal anti-human MCP-1 
antibodies (MAB2791) (white), and FITC-conjugated goat anti-mouse 
secondary antibodies. Isotype control shows background staining (grey). 
3.3 MCP-1 release form apoptotic BL2 
cells 
Having shown that MCP-1 is produced by BL cells, it was important to determine 
whether, and under what conditions MCP-1 is released from these cells.  
It has previously been demonstrated that apoptotic cells release molecules that are 
chemotactic for phagocytes (Horino et al. 1998; Knies et al. 1998; Lauber et al. 
2003). FKN, which has been shown to be involved in macrophage recruitment to BL 
tumours, is also released from BL cells rapidly following the induction of apoptosis 
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Figure 3.2 Expression of MCP-1 in tumour tissue in situ. 
Immunohistochemistry of SCID/BL2 sections. Sections were labelled with 
mouse monoclonal anti-human MCP-1 antibodies (MAB2791). Brown staining 
represents MCP-1. No primary antibodies were used in the control slides. 
Nuclei were counter-stained blue with haematoxylin. 
3.3.1 Induction and measurement of BL2 cells apoptosis 
Even though group I BL lines, such as BL2 retain the ability of biopsy tumour cells 
to undergo spontaneous apoptosis, the usual level of apoptosis in BL2 cell culture 
does not exceed 10-15 per cent. Therefore it was necessary to establish an efficient 
and reliable method of triggering apoptosis of BL cells. The protein kinase inhibitor 
staurosporine was used as an apoptotic stimulus and the induction of apoptosis was 
assessed by staining the cells with Annexin V-FITC (AxV) and propidium iodide 
(PI) followed by FACS analysis. Figure 3.3 shows the typical pattern of AxV/PI 
staining obtained from staurosporine-treated BL2 cells in which staurosporine-
exposure generates a fairly uniform population of cells displaying typical features of 
early apoptotic cells (PS exposure on the outer leaflet of the plasma membrane but 
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Figure 3.3 Staurosporine is a potent inducer of apoptosis. 
BL2 cells were treated with 1µM staurosporine. Cells were harvested and 
stained with annexin V-FITC (AxV) and propidium iodide (PI) at the indicated 
times after apoptosis induction. Percentage of AxV+ and PI+ cells was 
measured by flow cytometry. Summary graph shows the percentage of viable 
(AxV-PI-) (blue bars), early apoptotic (AxV+PI-) (red bars) and late apoptotic 
(AxV+PI+) (black bars) cells at different time points (hrs) after induction of 
apoptosis. One representative result of more than thirty similar is shown. 
3.3.2  Measurement of MCP-1 release from apoptotic 
BL2 cells by ELISA   
Two cell lines - BL2 and BL2/Bcl-2 - were chosen for measurements of MCP-1 
secretion. BL2/Bcl-2 cells, which were resistant to apoptotic stimuli, were used to 
compare the MCP-1 release from non-apoptotic cells to that from the early apoptotic 
ones. Staurosporine was added to the cells and cell-free supernatants were collected 
at the indicated time points following its addition. Initially, the supernatants were 
analysed by a sandwich ELISA kit (R&D Systems) specific for MCP-1. However, by 
using this technique it was not possible to detect any MCP-1 in the samples (this data 
is not shown, but it is visible also in Figure 3.8). Similar problems have been faced 
by the previous group members while they were trying to measure the amount of 
other chemokines in BL cell supernatants but adopting a “direct” ELISA seemed to 
improve the assays sensitivity (Wilkinson 2006). Thus, a “direct” ELISA using anti-
MCP-1 mAb (MAB679) was set up. As presented in Figure 3.4a, MCP-1 was 
detected in the samples. Importantly, MCP-1 concentrations in the supernatants from 
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BL2 cells seemed to increase as the apoptosis programme progressed (Figure 3.4b). 
The level of MCP-1 increased considerably within only 2 hrs of staurosporine 
exposure, when the majority of cells became apoptotic but their cell membranes were 
still intact (AxV+PI-), suggesting that MCP-1 is actively released from early 
apoptotic cells. 
However, the most dramatic change in the MCP-1 concentration was observed 
between the samples from 2 and 3 hrs post staurosporine treatment, when the rise in 
a number of PI positive, and thus probably leaky, cells was also detected. In contrast, 
in the supernatants collected from BL2/Bcl-2 cells which remained more viable 
throughout the course of the assay, the amounts of MCP-1 were smaller (Figure 3.4a, 
right panel). A slight increase was only observed at 3 hrs post-staurosporine 
exposure, when the number of viable cells dropped to approximately 50 per cent 
(Figure 3.4b). These results led to the conclusion that the secretion of MCP-1 from 
BL cells is an apoptosis-dependant process.  
3.4 Role of MCP-1 in mononuclear 
phagocyte migration to BL 
Having established that MCP-1 is released from apoptotic BL cells, the role of  
MCP-1 in macrophage migration to these cells was examined. This was made 
possible by the use of a Boyden chamber-based transmigration assay in which 
mononuclear phagocytes are placed in a transwell, on top of a pored membrane, and 
allowed to transmigrate to the lower compartment, following the gradient of a 

































Figure 3.4 Release of MCP-1 from apoptotic BL cells. 
BL2 and BL2/Bcl-2 cells were induced to apoptosis by staurosporine treatment. 
Cells and cell supernatants were collected at the indicated times (hrs) after 
apoptosis induction. (a) Cell-free supernatants were tested for MCP-1 presence 
by direct ELISA. The error bars show the pooled standard deviation (n=2). (b) 
Apoptosis was assessed by AxV/PI staining. 
3.4.1 Human monocyte migration to recombinant 
human MCP-1 
In the first instance, the chemoattractant potential of MCP-1 for mononuclear 
phagocytes was tested using freshly isolated human monocytes that were allowed to 
migrate to a range of concentrations of rh MCP-1. Rh MCP-1 proved to efficiently 
induce transmigration of human monocytes in a concentration dependent manner 
(Figure 3.5a).  
3.4.2 Human monocyte-derived macrophage (HMDM) 
migration to supernatants from BL2 cells 
To further test the hypothesis that MCP-1 has a role in macrophage migration to 
dying BL cells, supernatants from apoptotic BL2 cells were used as a 
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Figure 3.5 Migration of mononuclear phagocytes to recombinant and BL 
cell-derived MCP-1 
(a) Migration of fresh CD14+ monocytes to a range (1-100 ng/ml) of rhMCP-1 
concentrations. C5a was used as a positive control and assay medium as a 
negative control. The error bars show the pooled standard deviation (n=2). One 
representative result from three is shown. (b) Six-day-old HMDMs were 
migrating towards rhMCP-1 (5ng/ml) and cell-free supernatants from apoptotic 
BL2 cells (collected 3 hrs after UV-irradiation). Addition of mouse polyclonal 
neutralising anti-human MCP-1 antibodies (2µg/ml) (AF-279-NA) inhibited 
macrophage migration. C5a was used as a positive control and assay medium as 
a negative control. The error bars show the pooled standard deviation (n=2). 
One representative result from two is shown. 
However, since staurosporine present in BL2 cell supernatants would affect the 
viability of tested macrophages, BL2 cells were instead induced into apoptosis by 
UVB exposure (Truman et al. 2008). Cell-free supernatants were collected after 3 hrs 
and subsequently used in a transmigration assay with six-day-old HMDMs. Rh 
MCP-1 was also included as a positive control in the assay. The chemotactic role of 
MCP-1 was examined by addition of neutralising anti-human MCP-1 antibodies 
(nAb) (AF279-NA). As shown in Figure 3.5b, HMDMs migrated to supernatant from 
apoptotic BL2 cells and rh MCP-1. The presence of nAb in the samples resulted in 
the impaired migration of macrophages to both rhMCP-1 and supernatants from 
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apoptotic BL cell, suggesting that MCP-1 is a potentially important factor in 
macrophage migration to dying BL cells.  
Based on the simple experiments presented here it would be impossible to establish if 
the observed migration of macrophages was a movement along the concentration 
gradient and can therefore be called chemotaxis. However, the chemotactic 
properties of the apoptotic BL cell supernatants have been extensively analysed by 
the previous members of this group. In the initial studies, Truman examined if the 
macrophage movement to the lower chamber was truly chemotactic by placing the 
BL cell supernatants also in the upper chamber and therefore, abolishing the 
chemotactic gradient. Subsequent calculation of the difference in number of 
migrating cells between the wells with and without the supernatants added above the 
filter allowed for confirmation that the apoptotic BL cell-derived supernatants truly 
have chemotactic properties (Truman 2005).   
3.5 MCP-1 immunodetection in the 
supernatants from apoptotic BL cells 
In parallel with the experiments presented above, an attempt was made to detect 
MCP-1 in previously used, EBV-negative BL2 and BL2/Bcl-2 as well as in EBV-
positive BL Mutu I cell supernatants by Western blotting. Again, BL cells were 
induced to death by either staurosporine or UV exposure. As these cells had 
previously been shown to secrete MCP-1 in a constitutive manner (Steube et al. 
1999), supernatants from overnight cultures of untreated or LPS-exposed HL-60 cells 
were also tested in this assay and served as a positive control. Prior to the 
electrophoresis, cell-free supernatants were treated with trichloroacetic acid (TCA) in 
order to precipitate and concentrate the proteins present in the samples. Two different 
antibodies were used to detect MCP-1 on the nitrocellulose membranes: MAB679 – 
also used as a detection antibody in the direct ELISA (Figure 3.4a), and AF279-NA – 
the MCP-1-neutralising antibody from Figure 3.5b, both of them being 
recommended for Western blot analysis by the supplier. Figure 3.6a shows a blot 
stained with AF279-NA antibodies. Surprisingly, bands of the size of MCP-1 (9-15 
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kDa) (Yoshimura & Leonard 1991; Ishii et al. 1995) were only present in HL-60 but 
not in BL samples. Therefore, a suspicion arose that MCP-1 might after all not be 
expressed by BL cells and that the inhibitory effect of AF279-NA antibodies on 
macrophage migration, observed in the chemotaxis experiment (Figure 3.5b), could 







































































































































Figure 3.6 MCP-1 detection by Western blotting in BL and HL-60 cells. 
(a & b) BL2, Mutu I and BL2/Bcl-2 cells grown in serum-free RPMI 1640 or in 
X-Vivo (xv) were induced into apoptosis using either staurosporine (stauro) or 
UV exposure and cell-free supernatants were collected after 3 hrs of incubation. 
Supernatants from overnight cultures of HL-60 or LPS-treated HL-60 cells were 
also collected. Proteins were precipitated from the medium by TCA and 
analysed by Western blotting. (a) Membrane was labelled with AF279-NA  
anti-MCP-1 antibodies. (b) Membrane was labelled with MAB679 anti-MCP-1 
antibodies. (c) MCP-1 was detected by immunoblotting of HL-60, BL2, Mutu I 
and BL2/Bcl-2 whole cell lysates. MAB2791 antibodies were used to label the 
membrane. 
Even more puzzlingly, when MAB679 antibodies were used for the labelling of the 
membrane, no MCP-1-size band was detected, even in the HL-60 samples (Figure 
3.6b). The only clearly visible bands, detected in the BL cell supernatants 
exclusively, were of around 50 kDa. As MCP-1 has never been reported to be of a 
size other than 9 -15 KDa, typical for this group of small secretory chemokines, it 
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was concluded that the occurrence of the 50 kDa band might be a result of non-
specific or cross-reactive binding of the antibodies. This in turn, prompted concerns 
that the positive result of the direct ELISA (Figure 3.4a) may be due to a cross-
reactivity of the MAB679 antibodies. In conclusion, the experiments presented so far 
in this section failed to detect MCP-1 in the supernatants of BL cells raising 
questions about the validity of the results reported earlier in this chapter. 
MAB2791 antibodies initially detected MCP-1 in BL cells when used to label cells 
for FACS analysis (Figure 3.1) or in the immunohistochemistry (Figure 3.2). The 
ability of these antibodies to detect MCP-1 in BL and HL-60 whole cell lysates by 
Western blotting was thus tested despite these antibodies not being recommended for 
this technique by the supplier. Nonetheless, 15 kDa (one of the possible sizes of 
MCP-1) bands were visible in both HL-60 and BL samples (Figure 3.6c). Western 
blot with MAB2791 thus supported earlier observations made in this chapter 
concerning MCP-1 expression in BL. 
3.6 Analysis of BL cells expression of 
MCP-1 mRNA  
Being unable to produce conclusive evidence for MCP-1 expression or its lack at the 
protein level, the expression of its mRNA in BL cells was assessed.  
Total RNA was extracted from both viable and apoptotic BL2 cells as well as from 
HL-60 cells (untreated or stimulated with LPS). Next, cDNA was obtained from all 
the samples using reverse transcriptase and polymerase-chain reaction was carried 
out with MCP-1-specific primers. The reaction mixtures were analysed on the 
agarose gel (Figure 3.7a). 
Clear and bright product bands of the expected size were visible in both of the HL-60 
samples but in none of the BL2 ones. As the control reactions with the  
GAPDH-specific primers were also included in this experiment and the levels of the 
specific product bands in all the control samples were similar, it suggests that the 
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lack of MCP-1 band in BL2 samples is a result of MCP-1 mRNA being absent in 
these cells rather than being due to the analysis of poor quality cDNA.   
HL60+
LPSHL60 BL2 BL2 BL2
HL60+















Figure 3.7 Analysis of MCP-1 RNA transcripts present in HL-60 and BL 
cells. 
(a) Total RNA was extracted from HL-60, LPS-treated HL-60 and BL2 (x3) 
cells and reverse transcriptase PCR for MCP-1 was performed. Control 
reactions for GAPDH were also performed. (b)  Total RNA was extracted from 
HL-60, LPS-treated HL-60, BL2 (x3), Mutu I, BL2/Bcl-2 as well as from 
staurosporine-treated BL2 and Mutu I cells and reverse-transcriptase PCR for 
MCP-1 was performed. Selected bands (circled) were extracted from the gel, 
DNA was purified and sequenced. The sequence of the amplification product 
from HL-60 sample matched the sequence of human MCP-1. The sequences 
obtained from the other extracted samples did not match any known gene 
sequences. 
Although this seemed like a rather strong argument for the lack of MCP-1 expression 
in BL cells, the presence of the low intensity bands of the approximately MCP-1 size 
in some BL2 samples (not well visible in Figure 3.7a, but clear in Figure 3.7b) was 
still causing some concern. In order to resolve the remaining doubts, PCR reactions 
were performed with the previously analysed samples and with additional ones 
prepared from Mutu I BL cells. Some of the strong MCP-1 bands from HL-60 cell 
samples and faint and, incorrectly sized bands in BL cell samples (Figure 3.7b) were 
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extracted, purified and sent away to the University DNA sequencing facility 
(Ashworth Laboratories). Sequencing showed that only the sequence obtained from 
the HL-60 band analysis matched the MCP-1 sequence (NCBI Blast). Poor quality 
sequences from BL preparations did not match any of the known DNA sequences in 
the genome. In summary, the results presented in this section suggested that MCP-1 
RNA transcripts may not be present in BL cell lines and added to the evidence 
suggesting MCP-1 is absent from BL.  
3.7 Analysis of HL-60 cell-free 
supernatants by MCP-1 ELISA  
Although MCP-1 mRNA has been shown in the previous section to be expressed in 
HL-60 cells, the results obtained in the Western blot analysis of the HL-60 
supernatants (Figure 3.6a) did not provide consistent results proving the presence of 
MCP-1 in these cells. Since HL-60 cells were intended to serve as a positive control 
in the assays, a confirmation of the presence of MCP-1 in these cells was sought. For 
this reason, cell-free supernatants from HL-60 overnight cultures (untreated and 
LPS-stimulated) were analysed by sandwich ELISA (Figure 3.8). Significant levels 
of MCP-1 were detected in both samples whereas, consistent with the earlier 
observations, no MCP-1 could be found in supernatants from apoptotic BL2, 
BL2/Bcl-2 and Mutu I cells. Taken together, these observations strongly indicate that 
MCP-1 is not produced by Burkitt’s lymphoma cell lines rather than there being a 































Figure 3.8 Release of MCP-1 from HL-60 cells. 
Cell-free supernatants from HL-60 and LPS-treated HL-60 cells overnight 
cultures as well as the supernatants from BL2, BL2/Bcl-2 and Mutu I induced 
into death with staurosporine for 3 hrs were analysed by sandwich ELISA. The 
error bars represent the standard error of the mean (n=3). One representative 
result from two is shown. 
3.8 Conclusions and Discussion     
In summary, the work described in this chapter: 
• confirmed previous observations (Truman 2005) that apoptotic Burkitt’s 
lymphoma cells release factors that induce macrophage migration 
• demonstrated that, although some of the tested anti-human MCP-1 antibodies 
bound to the epitopes present in BL cells, MCP-1 is, most likely, not 
expressed by these cells 
MCP-1 is known to be a strong chemoattractant for monocytes. It is also one of the 
most commonly found chemokines of the tumour environment (Nesbit et al. 2001). 
MCP-1 was thus selected as a candidate chemoattractant that could work alongside 
fractalkine (Truman 2005) to enable macrophage infiltration in Burkitt’s lymphoma. 
For this reason, attempts were made to assess the levels of MCP-1 in BL samples. 
The high intensity of the MCP-1 staining seen in both immunohistochemistry and 
FACS measurements (Figure 3.1 and Figure 3.2) initially seemed very promising and 
prompted the subsequent studies presented here. These included demonstrating the 
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presence of MCP- 1 in BL cells using a direct ELISA (Figure 3.4a) as well as 
(although indirectly) using transmigration assays (Figure 3.5b). The inhibition of 
macrophage migration observed after the addition of anti-MCP-1 neutralising 
antibodies seemed consistent with the hypothesis that apoptotic BL cells release a 
chemokine(s) other than fractalkine to attract macrophages (Truman 2005). Taken 
together, these observations suggested that MCP-1 is highly expressed by, and 
released from, BL cells early in the apoptotic cell death programme. 
However, doubts were raised as to the accuracy of this conclusion when Western 
blotting was used to detect MCP-1 in apoptotic BL cell supernatants. None of the 
antibodies previously used to test for MCP-1 presence in BL cell supernatants were 
able to detect MCP-1 in the samples by Western blotting. When MAB679 antibodies 
were used (the same as in the direct ELISA), the only strong bands that were 
detected were of 50 kDa in size and were of unknown identity (Figure 3.6b). The 
presence of these bands was limited to BL cells - they were not observed in HL-60 
cell supernatants. Intriguingly, MCP-1 (band of 9 - 15 kDa) was also absent from 
HL-60 cell samples (these cells are known to express this chemokine (Steube et al. 
1999). These results suggest that MAB679 antibodies may not be very good at 
detecting 9-15 kDa MCP-1 in Western blotting and that the apparent detection of 
MCP-1 in BL cells using the direct ELISA may have been due to detection of the 50 
kDa protein of unknown identity.  
By contrast, AF279-NA antibodies were able to detect 9-15 kDa MCP-1 bands in 
HL-60 samples but were unable to detect these MCP-1 bands in BL cell supernatants 
(Figure 3.6a). These observations raise the question: how did these antibodies impair 
macrophage migration when added to BL supernatants, if they did not detect MCP-1 
in the same samples by Western blotting despite MCP-1 bands being detectable in 
Western blots of HL-60 supernatants? One possible explanation is that AF279-NA 
antibodies blocked the action of another macrophage chemoattractant present in the 
apoptotic BL cell supernatants (and thus inhibited macrophage migration) but 
binding to this protein was not visualised by Western blotting perhaps due to the 
denaturation of proteins whilst TCA-precipitating the supernatants and heating the 
samples in preparation for Western blotting. It would be feasible to test this 
possibility by pre-incubating the antibodies with recombinant MCP-1 prior to testing 
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their inhibitory effect on the macrophage migration. If this is indeed what is 
happening it would be interesting to identify this protein, for example by 
immunoprecipitating it with the AF279-NA antibodies. However, it is equally 
possible that the observed inhibition of the macrophage transmigration was caused 
by alternative effects these antibodies could have had on macrophage migration or 
viability. It would therefore be important to confirm these results by using suitable 
isotype control antibodies in the transmigration assay.  It is possible that the observed 
impairment of the phagocyte migratory properties was caused by a binding of 
antibody aggregates or antibody-antigen complexes to the Fc receptors on their 
surface, macrophage activation and consequently, adhesion. In order to eliminate 
such a risk, it would be profitable to employ in this assay the MCP-1-specific Fab (or 
F(ab)’2) fragments of antibodies, which contain their antigen-binding domain but are 
deprived of their power to ligate receptors on the surface of phagocytes. 
The use of a third anti-MCP-1 antibody in Western blotting (MAB2791 - previously 
used to detect MCP-1 in BL samples by immunohistochemistry and FACS analysis 
(Figure 3.1 and Figure 3.2) produced a different set of results with 15 kDa bands - 
one of the possible sizes of MCP-1 (Ishii et al. 1995) - being clearly visible in all the 
BL and HL-60 cell lysate samples (Figure 3.6c). This suggested that BL cells might 
contain MCP-1.   
Having obtained such an inconsistent set of results it was important to examine 
MCP-1 mRNA levels in BL cell lines (Figure 3.7). By showing the absence of  
MCP-1 mRNA in BL cells, despite this mRNA being detectable in HL-60 cells, it 
seemed highly likely that MCP-1 is not produced by BL cells.  
The results gathered from RT-PCR analysis, sandwich ELISA and WB analysis with 
AF279-NA antibodies, weighed strongly against MCP-1 presence in BL cells. The 
direct ELISA, WB with MAB679 antibodies and inhibition of chemotaxis by AF279-
NA antibodies were shown to be unreliable because of the cross-reactivity of the 
antibodies. The only evidence supporting MCP-1 presence in BL cells therefore 
come from the experiments where MAB279 antibodies were used.  
As the negative results, produced by a variety of techniques, seem to overwhelm the 
positive results, it is necessary to conclude that MCP-1, most likely, is not expressed 
 
 91 
in Burkitt's lymphoma. Interpretation of the MCP-1 data has been greatly 
complicated by the cross-reactivities of the anti-MCP-1 antibodies (at least one – 
MAB679 – out of three of the antibodies used in this study appears to cross-react 
with other protein species).  
In hindsight, the inability to detect MCP-1 in BL samples using the sandwich ELISA 
should have been better recognised as a strong indication that the BL cells may not 
release MCP-1. Since the sandwich ELISA requires two different epitopes on the 
same protein to be bound by two different antibodies in order for the assay to give a 
positive result it should not be prone to generate false positive results. This was 
clearly exemplified in the results – the sandwich ELISA only detected MCP-1 in the 
samples with clearly confirmed MCP-1 expression (HL-60) and was unable to show 
MCP-1 expression in samples in which the expression of MCP-1 had not been 
confirmed (BL cells) (Figure 3.8). By contrast, the direct ELISA (Figure 3.4a), as 
with other techniques based on a single type of antibody, is more likely to be 
impaired by antibody cross-reactivity.  
Although the work presented in this chapter may look unfinished, some of the results 
not utterly convincing and one would wish to repeat them or include additional 
controls where appropriate, when the convincing proof had been obtained for the 
lack of MCP-1 mRNA expression in BL cell lines, the decision was made to halt all 
further work concerning MCP-1. 
This chemokine has been detected in several types of cancer, including lymphomas, 
and the roles of MCP-1 in macrophage infiltration of tumours (Graves et al. 1989) 
and in promoting tumour progression via enhancing angiogenesis (Salcedo et al. 
2000; Ma et al. 2007) are well recognised.  Furthermore, Luciani and colleagues 
demonstrated that it is widely expressed by Hodgkin’s lymphoma as well as some of 
the B-cell lymphoma cells (Luciani et al. 1998). However, the general experimental 
approach taken by the authors does not specify which cellular component of these 
tumours is responsible for the MCP-1 production and normally monocytes, 
endothelial cells and fibroblasts, but not B cells, are considered to be a source of 
MCP-1 (Schall 1991). A constitutive MCP-1 production is also characteristic of 
neoplastically transformed cells. MCP-1 expression has been studied in detail in two 
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types of B-cell lymphoma: in diffuse large B-cell lymphoma, malignant B cells have 
been found to produce MCP-1 whereas in follicular lymphoma, MCP-1 has been 
shown to be present in follicular dendritic cells, not in B cells (Husson et al. 2001; 
Kitai et al. 2007). Although data presented in this chapter shows that Burkitt’s 
lymphoma B cells most likely do not express MCP-1, the possibility that resident 
TAMs do, and therefore might self-regulate the level of macrophage infiltration to 
the tumour, was not excluded. For just now, the identification of the chemokine that 
works in conjunction with fractalkine to mediate macrophage recruitment in BL 
(Truman et al. 2008) remains unknown. A candidate chemokine will be discussed in 
Chapter 6.  
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Chapter 4  
FKN processing in 
apoptotic BL cells 
4.1 Introduction 
Fractalkine/CX3CL1 (FKN), the only member of CX3C chemokine family, is 
structurally unusual in that it, like CXCL16, is a transmembrane molecule. Its 
chemokine domain is situated at the end of long mucin-like stalk, fixed to the plasma 
membrane by a transmembrane domain and a cytoplasmic tail (Figure 1.1) (Bazan et 
al. 1997; Ludwig & Weber 2007). FKN present on the surface of cells (for example 
epithelial cells) plays a role in adhesion and migration of cells carrying the only 
known receptor for FKN – CX3CR1 (Imai et al. 1997; Lucas et al. 2001; Ludwig & 
Weber 2007). However, once the chemokine domain of FKN is freed it can act as a 
secretory chemokine - it is known to be a chemotactic factor for monocytes, T cells 
and natural killer cells (Tsou et al. 2001). In recent years several proteases engaged 
in the shedding of FKN from the cell membrane have been identified. At first, two 
metalloproteinases – ADAM-10 and ADAM-17 were found to be key players in this 
process (Garton et al. 2001; Hundhausen et al. 2003; Hundhausen et al. 2007; 
Schulte et al. 2007). More recently, however, cathepsin S and MMP-2 have also been 
shown to take part in the cleavage and release of FKN (respectively: Clark et al. 
2007; Clark et al. 2009; Bourd-Boittin et al. 2009; Dean and Overall 2007). 
As already mentioned in Chapter 3, previous work within the Gregory group has 
shown FKN to have a role in recruiting macrophages to Burkitt’s lymphoma tumours 
(Truman 2005; Truman et al. 2008). In this study, FKN was demonstrated to be 
released predominantly by dying BL cells and the initial Western blot analysis 
revealed that FKN present in BL cells was modified (presumably truncated) when 
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these cells underwent apoptosis. However, the nature of this process was not further 
characterised (Truman 2005; Wilkinson 2006).  
The studies presented in this chapter were carried out as a continuation of the 
research on FKN that was initiated by Truman. The aim of this study was to broaden 
our understanding of FKN biology in BL with the primary focus on explaining the 
modification of FKN during BL cell death. The mechanism of FKN release from 
dying cells was also examined. In particular, the possibility that FKN is released in 
microparticles (MPs) during the apoptotic blebbing of BL cells was explored. 
Furthermore, the analysis of FKN expression in germinal centre (GC) B cells – the 
healthy counterparts of BL cells – was investigated. 
4.2 Immunodetection of FKN in BL cells 
In an attempt to repeat the results generated by Truman, BL2 cells were induced to 
undergo apoptosis by exposure to staurosporine and were lysed at the indicated time 
points. Western blot analysis of the samples was carried out using monoclonal anti-
FKN chemokine domain and mucin stalk antibodies. An interesting correlation of the 
FKN band changes could be seen (Figure 4.1a) - as early as 2 hrs post-staurosporine 
exposure a 90 kDa band was replaced by a 60 kDa one. Importantly, the change took 
place when a large percentage of the cells started to display early apoptotic features 
i.e. PS exposure on cell surface (Figure 4.1b). 
Next, the supernatants gathered from the cultures of staurosporine-treated BL2 cells 
were analysed in the same manner. Again, the 60 kDa species of FKN was detected 
at 2 hrs after staurosporine exposure, but the accompanying loss of the 90 kDa one 























































Figure 4.1 FKN detection in BL2 cells by Western blotting. 
BL2 cells were induced to undergo death by staurosporine (stauro). The cells 
and cell-free supernatants were harvested at 1, 2 and 3 hrs after apoptosis 
induction. (a) The lysed cells and proteins precipitated from the medium by 
TCA were analysed by Western blotting. Blots were labelled using mouse anti-
human FKN monoclonal antibodies (MAB3651). (b) Apoptosis was assessed 
by AxV/PI staining (c) A view of the longer exposed film. One representative 
result of more than twenty is shown. (d) Schematic picture showing fragments 
of wild-type full-length FKN and recombinant human FKN (R&D Systems) 
which are recognised by mouse monoclonal anti-human FKN chemokine 
domain antibodies (MAB3651) and goat anti-human FKN C-terminal end 




The 90 kDa-sized FKN was reported to represent either a full-length chemokine or a 
FKN cleaved in a membrane-proximal region - consisting of the chemokine domain 
and the majority of the mucin stalk (Bazan et al. 1997; Garton et al. 2001). As the  
90 kDa FKN band was detected both in the lysates and as a soluble form in the 
supernatants (Figure 4.1a) of apoptotic BL cells it is possible that it represents the 
cleaved form of FKN. The 60 kDa FKN is believed to be another cleaved form of 
FKN, and based on its size, it is most likely cleaved further down the mucin stalk. 
However, due to the extensive and irregular glycosylation of FKN it is not possible 
to predict the exact cleavage site leading to the generation of the 60 kDa form.  
The identity of the 70 kDa band detected by anti-FKN antibodies is unknown. Its size 
suggests that it might be an incompletely glycosylated precursor form of FKN (what 
could perhaps be investigated by exposing it to deglycosylating enzymes and 
subsequently, comparing its size with that of the deglycosylated full-length form) 
(Garton et al. 2001) but it might as well represent another form of cleaved FKN. 
However, considering that no regular changes to the intensity of this band have been 
detected by Western blotting of samples prepared from BL cells treated in various 
ways, it is equally possible that this band represents a non-specific binding of the 
antibodies. The nature of this band was not explored further in the studies presented 
in this thesis.  
Although FKN bands presented in Figure 4.1 a were the most distinctive ones, within 
the size-range well characterised in the literature and will be in the focus of the 
studies presented later, it has to be noted that Western blots of apoptotic BL2 cells 
labelled with anti-FKN antibodies contained a wealth of differently sized bands 
(Figure 4.1c). The identity of those bands remains unknown and it cannot be excluded 
that some of them represent an unspecific antibody binding. However, their presence 
might also result from additional, yet unidentified, proteolytic events. 
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4.3 The role of apoptosis programme in 
FKN modulation in BL cells     
In order to confirm this initial observation that the modulation of FKN seems to 
correlate with apoptosis of BL cells (Figure 4.1), FKN was studied in BL2 cells in 
which the cell death process was inhibited. Firstly, BL2 cells that were resistant to 
apoptosis through their stable transfection with the pro-survival gene bcl-2  
(BL2/Bcl-2 cells) were used. Despite treatment with staurosporine, these cells 
remained viable (Figure 4.2b). Furthermore, the 90 kDa FKN was intact in the cell 
lysates and the 60 kDa FKN was neither detected in the cell lysates nor in the cell-
free supernatants (Figure 4.2a). 
Similar results were gathered when BL2 cells were pre-treated with a poly-caspase 
inhibitor Z-VAD-FMK before the addition of staurosporine. Again, the 60 kDa form 
of FKN was not observed in any of the samples and the cells remained highly viable 
(Figure 4.2c, d). 
Additional control reactions were also set up. Both BL2 and BL2/Bcl-2 cells were 
induced to death by UV light in order to exclude a possibility that the previously 
described (Figure 4.2a, c) modulation of FKN is a staurosporine-specific mechanism. 
As it is shown on Figure 4.3a, the pattern of FKN bands from UV-irradiated BL2 
cells repeated that of BL2 cells induced into apoptosis by staurosporine. Also, BL2 
cells cultured in RPMI 1640 with 10% FBS (as used in the experiments presented 
above) were compared with the cells cultured in X-Vivo media (serum-free) to 
ensure that the FKN previously detected by Western blotting was derived from BL 
cells and not form FBS. Figure 4.3b shows that the same pattern of FKN bands was 
detected in both samples indicating the FKN was not serum-derived. 
Data presented here strongly supported the notion that the processing of 90 kDa FKN 
is an apoptosis-driven process in BL cells that results in the generation of 60 kDa 
FKN in the cell-free supernatants. 
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4.4 Loss of FKN from the surface of 
apoptotic BL cells 
Given that FKN is modulated during BL cell death to generate a 60 kDa apoptosis-
associated form of the molecule (Figure 4.1 andFigure 4.2) and published 
observations have shown that membrane-associated FKN can be released from cells 
as a soluble form via proteolytic cleavage (Bazan et al. 1997), it was important to 
monitor the expression of FKN on the surface of Burkitt’s lymphoma cells. 
Surface expression of FKN on BL cells has previously been assessed by both 
Truman and Wilkinson (Truman 2005; Wilkinson 2006). Truman demonstrated that 
FKN that is normally present on the surface of Mutu I cells is lost quickly when the 
cells enter the apoptosis programme. This indicated that the shedding of FKN might 
be an apoptosis-related phenomenon. However, further analysis performed by 
Wilkinson showed that FKN was lost not only from UV-irradiated Mutu I cells but 
also from Bcl-2-overexpressing (and therefore apoptosis resistant) Mutu I cells 
suggesting that this process is not necessarily connected to apoptosis. The studies 
presented here were undertaken to determine the dependence of FKN shedding on 
apoptosis of BL cells. 
Initially, BL2 and BL2/Bcl-2 cells were exposed to staurosporine to induce 
apoptosis. The cells were collected up to 4 hrs post-staurosporine treatment, stained 
for surface FKN and subsequently analysed by flow cytometry (Figure 4.4a). The 
viability of the cells was also assessed by AxV/PI staining (Figure 4.4b). Although 
only the staurosporine-treated BL2 cells underwent apoptosis, a loss of surface FKN 
was observed at the 1 hr time-point in all the cases analysed. However, only the 
apoptotic BL2 cells showed a further decrease in surface FKN levels after 2-4 hr 
culture. In all the other cells the levels of FKN remained unchanged throughout the 
remainder of the experiment. This would suggest that only the loss of FKN observed 
at 2 hrs is related to apoptosis. Importantly, this correlates well with the Western blot 
data in which 60 kDa FKN was observed in the lysates and supernatants of apoptotic 
BL2 cells 2 hrs after staurosporine treatment of the cells (Figure 4.1). The loss of 
FKN recorded in all the samples at the 1 hr time-point might represent a constitutive 
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FKN shedding or be a consequence of cell handling during the early stages of the 
experimental procedure that could have caused damage or possibly, activation of the 
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Figure 4.2 Role of apoptosis in FKN processing in BL2 cells. 
(a) BL2 and BL2/Bcl-2 cells were induced to undergo death by staurosporine. 
The cells and cell-free supernatants were harvested at 1, 2 and 3 hrs after the 
apoptosis stimulus. The lysed cells and proteins precipitated from the medium 
by TCA were analysed by Western blotting. Blots were labelled using 
MAB3651 antibodies. (b) Apoptosis was assessed by AxV/PI staining. One 
representative result of more than five was shown. (c) BL2 cells were incubated 
for 30 min with caspase inhibitor Z-VAD-FMK and subsequently induced into 
death by staurosporine. The lysed cells and proteins precipitated from the 
medium by TCA were immunoblotted with MAB3651 antibodies. (d) 




















































Figure 4.3 Effect of experimental conditions on FKN detection in BL cell 
samples 
(a) BL2 and BL2/Bcl-2 cells were induced to death by either staurosporine or 
UVB light. Cell-free supernatants were immunoblotted using MAB3651 
antibodies. (b) BL2 and BL2/Bcl-2 cells were placed in RPMI 1640 + 10% FBS 
or in X-Vivo medium, induced to undergo death by staurosporine, collected 
after 3 hrs, lysed and immunoblotted using MAB3651 antibodies. 
A comparison of the levels of surface FKN at the 2 hr time-point of the differentially 
treated cells is presented in Figure 4.4c. A pre-incubation of BL2 cells with  
Z-VAD-FMK prior to staurosporine exposure, inhibited the loss of FKN. Similarly, 
BL2/Bcl-2 cells, even when incubated with staurosporine, again, showed no decrease 
in FKN levels. These observations led to the conclusion that substantial loss of FKN 
from the surface of BL cells is only observed when the cells undergo apoptosis and 
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Figure 4.4 Loss of surface FKN during apoptosis of BL2 cells. 
BL2 and BL2/Bcl-2 cells were either induced into death by staurosporine, pre-
treated with Z-VAD-FMK for 30 min and then treated by staurosporine or left 
untreated. (a) The samples were collected after 1, 2, 3 and 4 hrs of incubation, 
labelled with anti-FKN antibodies (MAB3651) or IgG1 isotype control 
followed by FITC-conjugated anti-mouse antibodies. FKN labelling was 
assessed by FACS. (b) Apoptosis was assessed by AxV/PI staining. (c)  FACS 
plots comparing the level of FKN on the cells harvested after 2 hrs of 
incubation and stained with anti-FKN antibodies (MAB3651) and matching 




4.5 Searching for a protease that cleaves 
FKN during apoptosis of BL cells 
4.5.1 The role of metalloproteinases 
Members of the metalloproteinase family of proteins have been well characterised as 
key proteases responsible for the processing of FKN. ADAM-10 has been shown to 
be engaged in the constitutive shedding of membrane-bound FKN, whereas ADAM-
17 (TACE) has been identified to play a role in its inducible cleavage (Garton et al. 
2001; Hundhausen et al. 2003). In addition, MMP-2 has more recently emerged as a 
FKN-specific protease (Dean & Overall 2007). As it seemed likely that the 60 kDa 
form of FKN is generated from the 90 kDa form of FKN through the proteolytic 
cleavage (Figure 4.1), the involvement of the metalloproteinases in this process was 
assessed. 
For this purpose, BL2 cells were pre-treated with the metalloproteinase inhibitors, 
GM6001, TIMP-1 and TAPI-2 (see Table 2-1 for details) prior to the induction of 
apoptosis. A range of inhibitors with slightly varied specificities for ADAM-10 and 
ADAM-17 was chosen to enable the identification of the protease involved. GM6001 
is a broad-range inhibitor, known to act both on MMP and ADAM protease families. 
Although it is able to inhibit both ADAM-10 and ADAM-17, it has much higher 
effectiveness against ADAM-17 (Moss & Rasmussen 2007) and has previously been 
reported to inhibit ADAM-17-dependant shedding of FKN (Garton et al. 2001). 
TIMP-1 belongs to the family of natural tissue inhibitors of metalloproteinases. 
Apart from inhibiting MMPs, it is known to specifically block the activity of 
ADAM-10, but not ADAM-17 (Amour et al. 2000; Rapti et al. 2008). TAPI-2, 
although developed to block ADAM-17 activity, is now recognised as a broad-
spectrum inhibitor of both MMP and ADAM family members (Ito et al. 2004; Kenny 
& Bissell 2007; Moss & Rasmussen 2007). 
After 30 min pre-incubation with the inhibitor of choice, the cells were induced into 
apoptosis using staurosporine and incubated for the indicated time. FKN was 
detected by Western blotting in both whole cell lysates (Figure 4.5a) and 
supernatants (Figure 4.5b). None of the metalloproteinase inhibitors prevented 
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staurosporine-treated cells from losing the 90 kDa FKN (in the whole cell lysate 
samples) and gaining the 60 kDa FKN (in both lysate and supernatant samples), 
suggesting that the process of FKN cleavage in apoptotic BL cells might not be 
driven by metalloproteinases. Although the inhibitor activity controls were not 
included in these preliminary experiments, the fact that the chosen compounds are 
widely used and in the presented study were employed in well-established working 
concentrations, together with their overlapping substrate specificities, provides a high 
level of authenticity to the gathered data. Also, the fact that unlike FKN fragments 
generated by ADAM proteases, which have a size of 80-90 kDa (Garton et al. 2001; 
Hundhausen et al. 2003), the FKN generated during BL cell death was only of 60 
kDa size may indicate that a protease different to those previously described is 
involved in this process. 
4.5.2 Effect of broad-spectrum inhibitors 
Having established that metalloproteinases are most likely not involved in cleaving 
FKN during BL cell death, a more general approach, involving the use of broad-
spectrum inhibitors with different specificities, was taken in order to get an 
indication as to what type of protease might be involved in the process. Again, a set 
of well-characterised inhibitors with overlapping properties was selected for the 
study (see Table 2-1 for details). As previously, BL2 cells were pre-treated with 
inhibitors for 30 min prior to the addition of staurosporine. Samples were collected 
after 1-3 hrs of incubation and changes in FKN band pattern were analysed by 
Western blotting (Figure 4.6). The results obtained were surprising, as none of the 
used inhibitors seemed to block the generation of the 60 kDa FKN.   
4.5.3 Role of caspases 
4.5.3.1 Specific caspase inhibitors 
From the inhibitors used thus far only the poly-caspase inhibitor Z-VAD-FMK was 
capable of constraining the generation of 60 kDa FKN (Figure 4.2c). Although, it is 
impossible to distinguish if the blockade of FKN cleavage was a direct consequence 
of Z-VAD-FMK inhibiting a caspase(s) responsible for cleaving FKN or it was an 
outcome of the blockade of apoptosis, resulting in an indirect inhibition of another 
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Figure 4.5 Effect of selected inhibitors with various specificity for MMP and 
ADAM protease families on FKN processing in apoptotic BL2 cells. 
BL2 cells were pre-incubated for 30 min with one of the inhibitors: TIMP-1, 
TAPI-2 or GM6001, and subsequently induced into death by staurosporine. The 
samples were harvested after 1, 2 and 3 hrs of incubation and immunoblotted 
with anti-FKN antibodies (MAB3651). (a) Western blot of the whole cell 
lysates. (b) Western blot of cell-free supernatants that were concentrated using 
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Figure 4.6 Effect of broad spectrum inhibitors on FKN processing in 
apoptotic BL2 cells. 
BL2 cells were pre-incubated for 30 min with one of the inhibitors: 
chymostatin, leupeptin, E-64, aprotinin, Z-Lu-Leu-CHO, calpeptin or DMSO 
(ctrl), and subsequently induced into death by staurosporine. The samples were 
harvested after 1, 2 and 3 hrs of incubation and immunoblotted with mouse anti-
FKN antibodies (MAB3651). (a) Western blot of the whole cell lysates. (b) 
Western blot of cell-free supernatants that were concentrated using TCA. One 
representative result from two is shown. 
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A set of more specific cell-permeable peptide inhibitors of caspases was tested at 
first. Although the suitability of these peptide inhibitors for identification of 
individual caspases involved in a studied process has been questioned (Pereira & 
Song 2008), it was believed that they would provide at least an indication as to if and 
which caspases might be involved in FKN processing. The cells were prepared as 
before and the obtained Western blots are presented in Figure 4.7. Two inhibitors, 
DEVD-FMK (inhibitor of caspase-3, -7) and AEVD-FMK (inhibitor of caspase-10 
(but possibly also -6, -8, -9 – Garcia-Calvo et al. 1998) were effective in inhibiting 
the changes in the FKN band pattern (the result could be seen both in the whole cell 
lysates – Figure 4.7a and in the cell supernatants – Figure 4.7b). Importantly, the 
AxV/PI staining showed that the addition of specific caspase inhibitors had a less 
profound effect than Z-VAD-FMK on apoptosis and neither DEVD-FMK nor 
AEVD-FMK did inhibit the staurosporine-induced death of BL2 cells (Figure 4.8). 
From these results, it would seem possible that a caspase cleavage might be 
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Figure 4.7 Effect of peptide caspase inhibitors on processing of FKN in apoptotic BL2 
cells. 
BL2 cells were pre-incubated for 30 min with one of the inhibitors: Z-YVAD-FMK,Z-
VDVAD-FMK, Z-DEVD-FMK, Z-LEVD-FMK, Z-WEHD-FMK, Z-VEID-FMK, Z-IETD-
FMK, Z-LEHD-FMK, Z-AEVD-FMK, Z-LEED-FMK or control compound –FMK (all at 25 
µM concentration, unless stated otherwise) and subsequently induced into death by 
staurosporine. The samples were harvested after 1, 2 and 3 hrs of incubation and 
immunoblotted with anti-FKN antibodies (MAB3651). (a) Western blot of the whole cell 
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Figure 4.8 Effect of peptide caspase inhibitors on viability of BL2 cells. 
 Apoptosis was assessed by AxV/PI staining. One representative result from 
three is shown. 
4.5.3.2 Cleavage studies 
Caspase-3 is responsible for processing the majority of caspase substrates cleaved 
during apoptosis (Kumar 2007; Walsh et al. 2008) and therefore was considered to 
be a likely candidate for a FKN-hydrolysing agent. A direct effect of caspase-3 on 
FKN was therefore investigated. Recombinant human caspase-3 was incubated for  
2 hrs with a whole cell lysate prepared from untreated BL2 cells. Subsequently, FKN 
from the samples was visualised by Western blotting (Figure 4.9a). A band, of the 
size of the 60 kDa FKN that is observed in BL2 cells that have been treated with 
staurosporine for 2 hrs, was produced in the sample when recombinant caspase-3 was 
added. The generation of the band was completely inhibited by Z-DEVD-FMK and  
Z-VAD-FMK. Similarly, recombinant caspase-3 was incubated with recombinant 
FKN (Figure 4.9b). A lower molecular weight, most likely a hydrolysis product – as 
it was sensitive to Z-DEVD-FMK, was detected after the addition of recombinant 
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Figure 4.9 Recombinant human caspase-3 cleaves FKN to generate 60 kDa 
form. 
(a) Whole cell lysate of viable BL2 cells was incubated for 2 hrs with 
recombinant human caspase-3 alone or with addition of either Z-DEVD-FMK 
or Z-VAD-FMK. Whole cell lysate of 2 hrs post-staurosporine BL2 cells was 
included for a comparison. (b) Recombinant human FKN was incubated for  
2 hrs with recombinant human caspase-3 alone or with addition of either Z-
DEVD-FMK or Z-VAD-FMK. Samples were immunoblotted using anti-FKN 
antibodies (MAB3651). One representative result from four is shown. 
The studies were later extended to caspase-10, as its inhibitor had also showed a 
potency to block generation of 60 kDa FKN (Figure 4.7), and to caspase-7 – another 
executioner caspase, believed to share a number of substrates with caspase-3 (Jang et 
al. 2007; Walsh et al. 2008). The activity of caspase-7 towards FKN was tested both 
in BL2 cell lysates and in an assay with recombinant FKN. However, the low 
molecular weight FKN was not detected this time (Figure 4.10a). Recombinant 
caspase-10, when incubated with recombinant FKN also did not seem to be able to 
cause hydrolysis of FKN under these conditions (Figure 4.10b). This data does not 
exclude the possibility that under different conditions e.g. physiological conditions or 
in a higher concentration of caspase, caspase-7 and caspase-10 (but also caspases-6, 
-8, or -9) may be capable of processing FKN. In fact, it seems to be consistent with 
the notion that caspase-3 is generally more potent than other caspases in cleaving 
most of their shared substrates (McStay et al. 2007; Walsh et al. 2008). However, in 
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order to confirm the validity of these results it would be important to perform 
additional control analysis of the activity of recombinant caspase-7 and caspase-10. 
An assay monitoring the ability of these caspases to process some of their well 
known substrates (like p23 for caspase-7 or Bid for caspase-10) in parallel to 
assessing their capacity for cleaving FKN would be of use here (Walsh et al. 2008; 


















































Figure 4.10 Examining capability of caspase-7 and caspase-10 to cleave FKN 
(a) Whole cell lysate of viable BL2 cells was incubated for 2 hrs with  
rh caspase-7 or rh caspase-3, alone or with addition of Z-DEVD-FMK. One 
representative result from two is shown. (b) Rh FKN was incubated for 2 hrs 
with rh caspase-7, caspase-3 or caspase-10. One representative result from two 
is shown. Samples were immunoblotted using anti-FKN antibodies 
(MAB3651). 
4.5.3.3 Down-regulation of caspase-3 in BL2 cells 
To attempt to confirm the involvement of caspase-3 in FKN processing in the course 
of apoptosis of BL2 cells, the decision was made to silence the caspase-3 gene in 
BL2 cells. The addition of caspase-3 inhibitor – Z-DEVD-FMK did not previously 
block apoptosis of BL2 cells (Figure 4.8), indicating that other proteases activated 
during the staurosporine-induced death can compensate for caspase-3. Therefore, the 
down-regulation of caspase-3 in BL2 seemed to be an appropriate measure for 
discriminating between the role of caspase-3 as an apoptosis executioner and FKN-
cleaving protease.  
The caspase-3 gene was knocked-down using a lentiviral shRNA system and stably 
transduced cells were selected using puromycin. The non-targeting shRNA vector 
was used as a control. Figure 4.11a shows the efficiency of the caspase-3 down-
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regulation, as assessed by reverse transcription PCR with caspase-3 specific primers. 
The presence of a very faint band representing the caspase-3 product proved the 
success of the gene knock-down. 
The successful generation of caspase-3-depleted BL2 cells enabled the effect of 
caspase-3 knock-down on FKN processing during cell death to be evaluated. 
Caspase-3 knocked-down BL2 cells (BL2/casp3kd), control BL2 cells (infected with 
control vector-expressing lentivirus) (BL2/ctrl) and parental BL2 cells were 
incubated with staurosporine and analysed after 2 hrs. Both cell lysates and 
conditioned media were immunoblotted using anti-FKN and anti-caspase-3 
antibodies (Figure 4.11b). Although the substantial reduction in caspase-3 protein 
level was clearly visible in the BL2/casp3kd samples, it did not seem to have any 
effect on the level of the 60 kDa FKN, which remained similar to that in control 
samples. Again, this was not due to blockade of apoptosis in BL2/casp3kd cells as 
the amount of AxV+/PI- cells was comparable among all the analysed cell types 
(Figure 4.11c). As the expression of caspase-3 was not completely abrogated and 
some portion of the protein was still present in the BL2/casp3kd cells, it is, 
unfortunately, impossible to state if the complete processing of the 90 kDa FKN was 
possible because the remaining amount of caspase-3 was sufficient to cleave it or the 
cleavage was carried out by another protease. The possibility that the remaining 
caspase-3 can still cause the complete degradation of its substrates might be further 
examined by analysing the rate of cleavage of another known substrate of caspase-3 
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Figure 4.11 Down-regulation of caspase-3 in BL2 cells. 
(a) Total RNA was extracted from BL2/casp3kd (casp3kd), BL2/ctrl (ctrl1, 
ctrl2) and parental BL2 (BL2) cells and reverse-transcription-PCR for caspase-3 
was performed. Control reactions for GAPDH were also included. One 
representative result from five is shown. (b) Caspase-3 and FKN expression in 
BL2/casp3kd, BL2/ctrl and parental BL2 cells was analysed by Western 
blotting. Cell lysate samples from untreated cells as well as cell lysate and 
supernatant samples from 2 hrs post-staurosporine cells were immunoblotted 
using anti-caspase-3 antibodies (9662) or anti-FKN antibodies (MAB3651). 





4.5.3.4 Introducing point mutation into the FKN gene sequence 
The work presented thus far did not give the final confirmation for the involvement 
of caspases in FKN cleavage in BL cells. As caspases are highly conserved and are 
only able to cleave their substrates after aspartic acid residues (Asp; D) (Timmer & 
Salvesen 2007), it should be possible to determine their role in processing of FKN by 
introducing point mutations in the Asp residues of the FKN sequence. The sequence 
of FKN mucin stalk, accommodating putative cleavage sites for proteases, contains 
seven aspartic acid residues (see Appendix A). Computational tools were used to 
predict which of them might be involved in caspase-mediated cleavage. No 
consensus cleavage site was detected, but one of the used applications identified 
sequence STQD (D223) as a possible site of cleavage. Nonetheless, it was decided to 
introduce the mutations not only in D223 but also in the remaining mucin stalk Asp 
residues. Plasmid constructs carrying the FKN gene sequence were used for site-
directed mutagenesis and all the Asp residues were successfully replaced with 
glutamic acid (Glu; E) (see Appendix A for details). Glutamic acid was chosen for 
the substitution as it should be able to impede caspase-3-driven cleavage (caspases 
were shown to have 104 lower specificity for Glu than Asp (Stennicke et al. 2000) 
but at the same time glutamic acid has similar physical and chemical properties to 
aspartic acid so is not believed to cause a change to the structural conformation of the 
protein. As the conformation is known to play a role in substrate - caspase 
interactions (Timmer & Salvesen 2007) it seemed important to ensure that this aspect 
of the protein structure remained unchanged. Unfortunately, due to the technical 
problems encountered during the attempts to express the mutated-FKN plasmids in 
human cells, it was not possible to determine the effect of the mutations on the 




4.6 Role of apoptosis-derived 
microparticles (MPs) in the release of 
FKN from BL cells          
Generation of membrane blebs carrying portions of dying cell content is one of the 
most characteristic features of apoptosis (Kerr et al. 1972). There is a growing 
recognition of the importance of MP-carried signals in various physiological 
conditions. In particular, apoptotic cell-derived MPs have been reported to have a 
potency to induce death of macrophages (Distler et al. 2005). In another study 
Segundo et al. demonstrated that blebs derived from germinal centre B cells were 
able to cause macrophage chemoattraction (Segundo et al. 1999). Studies undertaken 
previously in this group have revealed that FKN was also released in association with 
MPs (Truman et al. 2008). Very intriguingly, it was demonstrated that 60 kDa FKN 
is present exclusively in MPs but not as a soluble form in MP-free supernatants. 90 
kDa FKN, on the other hand, was found both in MPs and MP-free supernatants. The 
possibility that 90 kDa FKN may be processed to 60 kDa FKN while in MPs seemed 
plausible. 
Following on from the observation that various proteases were found to be secreted 
in MPs (Taraboletti et al. 2002), it was decided to investigate caspase-3 presence in 
MPs released from BL cells. 
4.6.1 FKN and caspase-3 co-release in BL2-derived MPs 
At first, the presence of caspase-3 in BL2-derived MPs was examined by Western 
blotting. The MP fraction was acquired by ultracentrifugation of cell-free 
conditioned media from staurosporine-treated BL2 cultures collected after 2 hrs. The 
MP fraction was lysed using mild detergent prior to electrophoretic separation. Two 
different anti-caspase-3 antibodies were used to label the blots. The first one was 
able to recognise only the active form of caspase-3 whereas the second one was able 
detect both the active form and pro-caspase-3 (Figure 4.12a). Both antibodies 
visualised a substantial amount of caspase-3. Interestingly, the MP fraction contained 
both intact pro-caspase-3 as well as its active form, again suggesting that the 
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apoptosis-driven processing of cell content may well be extended into MPs. 
Similarly, MMP-2 and MMP-9 that were reported to be released in vesicles, were 
present in MPs both in their inactive (pro-enzyme) and active forms (Taraboletti et 
al. 2002). Subsequently, the particular ability of MP-derived caspase-3 to hydrolyse 
fluorescently-labelled specific peptide substrate ((Z-DEVD)2-Rh110) was tested. The 
intensity of fluorescent light emitted by the cleaved substrate was measured (Figure 
4.12b). Lysed MP samples and apoptotic BL2 cell lysate samples were equally 
potent in generating fluorescent cleavage product, thus, supporting the possibility 
that proteolytic cleavage of caspase substrates might be continued in vesicles that 
detached from the cells. The main requirement for this is that both protease and its 
substrate are released in the same vesicles. It was therefore decided to examine if 
FKN and caspase-3 are co-released in the same MPs. For this reason MPs obtained 
from the supernatants of 2 hrs post-staurosporine-treated BL2 cells that were labelled 
with DAPI (DNA stain) as well as with anti-FKN and anti-active caspase-3 
antibodies and matching fluorescently-labelled secondary antibodies, were analysed 
by confocal microscopy. Figure 4.12c shows a representative picture of stained MPs. 
Although these very basic experiments do not allow the percentage of MPs that were 
positively stained with both of the used antibodies in the whole MP population to be 
calculated, they clearly demonstrated that at least some of the MPs contain both FKN 
and caspase-3. Taken together, the studies presented in this section revealed that 
FKN and proteolytically active caspase-3 can be co-released from dying BL2 cells in 
the process of membrane-blebbing. This mechanism can possibly enable a further 



































































Figure 4.12 Presence of FKN and active caspase-3 in MPs from BL2 cells 
(a) Cell lysates from untreated or staurosporine-treated BL2 cells and MPs acquired by 
ultracentrifugation of supernatants from BL2 cells induced into death with staurosporine for 
2 or 3 hrs were immunoblotted using anti-FKN antibodies (MAB3651) or anti-active 
caspase-3 antibodies (PC679-upper panel or 9662-lower panel). One representative result 
from four similar experiments is shown. (b) Detection of active caspase-3 in the assay with 
caspase 3-specific fluorogenic peptide substrate (Z-(DEVD)2-Rh110). Cell lysates from 
untreated or 2 hrs staurosporine-treated BL2 cells and lysed MPs acquired from supernatants 
of staurosporine-treated BL2 cells were incubated for 1 hr with the substrate. Samples were 
analysed by measurement of fluorescence. One representative result from two is shown. The 
error bars represent the standard error of the mean (n=3). (c) MPs acquired by 
ultracentrifugation of supernatants form staurosporine-treated BL2 cells were labelled using 
anti-FKN antibodies (MAB3651) and anti-active caspase-3 antibodies (9661) as well as with 
nuclear stain - DAPI, mounted on the microscope slide and analysed by confocal 
microscopy. One representative result from two is shown. 
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4.6.2 Characterisation of BL cell-derived MPs       
To increase our understanding of the mechanisms of FKN release, an attempt was 
made to further characterise BL cell-derived MPs. 
4.6.2.1 Time lapse imaging of MP release from apoptotic BL cells 
The formation and subsequent release of MPs from staurosporine-induced BL2 cells 
were monitored using phase contrast widefield microscopy and a time lapse imaging 
system. Figure 4.13 contains the representative stills from the picture sequence, 
showing the morphology of the cells from the beginning of the experiment (~ 40 min 
post-staurosporine) and when the apoptotic features were clearly visible (~120 min 
post-staurosporine). The whole picture sequence can be found in Appendix B. 
Analysis of the gathered material revealed that the intensity of vesicle budding and 
detachment increased dramatically around 90 min after the induction of apoptosis. 
The observed time of MP release seemed to correlate very well with previously 
described changes in FKN expression e.g. the loss of surface expression detected in 
apoptotic BL2 cells (Figure 4.4).     
4.6.2.2 Morphological characteristics of vesicles produced during BL cell 
death 
It was also decided to examine the morphological characteristic of MPs produced by 
BL cells. For this purpose, BL2 cells were induced into death by 2 hrs of 
staurosporine treatment. The MP fraction was acquired by ultracentrifugation of 
conditioned media and the MPs were analysed by flow cytometry. Two control 
samples containing 50 nm and 1 µm beads (Figure 4.14 a and b, respectively) were 
also measured using the same protocol to allow an approximate size-estimation. 
From the dot plots of isolated MPs two major populations could be distinguished: 
population of small vesicles (possibly around 50 nm size), which accounted for less 
than 30% of events and a larger population of bigger vesicles (probably below 1 µm 
size) (Figure 4.14). Vesicles with a diameter of around 1 µm are generally believed 
to be cell membrane-derived MPs whereas a size of 30-100 nm is usually assigned to 
exosomes - vesicles of endocytic origin (Denzer et al. 2000; Aharon et al. 2008; 
Lakkaraju & Rodriguez-Boulan 2008). This study revealed that the vesicle fraction 
acquired by ultracentrifugation of apoptotic BL2 cell-conditioned media, not only 
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contained the characteristic apoptotic cell-derived MPs but also had a population of 
smaller vesicles, possibly exosomes. 
In order to understand the cellular origin of the BL cell-derived vesicles, examination 
of markers present on the surface of the vesicles would be required. MPs are known 
to express cell surface antigens whereas exosomes are characterised by expression of 
proteins like MHC molecules or members of the heat shock protein family (Aharon 
et al. 2008). The analysis of apoptotic BL2 cell-derived vesicles (Figure 4.12c) using 
confocal microscopy demonstrated that FKN and caspase-3 expression was 
associated with MPs (~ 1 µm). It would however be interesting to try to determine if 
any FKN is present in smaller vesicles or if there is any difference in the distribution 







Figure 4.13 Time lapse imaging of MP release from apoptotic BL cells 
BL2 cells in 25 mM HEPES-buffered RPMI 1640 + 10% FBS medium that was 
saturated with 5 % CO2 were placed in POC mini chamber on a heated 
microscope stage (37°C) of an inverted microscope. A low-magnification image 
(10x objective) of the cells was collected every 15 sec, for 150 min, starting 30 
min after the cells were exposed to staurosporine. (a) BL2 cells ~ 40 min post-
staurosporine (b) BL2 cells ~ 120 min post-staurosporine. The full sequence of 



















































































































































Figure 4.14 Flow cytometric analysis of vesicles derived from apoptotic BL 
cells. 
Dot plots of logarithmic forward versus side scatters of (a) 50 nm diameter 
beads (b) 1 µm diameter beads (c) MPs acquired by ultracentrifugation of 
supernatants form BL2 cells induced into death with staurosporine for 2 hrs (d) 
control: filtered PBS – MPs diluent. Values on top of gates represent the 
number of gated events, whereas values at the bottom of gates show the 
percentage of gated events in total number of events. One representative result 
of five similar is shown. 
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4.7 FKN localisation in apoptotic BL 
cells  
Surface expression of FKN has been studied extensively whereas intracellular 
localisation of FKN remains poorly characterised. Liu et al. have found that in 
human endothelial cells stably transfected with FKN, the chemokine is dynamically 
distributed between two cellular compartments: cell surface and juxtanuclear 
endomembrane vesicles (Liu et al. 2005). The results presented thus far indicated 
that most of the FKN processing in BL2 cells takes place intracellularly (Figure 4.1). 
The subcellular localisation of FKN in BL cells was thus investigated. The 
localisation of caspase-3 was also examined in BL2 cells. Two hours after the 
induction of apoptosis by staurosporine, the BL2 cells were fixed, permeabilised and 
stained with DAPI as well as anti-FKN, anti-active caspase-3 and matching 
fluorescently-labelled secondary antibodies. The samples were analysed by confocal 
microscopy (Figure 4.15). FKN, although distributed throughout the cytoplasm, 
seemed to be more abundant in the membrane-proximal area. Furthermore, active 
caspase-3 appeared to co-localise with FKN in the proximity of the cell membrane. 
To determine whether the visualised FKN was localised inside the cell or 
extracellularly, the intact BL2 cells were stained with anti-FKN antibodies. This 
showed that a substantially lower level of clustered FKN was detected on the cell 
surface (Figure 4.16), indicating that the membrane-proximal FKN was mainly 




active casp3DAPI FKN merge




Figure 4.15 FKN and active caspase-3 localisation in apoptotic BL cells 
BL2 cells were induced into death with staurosporine for 2 hrs, fixed, 
permeabilised and labelled using mouse anti-FKN antibodies (MAB3651) and 
rabbit anti-active caspase-3 antibodies (9661) and matching fluorescently-
labelled secondary antibodies. Nuclear stain – DAPI (blue), was also used. 
Labelled cells were mounted on a microscope slide and analysed by confocal 
microscopy. The two rows of pictures represent different optical sections of the 
cell. Control staining with DAPI and the secondary antibodies was included. 









Figure 4.16 FKN staining of non-permeabilised BL cells  
BL2 cells were fixed and labelled using DAPI (blue), mouse anti-human FKN 
monoclonal antibodies (MAB3651) and isotype matched AF488-conjugated 
goat anti-mouse IgG antibodies (green). Labelled cells were mounted on a 
microscope slide and analysed by confocal microscopy. Control staining with 
DAPI and IgG1 isotype control was included. One representative result from 
two is shown. 
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4.8 Release of FKN by germinal centre B 
cells 
The occurrence and release of the 60 kDa form of FKN observed in Burkitt’s 
lymphoma cells has been shown to be of prime importance for the attraction of 
macrophages to the site of apoptosis and hence for clearance of apoptotic debris 
(Truman et al. 2008). The potential role of FKN during the cell death of other cell 
types remains unknown. The studies presented here aimed at extending our 
knowledge to germinal centre (GC) B cells – the healthy counterparts of Burkitt’s 
lymphoma cells (Gregory et al. 1987). During affinity maturation in the germinal 
centre apoptosis of B cells occurs at a very high rate therefore it seemed likely that 
FKN may play a key role in attracting tingible body macrophages and ensuring 
effective clearance of apoptotic cells. 
Murine germinal centre B cells were isolated from the spleens of animals immunised 
with sheep red blood cells. Germinal centre and follicular (resting) B cells were 
separated based on their IgD expression. As GC B cells are known to undergo 
spontaneous apoptosis also in the culture conditions (Liu et al. 1989), IgD- germinal 
centre B cells and IgD+ follicular B cells were placed in fresh media, cultured for a 
specified time and subsequently, their supernatants were immunoblotted using anti-
mouse FKN antibodies (Figure 4.17a). The 60 kDa form of FKN was detected in all 
the samples. However, its level was considerably higher in GC B cells, which are 
known to undergo spontaneous apoptosis (Figure 4.17b). 
Next, germinal centre and follicular B cells were separated from human tonsils 
excised from healthy individuals. Similarly, the cells were cultured for the indicated 
time and conditioned media was analysed by Western blotting using anti-human 
FKN antibodies (Figure 4.17c). The results resembled those obtained from murine 
germinal centres, that is a substantial amount of the 60 kDa FKN was detected in GC 
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Figure 4.17 FKN release from GC B cells 
 (a) Cell-free supernatants were collected from murine germinal centre (GC) 
and follicular (resting) B cells (rB) after 2 and 18 hrs of culture. Proteins were 
precipitated from the medium by TCA and immunoblotted using rabbit anti-
mouse FKN antibodies (TP-213). One representative result from three similar 
experiments is shown (b) Supernatants were collected from human germinal 
centre and resting B cells after 3 and 9 hrs of incubation and immunoblotted 
using mouse anti-human FKN monoclonal antibodies (MAB3651). One 
representative result from three is shown (c) Control Western blots of murine 
germinal centre and resting B cells labelled using rabbit anti-mouse FKN 
antibodies (TP-233), followed with goat anti-rabbit Ig antibodies (left); goat 
anti-rabbit Ig antibodies only (middle); rabbit anti-mouse FKN antibodies (TP-
233) followed with goat anti-rabbit Ig antibodies together with sheep anti-
mouse IgG antibodies (right). 
Out of concern over the specificity of the anti-mouse FKN antibody binding and the 
possibility that what the antibodies detected on the Western Blot was not 60 kDa 
FKN but rather was an immunoglobulin heavy chain, which is of a similar size, some 
additional controls were performed for these experiments. The blots that were 
previously labelled with rabbit anti-mouse FKN antibodies were stripped and re-
labelled. Initially, to highlight the real position of the mouse IgG on the blots and to 
compare its size with the size of FKN, rabbit anti-mouse FKN and goat anti-rabbit 
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IgG were used together with goat anti-mouse IgG antibodies. The antibodies clearly 
detected two separate bands (Figure 4.17c). This result was additionally supported by 
the fact that goat anti-rabbit antibodies alone were unable to label any proteins on the 
blots. 
This subsection demonstrates that the apoptosis-dependant release of FKN is not just 
restricted to Burkitt’s lymphoma cells, but is also characteristic of normal B cells 
undergoing selection in germinal centres. Further analysis carried out in the group, 
involving comparing the numbers of macrophages in the active germinal centres of 
wt and CX3CR1-/- mice, proved that FKN is, indeed, involved in attracting tingible 
body macrophages to germinal centres (Truman et al. 2008). 
4.9 Conclusions 
In summary, the studies described in this chapter: 
• showed that, in BL cells, the hydrolysis of 90 kDa FKN resulting in the 
generation of a 60 kDa fragment of FKN as well as the loss of surface FKN 
are apoptosis-dependent processes 
• identified FKN as a potential substrate for caspases 
• demonstrated that caspase-3 is capable of cleaving FKN in vitro 
• showed that FKN and fully functionally active caspase-3 are released 
together in apoptotic BL cell-derived MPs       
• illustrated that FKN and active caspase-3 co-localise together in the 
membrane-proximal region of BL2 cells 




Chapter 5  
Role of calpain in FKN 




The previous chapter has demonstrated that the 60 kDa form of FKN, previously 
shown to be generated in BL2 cells during apoptosis, is a likely product of caspase-
dependent proteolysis. Here, the appearance of another cell-death-related form of 
FKN in BL cell lines is reported and further studies aiming at explaining its origin 
are presented.      
5.2 Expression of FKN in group I BL 
lines 
The studies on FKN expression and processing in Burkitt’s lymphoma, presented in 
Chapter 4, were performed using the BL2 cell line. Here, FKN expression analysis 
was extended to other group I BL cell lines. This included another EBV-negative line 
– L3055 as well as two EBV-positive lines: Mutu I and SAV (Gordon et al. 2000). 
The cells were induced to undergo apoptosis by exposure to staurosporine. At 
indicated time points whole cell lysate and cell-free supernatant samples were 
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prepared. Cell viability was assessed by AxV/PI staining. FKN was detected by 
immunoblotting with mouse monoclonal anti-FKN antibodies (Figure 5.1a). FKN 
band pattern in apoptotic L3055 cells resembled that observed in BL2 cells (Figure 
4.1a). However, in SAV cells (which remained mostly viable) the 60 kDa form of 
FKN was not observed. Instead, a band of approximately 55 kDa was present in all 
the SAV samples. In addition, the intensity of the 90 kDa FKN was reduced. 
Interestingly, in apoptotic Mutu I cells 60 kDa FKN was detected in cell lysates but 
in the supernatants the 55 kDa band was present instead. This analysis suggested the 
existence of a possible alternative to the caspase-dependent mode of processing 
FKN. The results obtained from Mutu I cells were further confirmed when UVB 
light exposure was used to induce these cells into apoptosis (Figure 5.2). Again, an 
unusual FKN band pattern was observed with the 60 kDa form present in the cell 
lysates and 55 kDa form in cell-free supernatants, indicating that this mechanism of 
FKN processing is independent of the type of apoptosis stimulus.  
60 kDa FKN has previously been reported to be released from apoptotic BL2 cells in 
association with MPs (Truman et al. 2008). It therefore seemed interesting to 
determine whether FKN released from Mutu I cells is also released in MPs. Also, 
establishing which of the two processed forms (60 or 55 kDa) is present in MPs 
would shed some light on the mechanism of FKN release. MP lysate samples 
prepared from supernatants of 2 hrs post-staurosporine BL2 and Mutu I cells were 
analysed by Western blotting. Figure 5.1b shows that apoptotic Mutu I-derived MPs 
contained 90 and 55 kDa species of FKN. As none of the 55 kDa FKN was present in 
the Mutu I cell lysate and none of the 60 kDa FKN was detected in MPs it seemed 
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Figure 5.1 Expression of FKN in group I BL lines 
(a) Type I BL cell lines L3055, SAV and Mutu I were induced to undergo 
apoptosis by staurosporine. Cells and cell supernatants were collected at the 
indicated times after apoptosis induction. Lysed cells and proteins precipitated 
from the medium by TCA were immunoblotted using anti-FKN antibodies 
(MAB3651). Cell death was assessed by AxV/PI staining and the percentage of 
AxV+PI- cells at the 3 hrs time point is shown underneath the blots. One 
representative result of more than five is shown. (b) MPs collected from the 
supernatants of BL2 and Mutu I cells 2 hrs post-staurosporine treatment, were 





























Figure 5.2 Effect of different apoptosis induction methods on the FKN 
processing in Mutu I cells  
Mutu I were induced to undergo death by either staurosporine or UV treatment. 
(a) Cell lysates and proteins precipitated from the supernatants were 
immunoblotted with MAB3651 antibodies. (b) Apoptosis was assessed by 
AxV/PI staining. 
5.3 Involvement of calpain in cleavage of 
FKN 
The analysis of FKN release from Mutu I cells (Figure 5.1 and 5.2) showed that, 
similarly to the generation of 60 kDa FKN, cleavage of FKN to 55 kDa might be a 
cell-death-driven process. Calpain, a ubiquitous, Ca2+-activated protease, has a well-
recognised role in various types of cell death (e.g. Blomgren et al. 2001; Gil-Parrado 
et al. 2002; Mandic et al. 2002; Fettucciari et al. 2006; Golstein & Kroemer 2007). 
While interplaying with caspases in inducing cell death under different conditions, it 
is also known to share with them a number of substrates (Wang 2000). Therefore, it 
was hypothesised that it is calpain that is involved in proteolytic cleavage of FKN 
and generation of a 55 kDa cleavage product. In order to test this hypothesis, the  
in vitro cleavage assay was set up: recombinant human FKN was incubated with 
active human calpain I. This resulted in generation of two different product bands 
and suggested that calpain might not only be capable of cleaving FKN but also might 
have more than one cleavage site within the FKN sequence (Figure 5.3a). 
Subsequently, the sizes of the products of calpain and caspase cleavages of 
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recombinant FKN were compared (Figure 5.3a). The largest product from the calpain 
cleavage-derived bands appeared to be smaller than that generated by recombinant 



























Figure 5.3 Involvement of calpain in FKN cleavage 
(a) Recombinant human FKN was incubated for 2 hrs with human calpain I 
alone or with addition of specific calpain inhibitor - calpeptin. The sizes of 
recombinant FKN processed by recombinant caspase-3 or calpain I were 
compared. Samples were immunoblotted using anti-FKN monoclonal 
antibodies (MAB3651). One representative result from 3 is shown. (b) Whole 
cell lysate of viable BL2 was incubated for 2 hrs with calpain reaction buffer 
only, human calpain I or calpain I with addition of calpeptin. Samples were 
analysed by Western blotting using MAB3651 antibodies. One representative 
result of three similar is shown. 
The addition of recombinant caspase-3 to the BL2 whole cell lysate samples has been 
proven effective in mimicking the process of generation of 60 kDa FKN in the 
apoptotic cells (Figure 4.9). Consequently, human calpain I was added to BL2 cell 
lysates in order to confirm its involvement in the production of 55 kDa species of 
FKN. This approach, however, proved to be ineffective, as the excess of calpain in 
the sample caused the complete degradation of proteins (Figure 5.3b). Interestingly, 
incubation of the cell lysate in the calpain reaction buffer alone (containing Ca2+ of a 
concentration within the calpain activation range) caused the generation of 
approximately 55 kDa-size form of FKN. The specific calpain inhibitor, calpeptin, 
managed to inhibit the degradation. Of note, the amount of 55 kDa band in the 
sample containing both calpain and calpeptin seemed to be reduced when compared 
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with the sample containing buffer alone. This could have been due to the incomplete 
inhibition of degradation as well as to calpeptin inhibiting calpain-dependent 
cleavage of FKN and production of 55 kDa species. These observations were 
compared with the results obtained from incubation of BL2 lysates in caspase 
reaction buffer (Figure 5.4a). Here as well, the generation of 55 kDa FKN was 
observed in the samples incubated in the buffer only. However, further analysis using 
various protease inhibitors revealed that the cleavage of FKN can be blocked by 
chymostatin (known to inhibit calpain activity – Nilsson & Karlsson 1986), calpeptin 
and Z-Leu-Leu-CHO (two calpain inhibitors). On the other hand, metalloproteinase 
inhibitors – GM6001 and TIMP-2 – were not able to inhibit this process. Taken 
together, these studies implied that cell-derived calpain might, under certain 
conditions, be activated in the samples and drive FKN proteolysis. An interesting 
question arose here as to which component of the reaction buffers used was 
responsible for the calpain activation. Two buffers presented here were compared 
with the ADAM reaction buffer that was previously demonstrated not to trigger 
uncontrolled protein degradation (Figure 4.9) (see section 2.9 for buffer 
compositions). As only one of the buffers causing FKN degradation contained Ca2+ it 
seemed that increased Ca2+ concentration in the samples was not a requirement for 
calpain activity. The only compound common to the degrading buffers but not 
present in the non-degrading one was dithiothreitol (DTT). DTT is used for its strong 
reducing capability. The role of DTT in FKN degradation is in accord with the work 
of Guttmann et al., reporting that oxidation causes inhibition of substrate hydrolysis 
by calpain (Guttmann et al. 1997). Therefore, it seems possible that DTT facilitates 




































Figure 5.4 Effect of protease inhibitors on FKN cleavage in BL2 cell lysates 
(a) Whole cell lysate of viable BL2 was incubated for 2 hrs with caspase 
reaction buffer only or with reaction buffer with addition of inhibitors: 
chymostatin, GM6001, TIMP2, calpeptin or Z-Leu-Leu-CHO. Samples were 
analysed by Western blotting using MAB3651 antibodies. One representative 
result from 2 similar is shown. (b) Sizes of the FKN bands generated in BL2 
cell lysates incubated in caspase reaction buffer and staurosporine-treated SAV 
and BL2 cells were compared. 
Figure 5.4b shows the comparison of the size of FKN detected in SAV BL cell line 
with FKN generated in the calpain reaction buffer by uncontrolled proteolysis of 
BL2 cell lysates as well as with lysates of BL2 cells exposed to staurosporine for 2 
hrs. Demonstration that the 55 kDa FKN band from SAV cells (and also from Mutu I 
cells – Figure 5.1) was the same size as buffer-generated FKN seemed to support the 




5.4 Ionomycin-induced death of BL2 
cells 
Further work focused on examining the role of calpain involvement in the proteolytic 
processing of FKN in the cellular system. For this purpose, BL2 cells were incubated 
with calcium ionophore – ionomycin, known to activate calpain and to induce BL 
cell death (Gil-Parrado et al. 2002; Truman 2005). Figure 5.5a shows that although in 
the lysates of ionomycin-treated cells only 60 kDa FKN was present, in the 
supernatants 55 kDa was detected as early as 30 min after the addition of ionomycin, 
much before the 60 kDa band was also visible. Interestingly, 55 kDa FKN had 
started to be visible before any active caspase-3 was detected in the samples and 
even after 3 hrs of incubation with ionomycin not all the pro-caspase-3 was 
transformed to its active form. In addition, unlike in the staurosporine-treated BL2 
cells, not all the 90 kDa FKN disappeared from the lysate at the time when 60 kDa 
form emerged. The appearance of 55 kDa FKN in the ionomycin-treated BL2 cell 
supernatants gave further evidence for a possible calpain activity in hydrolysis of 
FKN. Intriguingly, both for BL2 cells incubated with ionomycin and for Mutu I cells 
that were UVB-irradiated or incubated with staurosporine (Figure 5.1 and Figure 
5.2), 55 kDa FKN was only observed in cell supernatants. This indicated that this 
form might be shed from the cell surface.  
The AxV and PI labelling of ionomycin-treated BL2 cells (Figure 5.5b) revealed that 
the effect of ionomycin on BL2 cells differs considerably from what was previously 
observed with staurosporine (Figure 4.1). Unlike staurosporine, ionomycin caused a 
rapid increase in the number of PI-positive, and thus presumably leaky, cells. The 
population of AxV-positive (PS-displaying) cells, however, only counted for 
approximately 30 per cent of cells after 3 hrs (compared with around 75% of 
staurosporine-treated cells). Early loss of plasma membrane integrity, lack of the 
characteristic features of apoptosis (such as PS exposure and caspase activation) and 
frequently an increase of Ca2+ concentration are considered to be characteristic for 
necrosis (Golstein & Kroemer 2007). Thus, it was concluded that ionomycin-induced 
death of BL2 cells is more similar to necrotic rather than apoptotic cell death. 
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Importantly, calpain activity is also often associated with necrotic cell death 
(Harriman et al. 2002; Liu et al. 2004; Moubarak et al. 2007).  
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Figure 5.5 Ionomycin-induced death of BL2 cells 
BL2 cells were induced to undergo death by ionomycin. (a) Cells and cell 
supernatants were collected at the indicated times (hrs) after death induction. 
Lysed cells and proteins precipitated from the medium by TCA were analysed 
by Western blotting. Blots were labelled using mouse anti-FKN antibodies 
(MAB3651) or rabbit anti-caspase-3 antibodies (9662). (b) Cell death was 




5.5 Ionomycin-induced death of Mutu I 
cells  
The effect of ionomycin on FKN cleavage in Mutu I cells was also assessed. These 
cells have already been reported to release 55 kDa FKN in response to staurosporine 
(Figure 5.1), however, after exposure to ionomycin, 55 kDa FKN was detected not 
only in the supernatants but also in the cell lysates (Figure 5.6a). At the same time, 
no 60 kDa form of FKN was detected in these cells. In Mutu I, similar to BL2, 
ionomycin induced only partial activation of caspase-3 and a low percentage of cells 
became AxV-positive (Figure 5.6a, b). These results suggested that the ionomycin-
driven increase in the intracellular Ca2+ level in Mutu I cells may lead to altered 
processing of FKN and generation of products other than the previously described 
form of FKN. Dependence of this process on ionomycin stimulation further 
supported a role for calpain involvement. In addition, the differences in BL2 and 
Mutu I cell response to various stimuli became more clearly visible here. 
 
5.6 Effect of calpeptin and Z-VAD-FMK 
on the FKN processing in ionomycin-
treated BL cells      
Having established that ionomycin induces release of 55 kDa FKN from both BL2 
and Mutu I cells it was next decided to examine if the specific calpain inhibitor – 
calpeptin is capable of inhibiting this release. Poly-caspase inhibitor Z-VAD-FMK 
was also included in the experiment in order to investigate the level of caspase 
involvement in the supposed calpain-induced cleavage of FKN. BL2, Mutu I and 
L3055 cell-free supernatants were collected 2 hrs after addition of ionomycin. The 
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Figure 5.6 Ionomycin-induced death of Mutu I cells 
Mutu I cells were induced to undergo death by ionomycin or staurosporine.  
(a) Cells and cell supernatants were collected at the indicated times (hrs) after 
death induction. Lysed cells and proteins precipitated from the medium by TCA 
were analysed by Western blotting. Blots were labelled using anti-FKN 
antibodies (MAB3651) or anti-caspase-3 antibodies (9662). (b) Cell death was 
assessed by AxV/PI staining. One representative result of four similar is shown. 
resulting pattern of FKN bands (Figure 5.7a) revealed that calpain- and caspase-
mediated proteolysis seemed to be two mostly independent processes. In BL2 and 
L3055 ionomycin-treated cells, which contained both the 60 and 55 kDa forms of 
FKN in the supernatants, the addition of calpeptin caused complete inhibition of the 
release of the 55 kDa FKN. When Z-VAD-FMK was added to these cells, the 
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production of 60 kDa was completely blocked but the amount of 55 kDa band was 
inhibited only partially. When calpeptin was added to ionomycin-treated Mutu I cells 
the generation of the 55 kDa band was significantly reduced. The addition of  
Z-VAD-FMK did not have such a profound effect, although some degree of cleavage 
inhibition was also observed. The high efficiency of calpeptin in abolishing the 
release of 55 kDa FKN seemed to further advocate calpain engagement in FKN 
hydrolysis. At the same time, calpeptin appeared not to affect the production of  
60 kDa FKN, thus suggesting that although in ionomycin-treated cells activation of 
caspases is a Ca2+-dependent process, the direct involvement of calpain is not needed 
for caspase activation. Similarly, as was demonstrated by addition of Z-VAD-FMK, 
the activity of caspases appeared to be only partly required for calpain activation. 
Although calpeptin had a strong effect on specific FKN cleavage inhibition, it did not 
seem to be as powerful in blocking other cell death-related events (Figure 5.7b). 
Strikingly, Z-VAD-FMK was able to inhibit to a certain extent loss of membrane 
integrity, which normally is not thought to be caused by caspases. As calpain 
appeared not to have a leading role in driving cell death induced by ionomycin, it 
also seemed less likely that the calpeptin-mediated blockade of FKN cleavage was a 
result of indirect inhibition of other proteases. Additionally, AxV and PI staining 



























































   
Figure 5.7 Effect of calpeptin and Z-VAD-FMK on the FKN processing in 
ionomycin-treated BL cells 
BL2, Mutu I and L3055 cells were incubated with ionomycin alone or in the 
presence of inhibitors: calpeptin or Z-VAD-FMK. (a) Cell-free supernatants 
were collected after 2 hrs. Proteins were precipitated from the medium by TCA 
and were analysed by Western blotting using MAB3651 antibodies. (b) Cell 
death was assessed by AxV/PI staining. One representative result of two similar 
is shown. 
5.7 Calpain expression in BL cells    
Previous experiments have revealed the differences between BL cell lines as to the 
way in which FKN is processed after cell death stimulus. As the 55 kDa form of 
FKN was likely to be generated by calpain cleavage, it seemed possible that variation 
in FKN cleavage in different lines resulted from altered expression of calpain. Thus, 
FACS analysis of calpain I level was performed in the previously used cell lines. The 
effect of both ionomycin and staurosporine on calpain expression was compared as 
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these two compounds had differently affected FKN fate in these lines. Figure 5.8a 
shows the labelling of total calpain, performed in previously permeabilised cells. In 
the untreated BL2, Mutu I and L3055 cells the detected calpain levels were similar. 
Also, neither ionomycin nor staurosporine seemed to affect calpain expression as 
after 2 hrs incubation its levels remained unchanged. The appearance of the small 
calpain-low populations of ionomycin-treated BL2 and L3055 cells most probably 
results from the increase in the number of leaky cells (as showed in Figure 5.7b). 
Although presented results were plotted from the cells that fell into a “viable” gate 
according to their forward versus side scatter characteristic, it cannot be excluded 
that a small percentage of these cells were already leaky. Intracellular changes in 
calpain expression seemed therefore to be an unlikely cause of differences in FKN 
processing. The surface expression of calpain was also measured. Anti-calpain 
antibodies labelled surface of BL cells. Moreover, the staining revealed differences 
between analysed cell lines (Figure 5.8b). Untreated Mutu I cells, unlike untreated 
BL2 or L3055 cells, were shown to display convincing levels of calpain I on their 
surface. Interestingly, preliminary results of labelling of SAV cells also revealed 
calpain I presence on the surface. The addition of either staurosporine or ionomycin 
to Mutu I did not seem to dramatically change the level of calpain I on the cell 
surface. Moreover, none of the cell death-inducing compounds was able to induce 
calpain I expression on the surface of BL2 or L3055 cells. The small population of 
calpain-positive cells visible in the plot of ionomycin-treated L3055 cells is, again, 
believed to represent cells that have lost membrane integrity. The two isoforms of 
calpain (calpain I and calpain II) seem to have the same substrate specificity and 
therefore it was impossible to conclude from the results presented thus far which of 































































































































































































































































Figure 5.8 Calpain I expression in BL cells 
FACS plots showing (a) permeabilised BL2, Mutu I and L3055 cells or (b) 
intact BL2, Mutu I, L3055 and SAV cells, treated with staurosporine or 
ionomycin, which were stained for calpain I using rabbit anti-calpain I large 
subunit antibodies (2556), and FITC-conjugated goat anti-rabbit secondary 
antibodies. One representative result of four is shown. For SAV cells the only 




























































































































































































































+ ionomycin  
Figure 5.9 Calpain II expression in BL cells 
FACS plots showing (a) permeabilised or (b) intact BL2, Mutu I, L3055 cells 
which were, treated with staurosporine and ionomycin, stained for calpain II 
using rabbit anti-human calpain II large subunit antibodies (2539), and FITC-
conjugated goat anti-rabbit secondary antibodies. Control staining with 
secondary antibodies only was included. The only result is shown. 
For this reason, the staining was later repeated using anti-calpain II antibodies 
(Figure 5.9a, b). The preliminary results showed the pattern of calpain II expression 
to closely resemble that of calpain I. Although the detection of calpain on the cell 
surface seemed rather unusual, it was quite striking that the pattern of differences in 
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the surface levels of calpain closely resembled the pattern of the differences between 
the cell lines ability to produce 55 kDa FKN in response to staurosporine.  
5.8 Calpain activation in BL cells             
The variation in calpain expression between BL cell lines did not fully explain the 
discrepancy in their ability to generate 55 kDa FKN. Thus, the possibility that 
calpain activity is diversely regulated between the cell lines under different 
conditions was explored. In the event of an increase in the Ca2+ concentration, 
calpain is known to undergo autolytic proteolysis. In this two-step process, the 80 
kDa large subunit of calpain is initially cleaved to a 78 kDa form of calpain, which is 
subsequently trimmed  to a 76 kDa form (sizes given are for calpain I) (Zimmerman 
& Schlaepfer 1991; Michetti et al. 1996). The second of these two proteolytic events 
is responsible for reducing the Ca2+ concentration required for calpain activity (Li et 
al. 2004). Calpain I was detected by immunoblotting in ionomycin and 
staurosporine-treated cells (Figure 5.10). As predicted, the degradation of calpain 
was observed under increased Ca2+ concentration in all the ionomycin-induced cells. 
The cleavage seemed to be inhibited by addition of both calpeptin and Z-VAD-FMK. 
Also, identical cleaved forms of calpain I were detected in the supernatants of 
ionomycin-treated cells regardless of cell type. The effects of staurosporine on the 
cells differed from that of ionomycin. The cleaved form of calpain I appeared not to 
be present in these cells. Intriguingly, soluble calpain I detected in the supernatants 
of all the staurosporine-treated cells was of the size of the active enzyme. 
Importantly, no differences in the way calpain I was activated under different 
conditions were detected between the studied cell lines although they have been 
shown to differentially process FKN (Figure 5.5 and Figure 5.7). This suggested that 
some other regulatory mechanism inhibiting calpain-driven cleavage of FKN must be 
in operation in these cells. Intriguingly, the presence of active calpain I was detected 
also in the cytosol of ionomycin-treated BL2 and L3055 cells, where 55 kDa of FKN 
has not been seen (Figure 5.7). Similarly, active calpain was detected in all the three 
cell lines, in the supernatants collected from staurosporine-treated cells, but 55 kDa 
FKN has been shown to be present only in Mutu I cells (Figure 5.1). An intriguing 
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effect of Z-VAD-FMK was also observed. Its addition to the cells that were 
subsequently exposed to ionomycin seemed to inhibit calpain I cleavage. At the same 
time, however, Z-VAD-FMK did not block the generation of 55 kDa FKN. Further 
studies need to be conducted in order to broaden our understanding of the complex 
interplay between availability of active hydrolases (caspases and calpain) and 
proteolytic processing of FKN. Calpastatin, a ubiquitously expressed natural calpain 
inhibitor, involved in regulating calpain activation and its proteolytic activity (Wendt 
et al. 2004; Melloni et al. 2006) is an obvious target for future examination. 
However, as it has been reported that calpain activity can be finely regulated by 
specific phosphorylation (Shiraha et al. 2002; Smith 2003; Chen et al. 2010) it also 
seems probable that phosphorylation of either calpain or FKN might be responsible 
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Figure 5.10 Calpain I activation in BL cells 
BL2, Mutu I and L3055 cells were incubated with stauro or with iono alone or 
in the presence of calpeptin or Z-VAD-FMK. Cells and cell-free supernatants 
were collected after 2 hrs. Cell lysates and proteins precipitated from the 
medium by TCA were immunoblotted using anti-calpain I antibodies (2556). 
One representative result of three similar is shown. 
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5.9 Monitoring FKN release from late 
apoptotic BL cells 
The initial studies presented in this thesis have demonstrated that the 60 kDa cleaved 
form of FKN is generated very early in the cell death process and thus, further 
analysis also focused at these early periods of BL cell death. Here, however, the 
pattern of FKN release was monitored for extended period of time, up to 24 hrs after 
BL2 cell death induction with staurosporine. The stability of 60 kDa FKN was of 
main interest here. As it can be seen in Figure 5.11, 60 kDa form of FKN, first 
detected 2 hrs post-staurosporine, seemed to disappear from the supernatants by  
6 hrs. In contrast the 90 kDa form of FKN remained stable in the supernatants until 
the end of the assay. Remarkably, as late as 12 hrs 55 kDa FKN started to be visible 
in the samples. The striking discrepancy in the lifespan of 60 kDa and 90 kDa FKN 
indicated that these two forms might have different functions. It appeared likely that 
60 kDa form serves only as a transient chemotactic signal for phagocytes sent by 
dying cells. Moreover, the observation that BL2 cells were able to produce 55 kDa 
FKN as late as 12 hrs post-staurosporine, presumably, when they already turned 
secondary necrotic, additionally confirmed calpain involvement in FKN processing 















Figure 5.11 Monitoring FKN release from late apoptotic BL2 cells 
BL2 cells were induced to undergo death by staurosporine. Cell supernatants 
were collected at the indicated times (hrs) after death induction. The proteins 
precipitated from the medium by TCA were analysed by Western blotting using 
anti-FKN (MAB3651) antibodies. One representative result of three is shown. 
5.10 Searching for FKN C-terminal 
cleavage products              
Having assumed that 60 kDa and probably 55 kDa FKN is generated by proteolytic 
cleavage of 90 kDa, it was next decided to look for the C-terminal products of this 
reaction. This was designed to clarify whether 90 kDa FKN detected in BL cells 
constitutes full-length or already cleaved FKN, as well as finding confirmation for 
the 55 kDa FKN origin from the 90 kDa form. Some previously performed Western 
blots were selected for this purpose and relabelled with antibodies raised against the 
C-terminal part of FKN (transmembrane and intracellular domains). The predicted 
size of the C-terminal fragments generated from the 90 kDa form FKN by caspase or 
calpain cleavage would be approximately 30 kDa and 35 kDa, respectively. 
However, bands of these sizes were not detected by the antibodies used (Figure 
5.12). Instead, a very intense band of around 25 kDa was visible in all the samples. 
The 25 kDa band remained unchanged throughout the time course of the experiment 
and was detected in all the assayed cell lines. Moreover, its presence was not 
correlated with the appearance of neither 60 kDa nor 55 kDa band. Altogether, these 
results suggested that the 25 kDa band is a product of different proteolytic process 
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than that presented here. Lack of both the 30 kDa and 35 kDa forms suggested that 
the 90 kDa form of FKN from which 60 and 55 kDa forms are generated might 
represent an already cleaved form of FKN. This, however, should result in 
production of small C-terminal fragment, probably around 6 kDa size (Hundhausen 































Figure 5.12 Searching for FKN C-terminal cleavage products 
(a) Cell lysates and cell-free supernatants from BL2 cells incubated for up to  
24 hrs with staurosporine, (b) BL2 cell lysates incubated for 2 hrs with 
recombinant human caspase-7 (c7) or caspase-3 (c3), (c) and cell lysates from 
staurosporine-treated Mutu I and L3055 cells were immunoblotted with  
anti-FKN antibodies (MAB3651) and anti-FKN C-terminus antibodies  
(sc-7225). 
5.11 Conclusions 
In summary, this chapter demonstrates that: 
• various BL cell lines may differently process FKN in response to the same 
death stimulus and that an “alternative” 55 kDa form of FKN might be 
released from dying cells along with 60 kDa FKN 
• calpain is capable of cleaving FKN and is likely to be responsible for 
generation of 55 kDa FKN   
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• differences in the way FKN was cleaved in different BL cell lines did not 
seem to be caused by altered levels of total calpain expression or its changed 
activation  
•  a 25 kDa C-terminal fragment of FKN is present in the BL cell lines 
independently of the occurrence of caspase-mediated cleavage, suggesting an 
existence of cleavage event other than those previously reported 
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Chapter 6  
Discussion of the results 
6.1 Introduction 
The work presented in this thesis was aimed at understanding the mechanisms 
responsible for attraction of macrophages to Burkitt’s lymphoma (BL) tumours. The 
initial, preliminary studies showed that monocyte chemoattractant protein 1 (MCP-1) 
is unlikely to play a role in this process. Fractalkine (FKN), which has previously 
been reported to be partly responsible for macrophage infiltration of BL (Truman 
2005), was shown here to be processed in dying BL cells via mechanisms that have 
not previously been described. Two new death-associated forms of FKN, of 60 and 
55 kDa, which are most likely responsible for attraction of macrophages to BL cells 
were identified. Moreover, caspase-3 and calpain I were demonstrated to be capable 
of cleaving FKN and to be likely to be responsible for generation of the 60 and 55 
kDa forms, respectively. Thus, it was proposed that apart from executing cell death 
the two proteases might at the same time able to send ‘find me’ signals to 
macrophages and thus, ensure effective clearance of dying cells. The potential 
participation of two distinct families of cell death-related proteases, caspases and 
calpains, in FKN cleavage suggests that the modulation of this molecule is important 
during cell death.  
Furthermore, the research presented here revealed the complexity of the mechanisms 
modulating the functions of FKN in the cells that naturally express FKN. It should be 
further investigated, however, whether the observed complexity is a consequence of 
aberrant processing of FKN in the BL tumour cells or is it also typical for 
untransformed cells.       
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6.2 FKN processing and role of 
differently cleaved fragments 
The processing of FKN by various proteases results in the generation of FKN 
fragments of different lengths and therefore, presumably different functions. 
Numerous studies on the signalling cascades triggered by FKN binding to its only 
known receptor – CX3CR1, showed differential responses to soluble and cell 
surface-bound FKN. Cell surface-exposed FKN has been shown to be able to 
mediate firm adhesion independently of signalling events mediated by CX3CR1 and 
this cell adhesion can persist in the presence of pertussis toxin (PTX) which is known 
to uncouple the receptor from G proteins responsible for transferring the signals 
downstream of the receptor (Imai et al., 1997; Fong et al., 1998). Other researchers 
have observed that FKN/CX3CR1 binding was able to induce Ca2+ flux in the 
adherent cells but the response was weaker than that stimulated by the soluble form 
of FKN (Harrison et al. 1998). Unlike membrane-bound FKN, its extracellular form 
has the ability to induce signalling cascades and chemotaxis (Haskell et al. 1999; 
Mizoue et al. 2001). Additionally, soluble FKN has been shown to increase cell 
adhesion by activating integrins (Goda et al., 2000; Cambien et al., 2001). Different 
roles of the various forms of FKN have also been observed in a series of in vivo 
experiments conducted by Vitale et al. As FKN has been reported to have the  
anti-tumour properties, the authors investigated the contribution of three forms of 
FKN: wild type, uncleavable membrane-bound and constitutively soluble, to the  
anti-tumour effects of FKN. The cell surface-exposed FKN showed virtually no 
effect on the tumour while both wild type and constitutively soluble forms seemed to 
inhibit its growth. Interestingly, the wild type FKN was shown to be more effective 
than the constitutively released form (Vitale et al. 2007). Unfortunately, limited 
information is available on the effect of differential cleavage on the function of FKN. 
The existence of conflicting reports on the capability of soluble FKN to induce the 
migration of mononuclear phagocytes, however, indicates the existence of some 
variability in FKN-mediated chemotaxis (i.e. good chemoattractant for mononuclear 
phagocytes: Bazan et al., 1997; Harrison et al., 1998; Chapman et al., 2000; Lucas et 
al., 2003; poor chemoattractant: Imai et al. 1997; Pan et al. 1997; Umehara et al. 
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2001; Ludwig et al. 2002; Vitale et al. 2004). The observed discrepancy in the 
response of phagocytes to FKN might be due to the use of phagocytes from different 
sources that could have different CX3CR1 expression levels or differential 
mechanisms of signal transduction. It could also be due to different origins and 
glycosylation of FKN, differences in other experimental conditions or from the 
differential cleavage of FKN. Although Harrison et al., who performed an extensive 
analysis of the role of the chemokine domain and the mucin stalk in the interaction of 
FKN with its receptor, did not find any correlation between the length of the mucin 
stalk and the ability of the chemokine to effectively bind to CX3CR1 or to induce the 
calcium flux (Harrison et al. 2001), there are some examples in the literature of 
differently cleaved FKN having different effects on the migration of monocytic 
phagocytes. Bazan and collaborators have demonstrated that the 95 kDa soluble FKN 
(containing probably the whole extracellular part of the chemokine) was very potent 
in mediating the migration of monocytes whereas a truncated form of soluble FKN 
(47-55 kDa) had significantly weaker chemoattractant properties (Bazan et al. 1997). 
In contrast, Pan et al. have demonstrated that neither the whole extracellular part of 
FKN nor the chemokine domain alone were capable of attracting monocytic 
phagocytes in the in vitro chemotactic assay but they also showed that the injection 
of the chemokine domain only but not the whole extracellular fragment of FKN to 
the mouse peritoneal cavity was able to regulate monocyte infiltration (Pan et al. 
1997). Similarly, the work presented by Imai and colleagues has revealed that the full 
extracellular FKN was less potent in attracting monocytes when compared with 
MCP-1 (Imai et al. 1997). These observations were further confirmed in another 
paper from this group (Umehara et al. 2001). In addition, Ludwig and colleagues 
have reported that 80 kDa soluble FKN (containing the majority of the extracellular 
part of FKN) did not induce migration of monocytes (Ludwig et al. 2002). By 
contrast, a recombinant fragment of rat FKN, containing the chemokine domain only, 
has been shown to be chemotactic for rat microglial cells (Harrison et al. 1998). 
Unfortunately, in the majority of the published studies on the chemotactic properties 
of FKN the information on the size of the chemokine was omitted (presumably due 
to the lack of recognition of possible importance of the soluble chemokine size for its 
function) and thus only a restricted number of papers contain more detailed analysis 
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of the roles of various sizes of soluble FKN. However, the work performed 
previously in our group seems to be in accordance with most of the results discussed 
above. It has been demonstrated that only the FKN released from dying BL cells was 
able to attract macrophages (Truman 2005; Truman et al. 2008). It has been shown in 
this thesis that while the 90 kDa soluble form of FKN was present in all the 
examined samples, both from viable and dying BL cells, FKN fragments of 60 and 
55 kDa were detected only in the supernatants from dying cells (Figures 4.2 and 5.1). 
Therefore, it was assumed that these two shorter forms of FKN, but not the 
constitutively released 90 kDa form, are inducing macrophage chemotaxis. 
Altogether, these results suggested that the specific proteolytic cleavage resulting in 
the generation of the shortened form of FKN is required to enable FKN to 
chemoattract mononuclear phagocytes. This hypothesis might be further supported 
by the fact that FKN has been reported to be cleaved by ADAM-10 and ADAM-17 
proteases (Garton et al. 2001; Tsou et al. 2001; Hundhausen et al. 2003). ADAM-10 
has been shown to induce constitutive shedding of surface FKN whereas ADAM-17 
is responsible for inducible cleavage of FKN. Both proteases are believed to play a 
role in regulating FKN-dependent cell adhesion (Hundhausen et al., 2003). Since the 
cleavage mediated by ADAM proteases takes place either constitutively or under 
non-inflammatory conditions it seems reasonable that the produced 90-95 kDa form 
of FKN has no chemoattracting properties and does not attract phagocytes in a 
constitutive manner. It is therefore imaginable that a regulatory step, such as another 
specific proteolytic cleavage, is required for FKN to gain new function. Furthermore, 
it has already been suggested that ADAM-cleaved FKN might act as a CX3CR1 
antagonist and in this way further regulate the level of cell adhesion (Hundhausen et 
al. 2007). As a form that was generated as a result of the negative regulation of FKN 
function, 90 kDa FKN seems likely to be unable to induce signal transduction and 
has an antagonistic role. Additionally, it is possible that 90-95 kDa soluble FKN, 
which contains almost all the extracellular part of FKN, retains the properties of the 
membrane-bound form of FKN and similarly does not induce signal transduction 
through CX3CR1. An interesting question to be addressed in the future is whether 
and how the change in the length of the soluble form of FKN can affect the way it 
interacts with its receptor. 
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6.2.1 Origin and function of 90 kDa form of FKN 
The origin of the 90 kDa form of FKN was not fully explained in this work. Based 
on the available literature, the 90 kDa form of FKN might represent either the full-
length protein or a form of the chemokine that is cleaved in a membrane-proximal 
region (Bazan et al., 1997; Garton et al., 2001). Although the 90 kDa FKN band was 
present in the BL cell lysates its detection as a soluble form also in the supernatants 
of BL cells would indicate that it may represent a cleaved form of FKN (Figure 4.1). 
On the other hand, no difference in size was detected between the 90 kDa FKN in the 
cell lysate and that in the cell-free supernatants, which would indicate that the  
90 kDa form observed in the supernatant was the full-length, uncleaved chemokine. 
Assuming that the 90 kDa FKN band visible in the lysate is representing cleaved 
FKN would mean that another, slightly bigger band of full-length FKN should be 
present in these cells since the presence of the full-length form of FKN in BL cells 
has been confirmed by FACS and confocal microscopy analysis, where membrane-
bound FKN was detected (Figures 4.4 and 4.16). However, bands of the correct size 
were not observed on the normally exposed Western blots. Some 95-100 kDa-sized 
bands became visible only on the overexposed films (Figure 4.1c). It is difficult to 
prove that these bands were representing FKN and were not a result of unspecific 
binding of the antibodies, it is, however, imaginable that the 95-105 kDa full-length 
FKN is an unstable form and its majority is proteolytically converted to 90 kDa form, 
which is abundant in BL cells (Figure 4.1). There is only one clear high molecular 
weight FKN band (~150 kDa) detected in the BL2 cell lysates (Figure 4.1c) and, 
despite the fact that it is approximately 40-50 kDa bigger than the reported size of 
full-length FKN (Bazan et al. 1997; Garton et al. 2001), it cannot be excluded that 
this band represents the full-length chemokine. However, the fact that neither the 150 
kDa form itself nor an expected C-terminal cleavage product of approximately 40-60 
kDa were detected by the anti-C-terminal FKN antibodies (Figure 5.12) would state 
against this possibility. 
Analysis of the FKN association with microparticles, which was previously 
performed by this group, suggested that the 90 kDa FKN is a soluble and therefore, 
most likely cleaved form of the chemokine. It was demonstrated that whereas 60 kDa 
FKN was found exclusively in MPs, the 90 kDa form was present both in MPs and in 
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the supernatants remaining after the MPs were collected by ultracentrifugation 
(Truman et al. 2008).       
Further support for the hypothesis that the 90 kDa FKN found in the lysates of BL 
cells a cleaved form of the chemokine comes from Western blot analysis using anti-
FKN C-terminus antibodies (Figure 5.12). The generation of a 60 kDa form of FKN 
from the 90 kDa fragment is expected to also produce a 30 kDa fragment. As no such 
fragment was found, it could perhaps mean that the 90 kDa form was already cleaved 
when the caspase-3-mediated generation of 60 kDa FKN took place. On the other 
hand, it would be expected that in the process of proteolytical generation of the 90 
kDa form of FKN from its bigger full-length precursor a small (6-9 kDa) fragment 
should be generated (Hundhausen et al. 2007). A fragment of this size, however, was 
not visualised by the antibodies recognising the C-terminal part of FKN.In future, 
immunoprecipitation and sequence analysis of the 90 kDa fragment of FKN will 
perhaps help explain the origin of this form. 
6.2.2 Origin of 25 (and 70) kDa FKN 
Intriguingly, the only distinctive band that was visible on the blots labelled with anti-
FKN C-terminus antibodies was 25 kDa in size (Figure 5.12). This band is most 
likely a product of the proteolysis of full-length FKN. Its most characteristic feature 
is a stable expression in all the analysed cell lines (BL2, Mutu I, L3055) and 
independently of the cell death programme or caspase-3-dependent proteolysis of 90 
kDa FKN. The size of this band indicates that it is unlikely to be a product of 
ADAM-mediated proteolysis. FKN C-terminal products generated by ADAMs have 
been shown to have a size of only 6 - 9 kDa (Hundhausen et al. 2007). Therefore, it 
appears likely that this band was a product of proteolytic events other than those that 
have been described thus far. As full-length FKN has been reported to have a size of 
around 90-105 kDa (Bazan et al., 1997; Garton et al., 2001; Hermand et al., 2008) a 
form of around 65-75 kDa should be produced alongside the 25 kDa one. It is 
therefore possible that the strong 70 kDa band detected in all BL cell samples (e.g. 
Figures 4.1, 5.1 and 5.12) might not reflect, as it was previously assumed (Truman et 
al., 2008 and earlier in this thesis), the unspecific binding of antibodies nor an 
unglycosylated FKN precursor but may in fact be another product of the proteolytic 
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cleavage of FKN. A similar, strong and constant expression of both bands seems to 
support this possibility.  
Importantly, Truman has also detected a 25 kDa band in the Mutu I cell lysates using 
other (than described in this thesis) types of anti-FKN C-terminus antibodies 
(Truman 2005). Although there does not seem to be FKN bands of these sizes 
mentioned elsewhere in the literature, it has to be remembered that the overwhelming 
majority of publications on the release of FKN and its role in various medical 
conditions is limited to the ELISA-based detection of FKN and therefore the 
presence of the 70 and 25 kDa bands in some of the studied conditions cannot be 
excluded. Furthermore, much of the literature has used cells transfected with FKN 
rather than studying endogenous FKN and due to the extensive post-translational 
modification of FKN this is likely to affect the size of this protein.  
In order to test this hypothesis, it should first be confirmed that the 70 kDa form of 
FKN is not an unglycosylated precursor. This could be achieved by comparing sizes 
of the various forms of FKN treated with deglycosylation enzymes. To try to identify 
the protease responsible for a potential cleavage, experiments involving protease 
inhibitors could be performed. The incubation times, however, would need to be 
longer than the ones used in the assays described in Chapter 4 and viable cells would 
need to be used. In addition, the function of these hypothetical forms of FKN would 
be an interesting subject of future studies. 
6.2.3 Role of caspases in FKN proteolysis 
The work presented in this thesis showed that caspase-3, the main executioner 
protease of apoptotic cell death, may be responsible for cleavage of FKN in apoptotic 
BL cells. The released 60 kDa product of this cleavage has been suggested to have 
chemotactic activity towards macrophages (Truman et al. 2008). This may be the 
first demonstration of the direct involvement of caspase-3 in the attraction of 
macrophages and warranting the efficient removal of dying cells. However, previous 
studies by Knies et al. have demonstrated that macrophage chemoattractant EMAP II 
is also processed and released from apoptotic cells in a caspase-dependant manner 
and Behrensdorf and colleagues have identified EMAP II to be a substrate of 
caspase-7 (Knies et al. 1998; Behrensdorf et al. 2000). However, the ability of this 
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caspase to cleave EMAP II has later been challenged (Zhang & Schwarz 2002). The 
report on the release from apoptotic cells of another chemotactic factor for 
mononuclear phagocytes - lysophosphatidylocholine (LPC) has proposed the indirect 
role of caspase-3 in these processes (Lauber et al. 2003).  The release of this 
phospholipid has been shown to depend on caspase-3-driven activation of 
phospholipase A2β (iPLA2β) (Lauber et al. 2003). 
Several lines of evidence presented in this thesis seemed to suggest that caspase-3 
might be responsible for the generation of the 60 kDa chemotactic form of FKN. 
However, this work did not address the important issue of spatial availability of FKN 
for caspases. It would be expected that FKN, a protein produced in the endoplasmic 
reticulum and destined for the plasma membrane, has its mucin stalk well hidden 
from enzymes operating in the cytosol, including caspases. The process of generating 
60 kDa FKN was shown here to be highly sensitive to caspase inhibitors (Figure 4.2 
and Figure 4.7). Some of the used inhibitors were able to effectively block cleavage 
of FKN even when they were not capable of inhibiting the cell death process itself 
(as assessed by AxV/PI staining – Figure 4.8). Presumably, the activity of the other 
cell death-related proteases was unaffected as they were still able to drive the process 
of death. It has to be noted, however, that the peptide caspase inhibitors, including Z-
VAD-FMK and Z-DEVD-FMK, which were used here, have also been shown to 
effectively block other cysteine proteases, particularly cathepsins (Rozman-
Pungercar et al. 2003). For this reason, it cannot be excluded that these are not 
caspases but cathepsins that are responsible for the production of the 60 kDa form of 
FKN. Particularly as cathepsins have already been shown to be involved in the 
processing of FKN (Clark et al. 2007; Clark et al. 2009) and are known to actively 
participate in the process of cell death (Conus & Simon 2008). The possibility that 
cathepsins participate in the hydrolysis of FKN in dying BL cells is also supported 
by the fact that these proteases are normally involved in the lysosomal degradation of 
membrane proteins internalised by endocytosis.       
On the other hand, the fact that the incubation of the lysates from untreated BL2 cells 
with rh caspase-3 resulted in the generation of one clear band of the size of  
the 60 kDa FKN that is observed in BL2 cells after staurosporine treatment (Figure 
4.9), would indicate that caspase-3 may be directly involved in this process. This 
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appeared particularly striking as another protease(s) (calpain?) that seemed to take 
part in the hydrolysis of FKN during cell death was responsible for the production of 
a band of a clearly different size (55 kDa) (e.g. Figure 5.1, Figure 5.5 and Figure 
5.6). Therefore, it seems rather unlikely that there is one particular position in the 
FKN mucin-like stalk that would serve as a cleavage hotspot, resulting in different 
proteases producing cleavage products of the same size.      
Further work would be required to assess how/if FKN cleavage by caspases might be 
achieved in BL cells. An attempt was described here (section 4.5.3.4, Appendix A) to 
confirm the position of the caspase cleavage site in the FKN sequence by replacing 
all the aspartic acid residues in the FKN mucin stalk sequence with glutamic acid 
residues using site directed mutagenesis. Due to technical difficulties the transfection 
of the mutated vectors turned out to be impossible within the period prescribed for 
submission of this thesis, however, the effect of the mutations on the FKN expression 
and cleavage in BL cells is currently being analysed in our laboratory. These studies 
are likely to tell us if it is possible that caspases are responsible for the production of 
the 60 kDa FKN in apoptotic BL cells. 
If these analyses confirm the involvement of caspases in the FKN processing, it will 
be important to understand the mechanisms that allow caspases to directly interact 
with FKN. Searching for an alternative, cytosolic form of FKN would be perhaps a 
good starting point. 
By contrast, if the role of caspases in the process of cleaving FKN is not confirmed, 
other factors (perhaps from among those known to operate within membrane 
compartments) will need to be considered. The possibility that FKN is hydrolysed by 
cathepsins would be the first to explore. In addition, although, some experiments 
presented in this thesis seemed to exclude the possibility that metalloproteinases may 
be responsible for the cleavage (Figure 4.5), in order to confirm those initial 
observations it would be sensible to repeat the experiments using more powerful 
inhibitors of metalloproteinases (e.g. 1,10-phenanthroline, captopril). Moreover, 
other proteases, which are known to operate in the lumen of the ER/Golgi system 
(e.g. cysteine protease ER-60), could be considered here. This would be particularly 




Assuming that the role of caspases in the processing of FKN will be confirmed it still 
should be remembered that although caspase-3 was shown here to be capable of 
hydrolysing FKN (Figure 4.9) the involvement of other caspases in this process  
in vivo cannot be excluded. Caspase-3 is generally considered to be the most potent 
of all the caspases since it has the highest affinity to its substrates and the largest 
number of identified substrates. However, the efficient knock-down of caspase-3 in 
BL2 cells did not block the generation of the 60 kDa form of FKN when the cells 
were induced into apoptosis, indicating that other caspases mighty compensate for 
caspase-3 in this circumstances (Figure 4.11). Therefore, it seems possible that 
caspase-7 and caspase-10, which were also tested for their FKN-cleavage properties 
(Figure 4.10) may (for example at higher concentration) be able to hydrolyse FKN. 
Although the caspase inhibitor studies (Figure 4.7) indicated that other caspase 
family members are not engaged in FKN cleavage during BL cell death, the 
specificity of the peptide inhibitors that were used in these assays has been 
questioned (Pereira & Song 2008) therefore it is feasible that they might play a role 
in this process.  
The work aiming at expressing vectors carrying the mutated FKN sequences 
(Appendix A) might reveal where in the FKN sequence is the location of the caspase 
cleavage place. However, even now, although the experimental evidence is not 
available, there are indications that the aspartic acid residue in position 223 (D223) 
might be recognised by caspases. In the paper of Bazan and colleagues is has been 
demonstrated that the 180 amino acid long fragment of human FKN sequence gives 
rise to a peptide of 47-55 kDa  in size (Bazan et al. 1997). From that it can be 
estimated that the remaining 161 (the sequence of FKN chemokine and mucin stalk 
is 341 amino acid-long) amino acid of the mucin stalk sequence would correspond 
with approximately 40 kDa of the molecular weight of the protein. Therefore, every 
10 kDa of mucin stalk would correspond to a 40 amino acid-long fragment of the 
nucleotide sequence and a 60 kDa fragment of FKN would be assumed to correlate 
to around 220 amino acids of the nucleotide sequence. This rough estimation was 
later confirmed by the search for putative caspase cleavage sites performed by 
CASVM prediction software. STQD (D223) was the only site identified in the 
human FKN sequence. Intriguingly, in mouse and rat FKN sequences the software 
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predicted caspase cleavage in sites distant from the one identified in the human 
sequence. For mouse FKN the sequence is placed in the N-terminal part of the mucin 
stalk (TLED, D136). This raises question as to the origin of the 60 kDa FKN that 
was detected in the supernatants collected from mouse germinal centre cell cultures 
(Figure 4.17). A proteolysis at D136 would be expected to result in the generation of 
a band with a molecular weight smaller than 60 kDa. Is it therefore possible that a 
protease other than caspase is responsible for FKN cleavage in dying mouse 
germinal centre cells? The form of FKN found in the supernatants of human 
germinal centre cells appears to be of the same size as the one produced by apoptotic 
BL2 cells suggesting similar processes take place in these two types of cells. 
Although it seems less likely, uneven distribution of glycans resulting in an increase 
of the molecular weight of the N-terminal part of the mucin stalk may be another 
explanation of the discrepancy between the predicted cleavage site and the 
unexpectedly high weight of the cleaved form of FKN released by mouse germinal 
centre cells. In addition, caspase cleavage in sites distinct from the predicted location 
of cleavage could result in the production of a larger than anticipated form of FKN. 
This is conceivable as caspase-3 has been shown to be hydrolysing its substrates in 
non-canonical sites (Fuentes-Prior & Salvesen 2004). 
Caspase-mediated proteolysis is widely believed to cause a modification of substrate 
function rather than its degradation. While some proteins might be inactivated and 
quickly degraded as a consequence of caspase cleavage (Ditzel et al. 2003), others 
can gain new function and become stabilised (Dix et al. 2008). Caspase-driven 
cleavage of FKN is likely to activate a new function as the apoptosis-derived FKN 
has been shown to mediate macrophage migration (Truman 2005). Interestingly, this 
form was present in the apoptotic BL2 cell supernatants very early after the cell 
death induction and only for approximately 2-3 hrs after the release. Thus, it is 
possible that it may serve as a transient signal, ensuring quick but limited phagocyte 
action. In the context of FKN gaining an ability to attract macrophages after the 
caspase-mediated hydrolysis it is, however, difficult to explain the role of the 60 kDa 
form of FKN that was produced in the apoptotic Mutu I cells since this form did not 
seem to be liberated from the cells (neither as a soluble form nor in association with 
MPs) but rather these cells released a 55 kDa form of FKN (Figure 5.1).   
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6.2.4 Role of calpain in FKN proteolysis 
The results presented in Chapter 5 indicate the involvement of another type of cell 
death-related protease, calpain, in the cleavage of FKN in dying BL cells. The 
generation of the 55 kDa form of FKN in BL cells was shown to be induced by the 
calcium ionophore, ionomycin (Figures 5.5 and 5.6) as well as to be sensitive to 
specific calpain inhibitors, calpeptin and Z-Leu-Leu-CHO (Figures 5.3 and 5.7). 
Furthermore, it was demonstrated that human calpain I is capable of cleaving 
recombinant human FKN (Figure 5.3).  
However, these results do not rule out the possibility that in vivo the generation of  
55 kDa form of FKN is mediated by other proteases. As cathepsins have a well 
recognised role in the effector phase of cell death (Conus & Simon 2008) and 
cathepsin S has already been demonstrated to be involved in FKN cleavage (Clark et 
al. 2007; Clark et al. 2009) it appears possible that these proteases might also be 
involved in the cleavage of FKN in dying cells. It is conceivable that the observed 
inhibition of the generation of the 55 kDa form of FKN (Figure 5.4 Figure 5.7) by 
calpeptin and Z-Leu-Leu-CHO might be a result of these compounds inhibiting 
action of calpain and thus, of calpain-dependent release of lysosomal cathepsins  
(Yamashima 2000). In addition, it is possible that these inhibitors had a direct effect 
on the activity of cathepsins (Barnoy et al. 1997). Evidence exists also for the role of 
ionomycin in directing the release of the lysosomal enzymes (Rodríguez et al. 1997) 
and a similar effect of ionomycin on BL cells has not been excluded by this work. 
Therefore, an investigation into the role of cathepsins in the FKN processing during 
BL cell death seems to be an important task for the future.     
In the previous section, an important issue concerning chances for spatial and 
temporal co-localisation of FKN, a protein produced in the ER and destined for the 
plasma membrane, and cytosolic caspases was discussed. Here, the same problem 
has to be addressed in the context of a potential calpain-driven cleavage of FKN. 
However, unlike in the case of caspases some evidence exists for calpain localisation 
in the lumen of the ER and Golgi apparatus. Calpain II, but not calpain I nor small 
regulatory subunit, has been detected in the ER lumen of pulmonary smooth muscle 
cells as well as in the lumen of the ER and Golgi complex of lung adenocarcinoma 
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(A-549) cells (Hood et al. 2004; Samanta et al. 2007; Samanta et al. 2010). The 
mechanism allowing for calpain II transport to this location, however, has not yet 
been provided. Nevertheless, these reports bring a potential explanation for the 
results presented in Chapter 5. However, the potential of this mechanism to be in 
operation in BL cells would need to be further investigated.        
It is impossible to establish based on the data presented in Chapter 5 which of the 
two ubiquitous form of calpain, calpain I (µ) or calpain II (m) might be responsible 
for the FKN cleavage in BL cells. Although only calpain I was tested here for its 
ability to cleave FKN, it is very likely that calpain II would be just as efficient since 
these proteases are known to have a very similar specificity for substrates (Goll et al. 
2003; Satish et al. 2005). For the same reason the experiments involving calpain 
inhibitors were unable to indicate which of the calpains were responsible for the 
cleavage. The two enzymes vary in the level of calcium required for their activation, 
with calpain I being activated by calcium concentrations within the low micromolar 
range and calpain II requiring near-millimolar Ca2+ concentrations (Friedrich 2004). 
Therefore, intracellular calcium levels as well as the availability of the enzymes are 
the two most likely factors affecting the FKN cleavage by either calpain I or calpain 
II. 
Although calpain has been shown to mediate very limited proteolysis it does not 
seem to require any specific amino acid sequence for its substrate recognition. Rather 
secondary structural features and the substrate conformation are responsible for the 
identification of its target (Tompa et al. 2004; Cuerrier et al. 2005). Thus, it was 
impossible to predict the calpain cleavage site from the FKN sequence. However, 
based on the calculations made for the putative caspase cleavage site it is possible to 
suggest that calpain cleavage may take place in the region between amino acids 190 
and 200 of the human FKN sequence. Assuming that caspases cleave after the Asp 
residue at the position 223 to generate the 60 kDa fragment of FKN, to produce a 5 
kDa smaller form of FKN the cleavage should take place around 20 amino acids 
toward the N-terminus of FKN (on the assumption that in the case of FKN  
10 kDa = 40 amino acids; see the previous section for details). There are some 
arguments in the literature in favour of these estimations. Hundhausen et al. have 
also shown the generation of a 55 kDa form of FKN in response to ionomycin 
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stimulation. Importantly, their observations were made using a hybrid protein 
consisting of the N-terminal fragment of FKN (amino acids 1-206) that was placed 
on top of the transmembrane fragment of the gp130 signal transducer (Hundhausen 
et al. 2007). This indicated that the cleavage responsible for the production of the 55 
kDa fragment of FKN takes place before residue 206. The authors have demonstrated 
not only that ionomycin drove the release of the 55 kDa FKN but also that 
ionomycin-induced release of FKN cannot be fully inhibited by the addition of 
specific inhibitors of ADAM-10 and ADAM-17. They therefore concluded that 
ADAM proteases are not the only proteases to process FKN during incubation with 
ionomycin, the other protease, however, was not identified. 
6.2.4.1 Regulation of calpain activity in BL cells 
The discrepancies in the way that FKN is processed in different BL cell lines 
continue to be an intriguing issue. BL2 and L3055 appeared to respond differently to 
Mutu I or SAV cells upon staurosporine and ionomycin exposure. In Mutu I and 
SAV cells staurosporine induced the release of 55 kDa FKN whereas in BL2 and 
L3055 a 60 kDa form of FKN was liberated in response to this stimulus (Figure 5.1). 
On the other hand, intracellularly, in all but one (SAV) of the examined cell lines 
staurosporine induced the generation of 60 kDa FKN only. Moreover, the cell lines 
responded differently when treated with ionomycin. In BL2 (and probably L3055) 
cells ionomycin caused the release of 55 kDa FKN but only the 60 kDa form was 
found intracellularly (Figures 5.5 and 5.7). Mutu I cells in response to ionomycin 
started to generate 55 kDa also intracellularly (Figure 5.6). Intriguingly, the 
differences in the staurosporine-driven release of FKN seemed to correlate with the 
exclusive presence of calpain on the surface of the cell lines (Mutu I and SAV) that 
released the 55 kDa form of FKN (Figures 5.8 and 5.9). Although the detection of 
calpain on the outer leaflet of the plasma membrane appeared at first rather unusual, 
careful analysis of the available literature revealed that calpain (particularly  
calpain II) has previously been observed in this location. It has been found to be 
exteriorised from activated platelets and to be responsible for the processing of 
surface glycoproteins (McGowan 1983, Schmaier 1990). Moreover, Dourdin and 
colleagues have shown that calpain is present on the outer surface of myoblasts and 
that the calpain-mediated proteolysis of fibronectin is indispensable for myoblast 
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fusion to take place (Brustis et al. 1994; Dourdin et al. 1997). A role of extracellular 
calpain in arthritis has also been described. Active calpain II has been found in the 
synovial fluid from arthritic joints as well as in the cartilage affected by arthritis, 
where it has been shown to process proteoglycans (Suzuki et al. 1990; Suzuki et al. 
1992; Yamamoto et al. 1992; Szomor et al. 1999). In addition, Shimizu and 
colleagues have demonstrated that extracellular calpain II has a role during the 
process of cartilage calcification and Nakagawa and co-workers have observed that it 
is also involved in the healing of fractured bones (Shimizu et al. 1991; Nakagawa et 
al. 1994). More recent advances in this field, demonstrating that calpain II can be 
associated with the ER/Golgi apparatus structures and with the Golgi microdomain-
derived vesicles as well as that calpain II can be secreted from various cell lines in 
vesicles, may help to understand how the action of calpain in the extracellular space 
can be achieved (Nishihara et al. 2001; Hood 2003; Hood et al. 2004). In the light of 
these observations, it seems that it is not impossible that the 55 kDa FKN detected in 
the supernatants of the staurosporine-treated Mutu I and SAV cells (Figure 5.1) 
might derive from the calpain-mediated cleavage of surface FKN. In support of the 
results showing calpain presence on the outer side of the plasma membrane, it should 
be remarked that, when the antibodies used for the FACS-based detection of surface 
calpain were used for immunoblotting, no unspecific (other than 78-80 kDa bands 
predicted for calpain) bands could be observed (Figure 5.10). Therefore, it does not 
appear very likely that the labelling of the surface of BL cells resulted from the 
unspecific binding of the anti-calpain antibodies to another protein. However, it still 
cannot be excluded that these are other proteases that are responsible for the 
cleavage. As was discussed above, cathepsins, having a well established role in cell 
death and cleavage of extracellular substrates, are possible candidates (Briozzo et al. 
1988; Buck et al. 1992; Conus & Simon 2008). Moreover, there is a growing 
recognition of the involvement of MMPs in cell death (Mannello et al. 2005). As it 
was proposed before, in order to exclude the possibility that MMPs are responsible 
for the production of 55 kDa form of FKN, it might be reasonable to repeat some of 
the experiments presented in Chapter 4 (Figure 4.5) using more powerful 
metalloproteinase inhibitors (e.g. captopril or 1,10-phenanthroline).             
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An explanation for the differences in the forms of FKN that were detected 
intracellularly is more difficult to identify. The total level of calpain expression in 
BL2, L3055 and Mutu I cells seemed to be the same (Figures 5.8 and 5.9). 
Furthermore, calpain I activation status (assessed by the level of its autoproteolysis) 
was the same (Figure 5.10). It should be noted, however, that calpain is known to 
have a certain level of activity even prior to its Ca2+-driven autoproteolysis (Johnson 
& Guttmann 1997; Li et al. 2004). These results were in line with expectations for 
ionomycin-treated cells in which increased calcium concentration would 
undoubtedly cause calpain activation and autolysis. In addition, the fact that calpain 
did not seem to become activated in the staurosporine-treated cells was 
understandable. It was, however, intriguing that the calpain forms detected in the 
supernatants of both ionomycin- and staurosporine-treated cells were different (more 
extensively processed) than the forms that were found in the cell lysates. This was 
particularly striking in case of the cells that were incubated with staurosporine. 
Moreover, although calpain inhibitors have previously been reported to be able to 
inhibit the conversion of the 78 kDa form of calpain into the 76 kDa one (Melloni et 
al. 1996; Michetti et al. 1996), the mechanism by which Z-VAD-FMK blocks this 
process is worth further investigation (inhibition of caspase-mediated cleavage of 
calpastatin (Wang et al. 1998; Shi et al. 2000) might be one possible explanation). 
These experiments were only performed for calpain I but it seems likely that similar 
results would be obtained for calpain II (as the dramatically elevated Ca2+ 
concentrations in ionomycin-treated cells should be sufficient for calpain II 
activation). Under physiological conditions, however, these two proteases might be 
both differentially activated and differentially localised. As neither the level of 
calpain expression nor the efficiency of its activation seemed to be responsible for 
the variance in FKN cleavage in different BL cell lines it seems possible that the 
different distribution of the two main calpain isoforms in the cell is responsible for 
the observed effect. As calpain II, unlike calpain I, might be found in the lumen of 
the ER/Golgi network, it is possible that it has better access than calpain I to the 
substrate. It would need to be further investigated if these are the differences in the 
subcellular localisation of calpain II that make the studied BL cell lines produce 
different forms of truncated FKN (Figure 5.1). Other mechanisms known to regulate 
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calpain function may also be responsible for the observed discrepancies. Among 
them the expression of the natural calpain inhibitor – calpastatin, known to regulate 
the action of the active form of calpain (Melloni et al. 2006), is potentially 
responsible for the observed discrepancies. Yet, the variance may also be caused by 
differences in the pattern of either calpain or FKN phosphorylation. Specific 
phosphorylation has been reported to cause either an increase in calpain activity 
(McClelland et al. 1994; Glading et al. 2001) or its inhibition (Shiraha et al. 2002; 
Smith et al. 2003). Moreover, also here, it might be the different expression or 
activation of proteases other than calpain that results in the observed discrepancies.  
Calpain-mediated proteolysis, like that of caspases, is believed to modify the 
function of its substrate rather than cause its degradation (Johnson & Guttmann 
1997; Goll et al. 2003). This might be true also in case of FKN since FKN derived 
from staurosporine- and ionomycin-treated Mutu I cells (which released 55 kDa 
FKN) has been shown to be responsible for attraction of macrophages (Truman 
2005).  
6.2.5 Possible cooperation of caspases and calpain in 
FKN cleavage 
Caspases and calpains are the major protease families with a recognised role in cell 
death. Caspases are the key mediators of apoptosis. Calpain, initially linked with 
acute necrotic death, has more recently gained recognition also for its function during 
apoptotic events (Wang 2000; Liu et al. 2004). 
While these two types of proteases are generally believed to cooperate during cell 
death, they have also been shown to influence each other’s activity. Calpain has been 
demonstrated to activate caspases under some death conditions (Ruiz-Vela et al. 
1999; Blomgren et al. 2001; Altznauer et al. 2004) but also to mediate caspase 
degradation and inactivation (Chua et al. 2000). On the other hand, caspases have 
been shown to regulate calpain activity (Wood & Newcomb 1999). The endogenous 
calpain inhibitor – calpastatin, has been reported to be hydrolysed by both caspases 
and calpain (Wang et al. 1998; De Tullio et al. 2000; Shi et al. 2000). Remarkably, 
calpastatin is not an exception as a considerable number of substrates that can be 
cleaved by both proteases have been identified (Chan & Mattson 1999; Wang 2000; 
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Liu et al. 2006). Among them many cytoskeletal, plasma membrane and signal-
transducing proteins have been found. In the experimental pathological conditions, 
like transient brain injury, where both the proteases are activated, they have been 
shown to be cleaving their substrates simultaneously (Liu et al. 2006). Interestingly, 
in many of the dually cleaved proteins caspases- and calpain-driven cleavage leads to 
the production of similarly-sized products; the differences between most of them are 
within a range of 0-10 kDa (Wang 2000). For instance, in the anti-apoptotic protein 
Bcl-XL the cleavage sites for caspases and calpain adjoin (Clem et al. 1998; 
Nakagawa & Yuan 2000). In α-fodrin the two cleavage sites are separated by only 
nine residues (Wang 2000). Similarly, the difference between the two cell death-
related forms of FKN amounted to 5 kDa and, according to the estimations presented 
above, the potential cleavage sites may be situated approximately 20-30 amino acids 
apart. The fact that the products potentially generated by calpain- and caspase-
mediated cleavage can have identical or comparable molecular weights might 
suggest that they can also have similar functions. Therefore, it is possible that the  
60 and 55 kDa forms of FKN are also playing similar roles. This, however, has to be 
further investigated. The chemotaxis experiments performed by Truman have 
revealed that only the cell death-derived FKN had the property of attracting 
macrophages. Unfortunately, the differences in FKN processing in different BL cell 
lines had not yet been perceived and Truman’s studies were limited to Mutu I cells 
induced into death by various compounds (Truman 2005). As Mutu I cells were 
shown here to exclusively release 55 kDa FKN (Figures 5.1 and 5.6), the 
chemotactic properties of 60 kDa FKN, although likely, have still to be additionally 
characterised.   
Interestingly, it was observed here that FKN as well can be simultaneously 
hydrolysed by two different enzymes, as it was visible in the staurosporine-treated 
Mutu I cells (Figure. 5.1).  
Moreover, the same cells were shown to produce both forms, one after another. In 
the 24 hrs time-course of staurosporine-treated BL2 cells, where 60 kDa form of 
FKN was detected in the supernatant at the 2 hrs time-point, the 55 kDa form became 
visible after 12 hrs (Figure 5.11). Interestingly, that pattern of FKN cleavage in the 
staurosporine-treated BL2 cells matched the pattern of cell-death related changes 
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observed by Wood and Newcomb in apoptotic HL-60 cells (Wood & Newcomb 
1999). They have reported that in drug (9-AC)-treated cells, the effects of caspase 
activity could be visible as early as 2 hrs after the treatment, while calpain action 
could be detected 10-12 hrs after the start of the experiment. This might be  
a confirmation of both caspase and calpain involvement in FKN cleavage. Also, the 
results from BL2 cell studies imply that early apoptotic (2 hrs post-treatment) cells 
send (caspase-mediated) “find-me” signals to macrophages to ensure they are cleared 
rapidly and that second (calpain-mediated) signal is sent when the still uncleared 
cells are becoming secondary necrotic (12 hrs post-treatment).    
 Altogether the observations presented here suggest that these complex mechanisms 
serve to ensure that, independently of nature of death stimulus and pathway involved 
in the cell death execution, the “find-me” signal will be sent by dying cells.  
6.3 Mechanism of FKN release  
The mechanism by which FKN is released from dying BL cells remains incompletely 
understood. The shedding of membrane-bound FKN by proteases ADAM-10 and 
ADAM-17 has long been seen to be a major method of generating soluble FKN. 
However, the experiments performed previously in this laboratory have revealed that 
a 60 kDa form of FKN, derived from apoptotic BL cells, is exclusively associated 
with MPs. The easiest explanation for the presence of 60 kDa FKN in MPs is that 
intracellularly cleaved FKN would subsequently be directed to MPs. Yet, it is also 
possible that the processing of FKN takes place in MPs themselves. The support for 
this hypothesis came from the experiments with staurosporine-treated Mutu I cells. 
Whilst the lysates of these cells only produced the 60 kDa FKN, the 
supernatants/MPs contained the 55 kDa form instead (Figure 5.1). Hence, it seems 
that intracellular cleavage of FKN and its hydrolysis in MPs are two independent 
processes. The fact that no 60 kDa FKN was found in supernatants from Mutu I cells 
also implies that two separate pools of FKN exist in these cells: one, which would be 
directed to MPs and another, which would not be released. This would be in 
accordance with the report by Liu et al. in which FKN was only detected as a 
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membrane-bound form and in a unique endomembrane compartment (Liu et al. 
2005). Likewise, Hermand and colleagues have demonstrated that only around 50% 
of cellular FKN is exposed on the plasma membrane (Hermand et al. 2008). The 
analysis of FKN localisation in apoptotic BL2 cells showed that although some 
portion of it was present on the cell surface, most seemed to be concentrated 
intracellularly, in the membrane-proximal area (Figures 4.16 and 4.15). FKN 
appeared to be equally distributed in other parts of the cells and no special 
cytoplasmic storage compartment could be distinguished. It was, however, difficult 
to assess the location of compartments without using additional markers in cells like 
lymphocytes since they contain only scarce amount of cytoplasm.  
In addition, the loss of FKN from the surface of BL2 cells that was observed 2 hrs 
after staurosporine treatment (Figure 4.4) is likely to be due to the release of MPs. 
Using time lapse microscopy it was revealed that the intensity of MPs formation and 
liberation from BL2 cells dramatically increased around 1.5 – 2 hrs after the 
induction of apoptosis (Figure 4.13, Appendix B). Segundo and colleagues have also 
observed a loss of cell surface proteins resulting from the release of MPs from 
apoptotic cells (Segundo et al. 1999). On the other hand, the decrease in the levels of 
surface FKN observed at the 1 hr time point was clearly independent of the apoptosis 
programme since the control cells were affected in the same way as the 
staurosporine-treated BL2 cells (Figure 4.4). At the same time, the release of 90 kDa 
FKN also appeared to be independent of apoptosis and was detected in the 
supernatants as early as 1 hr after the treatment. As it was discussed before  
(section 6.2.1), the results presented in this thesis do not allow for distinguishing if 
90 kDa form of FKN represents a full-length transmembrane molecule or a truncated 
form. However, as it was detected in the supernatants in a soluble form it seems 
possible that the observed, apoptosis-independent, loss of surface FKN expression 
results from an ADAM-mediated, constitutive or cell handling-induced, proteolysis 
of surface FKN. 
Furthermore, the role of two separate pools of microvesicles that were produced by 
staurosporine-treated BL2 cells (Figure 4.14) in the release of FKN could be 
investigated. FKN was shown here to be present in the bigger vesicles, which 
according to their size represent MPs (Figures 4.12 and 4.14) (Charras 2008). The 
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other population of vesicles were of around 50-100 nm in diameter (Figure 4.14) and 
probably represent exosomes. Unlike MPs, which are generated as protrusions from 
the plasma membrane, exosomes derive from the endosomal compartment 
(Lakkaraju & Rodriguez-Boulan 2008). Having different origins to MPs, exosomes 
are likely to carry distinct sets of proteins. Therefore, it would be interesting to assess 
whether exosomes also contain FKN and to determine the differences in the forms of 
FKN contained within these two populations of vesicles. 
 
6.4 Role of FKN in cell death  
The mechanisms responsible for migration of specialised phagocytic cells to the sites 
where cell death occurs are not well characterised. So far, only a few chemotactic 
factors released from dying cells have been described. First, endothelial monocyte-
activating polypeptide II (EMAP II), a cytokine with attractant properties for 
macrophages, has been found to be processed in apoptotic cells in developing mouse 
embryo. Its subsequent release has correlated with macrophage infiltration (Knies et 
al. 1998). In addition, ribosomal protein S19 has been identified as a factor mediating 
monocyte chemotaxis to heat-treated HL-60 cells (Horino et al. 1998). Moreover, 
Lauber et al. have demonstrated that a phospholipid lysophosphatidylcholine (LPC) 
drives the migration of THP-1 monocytic cells to UV-irradiated MCF-7 cells (Lauber 
et al. 2003). While some groups have also reported that LPC has chemotactic 
properties (Radu et al. 2004; Yang et al. 2005), its involvement in macrophage 
attraction to apoptotic cells has not been observed in other systems, e.g. studied by 
this group and others (Truman, unpublished; Elliott et al. 2009). In addition, another 
lipid, sphingosine-1-phosphate (SP1) has been reported to mediate both 
chemoattraction of macrophages to apoptotic cells as well as their survival and shift 
towards M2-like phenotype (Weigert et al. 2006; Gude et al. 2008; Johann et al. 
2008). More recently, Elliott and colleagues have shown that the release of the 
nucleotides ATP and UTP from apoptotic T cells induced migration of mononuclear 
phagocytes both in vitro and in vivo (Elliott et al. 2009). The identification of the role 
of the cell death-associated form of FKN in attraction of macrophages added the first 
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chemokine to this group (Truman et al. 2008). Here it was demonstrated that it might 
be caspases that are directly involved in the production of chemotactic signals for 
macrophages. Moreover, calpain – another protease that plays a crucial role in the 
execution of cell death, was also proposed here to potentially have a role in cleaving 
FKN during cell death. The susceptibility of FKN to hydrolysis by two proteases, 
known to complement one another during various types of death, suggests that this 
chemokine may have a crucial role during the process of cell death. 
The role of FKN in attracting macrophages has also been confirmed in systems other 
than BL environment. Germinal centre B cells (healthy counterparts of BL cells) 
which undergo spontaneous apoptosis during the process of specificity selection, 
have been shown to attract tingible body macrophages in a FKN-dependent manner 
(Truman et al. 2008). Here, it was established that dying GC B cells, unlike control 
follicular B cells, released a form of approximately 60 kDa molecular weight  
(Figure 4.17). It is therefore tempting to hypothesise that other FKN-expressing cells 
can also use it to signal their death.  
There are some indications that FKN can play a similar role during neuronal cell 
injury. Calpain activation is well established under various cell injury-causing 
conditions i.e. toxicants, hypoxia and ischemia, (Rami 2003; Liu et al. 2004). 
Moreover, it has been shown that during experimental excitotoxic injury, FKN, 
which is widely expressed by neurons, is released at an early stage of the death 
programme and that it has chemoattractant properties for monocytes (Chapman et al. 
2000). The authors have further demonstrated that the release can be inhibited by 
metalloproteinase inhibitors; this part of their study, however, was not performed 
under cell death conditions and the size of the chemotactic form of FKN was not 
provided. Finally, FKN-deficient mice have been shown to be partly protected from 
ischemia-mediated damage (Soriano et al. 2002). Based on the results presented in 
this thesis it can be speculated that injury-activated calpain would cleave FKN and 
that it would be the cleaved, chemotactic form of FKN that would drive an 
accumulation of microglial cells and monocytes. These cells could in turn mediate 
the damage observed following neuronal cell injury (Amantea et al. 2009). FKN is 
constitutively expressed in the central nervous system and is known to play various, 
often contradictory roles (e.g. Boehme et al. 2000; Meucci et al. 2000; Zujovic et al. 
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2000; Soriano et al. 2002; Cardona et al. 2006; Clark et al. 2007). Its specific 
cleavage by calpain might be indispensable to modulate its function and ensure 
specificity of its action.  
The final evidence for FKN having an important role in cell death comes from the 
fact that it has been found to be directly regulated by the transcription factor p53 
(Shiraishi et al. 2000). It might mean that FKN expression can be up-regulated by 
p53 (along with pro-apoptotic proteins, for example: Bak and Bax) as a part of the 
cells reaction to stress e.g. DNA damage or hypoxia (Levine 1997).  
6.5 Role of FKN in BL   
FKN has been shown to play an important role in the process of attracting 
macrophages to BL tumours (Truman et al. 2008). As tumour-associated 
macrophages (TAMs) are known to support tumour growth in many ways 
(Mantovani et al. 1992), FKN can be seen as a factor that exerts an indirect effect on 
tumour growth by shifting the immune response to act in favour of the tumour.  
It has, however, been shown that FKN is not the only chemokine released by dying 
BL cells to attract macrophages (Truman et al. 2008). Studies gathered in Chapter 3 
were focused on determining the role of MCP-1 in this process. As it was established 
that MCP-1 probably is not produced by BL cells, the chemokine(s) responsible for 
this process have yet to be identified. From the chemokines with known ability to 
attract mononuclear phagocytes, CXCL12 stands out as a potential candidate. This 
chemokine has been found to participate in the mediation of an immunosuppressive 
environment, neovascularisation and metastasis in various types of tumours, 
including non-Hodgkin’s lymphoma (Rempel et al. 2000; Kryczek et al. 2007; de 
Oliveira et al. 2009). Intriguingly, a strong expression of CXCL12 has been found in 
malignant B cells in MALT lymphoma, where it has been suggested to have a role in 
mediating B cell survival (Barone et al. 2008). The gene profiling analysis performed 
in this group has revealed that both BL cells and macrophages infiltrating BL 
tumours express CXCR4 – one of the receptors for CXCL12 (Sofia Petrova – 
unpublished results).  
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The migration of macrophages to BL is mediated by the cell death-associated forms 
of FKN (60 and 55 kDa). However, it is tempting to speculate that other forms of 
FKN that are present in BL could have additional, direct impacts on the tumour. 
FKN has been shown in other environments to carry out functions that could be 
potentially relevant also to BL. Boehme et al. have demonstrated that FKN acts as a 
strong survival factor for cultured microglia and is capable of even overcoming  
Fas-mediated death signalling (Boehme et al. 2000). 
FKN has also been shown to provide survival signals for monocytes in culture 
(Landsman et al. 2009). Furthermore, both FKN- and CX3CR1-deficient mice have 
been shown to loose a Gr1low CX3CR1high subset of monocytes as a consequence of 
the increased rate of their apoptosis (Landsman et al. 2009). In sum, these 
observations suggest that FKN could also constitute an anti-apoptotic signal for 
macrophages that infiltrate BL tumours. 
Moreover, apart from affecting viability of macrophages, FKN seems to be capable 
of moderating the type of immunological reaction that they mediate. It has been 
reported that FKN inhibited the release of TNFα, IL-6 and NO from LPS-  
and IFN-γ-treated microglia (Zujovic et al. 2000; Mizuno et al. 2003). This has been 
further confirmed by the observation that CX3CR1-deficient mice suffered from 
excessive neurotoxicity after LPS injection (Cardona et al. 2006). Following on from 
these observations it can be proposed that FKN might also suppress pro-
inflammatory factors released from macrophages in BL and thus, would take an 
active part in establishing the immunosuppressive environment of the tumour. 
In this respect, is also possible that FKN can indirectly contribute to the inhibition of 
immune response by stimulating MFG-E8 production and inducing apoptotic cell 
clearance by macrophages (Miksa et al. 2007). 
Finally, FKN is also likely to contribute to neoangiogenesis in BL tumours since its 
involvement in mediating endothelial cell proliferation and new vessels formation 
has been reported (Lee et al. 2006). It has also been shown to serve both as an anti-




Notable differences were observed in the way that FKN was cleaved in the different 
BL cell lines used in this study, suggesting the existence of similar discrepancy 
between the individual cases of lymphoma. Rather strikingly, the division between 
the cells that were prone to produce (after staurosporine treatment) 60 kDa FKN  
(i.e. BL2 and L3055) and those that were able to produce 55 kDa FKN (also 
expressing calpain on their surface) (Mutu I and SAV), overlapped with the division 
for those that were EBV-negative (BL2 and L3005) and EBV-positive (Mutu I and 
SAV) (Gregory et al. 1990; Milner et al. 1993; Gordon et al. 2000). This suggested 
that EBV infection might affect the mechanism of FKN processing. EBV-positive 
type I latency BL lines are known to express only three of the virus components: 
EBV-determined nuclear antigen 1 (EBNA-1), EBV-encoded small RNAs (EBERs) 
and BamHI A rightward transcripts (BARTs) (Rowe et al. 1987; Rowe et al. 2009). 
While EBNA-1 has initially been associated with subsistence and replication of the 
EBV genome in cells, more recent reports provide evidence for its involvement in 
the regulation of various genes of the host cell (Wood et al. 2007; Flavell et al. 2008; 
O'Neil et al. 2008; Tsimbouri et al. 2008; Canaan et al. 2009). Notably, EBNA-1 has 
also been found to protect BL cells from apoptosis (Kennedy et al. 2003). Another 
study, however, suggests that it is not able to fulfil its role alone and it has to work in 
conjunction with EBERs in order to exert the anti-apoptotic effect (Komano et al. 
1999). Furthermore, anti-apoptotic properties of both EBERs and BARTs acting 
independently have been reported (Nanbo et al. 2002; Choy et al. 2008). The 
observed interference of the virus components with the cell death signalling 
pathways indicates that they might have an effect on the way the cell reacts to a 
death stimulus, including activation of death-related proteases and in consequence, 
possibly also on the pattern of FKN cleavage.                    
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Appendix A  
Introducing point 
mutation into the FKN 
gene sequence 
 
In order to confirm caspase involvement in the FKN processing during apoptosis and 
to identify a potential site of cleavage it was decided to introduce point mutation in 
the Asp residues of the FKN sequence (see sections 2.13.3 and 4.5.3.4 for details). 
The position of targeted residues in the FKN mucin stalk sequence and the outcome 







10  20 30 40 50 60 70
MAPISLSWLL RLATFCHLTV LLAGQHHGVT KCNITCSKMT SKIPVALLIH YQQNQASCGK RAIILETRQH
80 90 100 110 120 130 140
RLFCADPKEQ WVKDAMQHLD RQAAALTRNG GTFEKQIGEV KPRTTPAAGG MDESVVLEPE ATGESSSLEP
150 160 170 180 190 200 210
TPSSQEAQRA LGTSPELPTG VTGSSGTRLP PTPKAQDGGP VGTELFRVPP VSTAATWQSS APHQPGPSLW
220 230 240 250 260 270 280
AEAKTSEAPS TQDPSTQAST ASSPAPEENA PSEGQRVWGQ GQSPRPENSL EREEMGPVPA HTDAFQDWGP
290 300 310 320 330 340        350
GSMAHVSVVP VSSEGTPSRE PVASGSWTPK AEEPIHATMD PQRLGVLITP VPDAQAATRR QAVGLLAFLG
360 370 380 390
LLFCLGVAMF TYQSLQGCPR KMAGEMAEGL RYIPRSCGSN SYVLVPV
SIGNAL























































Figure A.3. Schematic picture of TrueORF pCMV6-Entry vector. 
TrueORF pCMV6-Entry carrying FKN gene (C-terminal Myc and DDK 
Tagged) was used for site-directed mutagenesis. Supplied by Origene.  




















Figure A.4. Introduction of the point mutations in the FKN sequence. 


















































Time lapse imaging of 
MP release from 
apoptotic BL cells 
The formation and release of MPs from staurosporine-induced BL2 cells were 
recorded using phase contrast widefield microscopy and a time lapse imaging 
system. BL2 cells were placed in POC mini chamber on a heated microscope stage 
(37°C) of an inverted microscope. A low-magnification image (10x objective) of the 
cells was collected every 15 sec, for 150 min, starting 30 min after the cells were 
exposed to staurosporine. The full image sequence can be found on the CD attached 





CX3CL1/fractalkine is released from 
apoptotic lymphocytes to stimulate 
macrophage chemotaxis 
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Melville L, Melrose LA, Ogden CA, Nibbs R, Graham G, Combadiere C, Gregory 
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Cells undergoing apoptosis are efficiently located and engulfed by phagocytes. The 
mechanisms by which macrophages, the professional scavenging phagocytes of 
apoptotic cells, are attracted to sites of apoptosis are poorly defined. Here we show 
that CX3CL1/fractalkine, a chemokine and intercellular adhesion molecule, is 
released rapidly from apoptotic lymphocytes, via caspase- and Bcl-2-regulated 
mechanisms, to attract macrophages. Effective chemotaxis of macrophages to 
apoptotic lymphocytes is dependent on macrophage fractalkine receptor, CX3CR1. 
CX3CR1 deficiency caused diminished recruitment of macrophages to germinal 
centres of lymphoid follicles, sites of high-rate B-cell apoptosis. These results 
provide the first demonstration of chemokine/chemokine-receptor activity in the 
navigation of macrophages toward apoptotic cells and identify a mechanism by 
which macrophage infiltration of tissues containing apoptotic lymphocytes is 
achieved. 
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